

## SPIRE LABORATORY MEDICINE

Ref: SPS-QM-1200

Issued By: Head of Diagnostic Governance

Approved By: Laboratory Medicine Governance Committee

Date: February 2026

## SERVICE USERS GUIDE

Applies to sites: All Spire Hospitals where Spire Laboratory Medicine is the pathology services supplier

Applies to colleague groups: All colleagues using Spire Laboratory Medicine

# SPIRE LABORATORY MEDICINE USERS GUIDE

CONTROLLED DOCUMENT

## Table of Contents

|                                                                                           |           |
|-------------------------------------------------------------------------------------------|-----------|
| <b>Table of Contents.....</b>                                                             | <b>2</b>  |
| <b>1.0 Introduction.....</b>                                                              | <b>8</b>  |
| <b>2.0 Laboratory Medicine Location Details .....</b>                                     | <b>8</b>  |
| Contact information.....                                                                  | 8         |
| Service Delivery Overview .....                                                           | 8         |
| Laboratory Medicine Business Services Team.....                                           | 8         |
| Laboratory Medicine Senior Management Team .....                                          | 9         |
| Service Locations with hospitals supported .....                                          | 9         |
| 2.4.1 Spire Laboratory Medicine Bristol.....                                              | 11        |
| 2.4.1.1 Spire Laboratory Medicine Bristol – Spire Cardiff spoke site .....                | 11        |
| 2.4.2 Spire Laboratory Medicine Centennial Park Elstree.....                              | 13        |
| 2.4.2.1 Spire Laboratory Medicine Centennial Park Elstree – Spire Dunedin Spoke site..... | 13        |
| 2.4.3 Spire Laboratory Medicine Hartswood .....                                           | 14        |
| 2.4.4 Spire Laboratory Medicine Histology Centre, Manchester.....                         | 15        |
| 2.4.5 Spire Laboratory Medicine Services Leeds.....                                       | 16        |
| 2.4.5.1 Spire Laboratory Medicine Leeds – Spire Hull and East Riding spoke site.....      | 17        |
| 2.4.5.2 Spire Laboratory Medicine Leeds – Spire Washington spoke site.....                | 17        |
| 2.4.6 Spire Laboratory Medicine Manchester.....                                           | 18        |
| 2.4.7 Spire Laboratory Medicine Murrayfield Edinburgh .....                               | 19        |
| 2.4.8 Spire Laboratory Medicine Nottingham.....                                           | 20        |
| 2.4.8.1 Spire Laboratory Medicine Nottingham – Spire Leicester spoke site .....           | 20        |
| 2.4.9 Spire Laboratory Medicine Parkway.....                                              | 21        |
| 2.4.9.1 Spire Laboratory Medicine Parkway - Spire Little Aston spoke site .....           | 22        |
| 2.4.10 Spire Laboratory Medicine Southampton .....                                        | 22        |
| 2.4.10.1 Spire Laboratory Medicine Southampton - Spire Portsmouth spoke site .....        | 23        |
| 2.4.11 Spire Laboratory Medicine St Anthony’s .....                                       | 24        |
| 2.4.2.2 Spire Laboratory Medicine St Anthony’s – Spire Montefiore Spoke site.....         | 24        |
| <b>3.0 Laboratory Medicine Quality Policy.....</b>                                        | <b>26</b> |
| Our vision .....                                                                          | 27        |
| Our mission .....                                                                         | 27        |
| Our values .....                                                                          | 27        |
| Our Purpose.....                                                                          | 27        |
| <b>4.0 Quality assurance .....</b>                                                        | <b>27</b> |
| <b>5.0 Reports.....</b>                                                                   | <b>27</b> |
| <b>6.0 Request forms .....</b>                                                            | <b>28</b> |

|             |                                                                      |           |
|-------------|----------------------------------------------------------------------|-----------|
| 6.1         | Electronic requesting of pathology tests .....                       | 29        |
| <b>7.0</b>  | <b>Specimen collection .....</b>                                     | <b>29</b> |
|             | Splitting primary patient samples .....                              | 29        |
|             | Microbiology sample collection .....                                 | 29        |
|             | Histopathology sample collection and labelling.....                  | 29        |
|             | Specimens not handled by Spire Laboratory Medicine departments ..... | 29        |
| <b>8.0</b>  | <b>Specimen labelling .....</b>                                      | <b>30</b> |
| 8.1         | Blood transfusion specimens.....                                     | 30        |
| 8.2         | High Risk Specimens .....                                            | 30        |
| <b>9.0</b>  | <b>Transportation of Samples to the Laboratory .....</b>             | <b>31</b> |
| 9.1         | Classification of infectious substances for transportation .....     | 31        |
| 9.2         | Packaging and labelling for transport.....                           | 32        |
| 9.3         | Pneumatic tube system .....                                          | 32        |
| <b>10.0</b> | <b>Patient consent &amp; sharing of information .....</b>            | <b>32</b> |
| <b>11.0</b> | <b>Instructions for the preparation of the patient.....</b>          | <b>33</b> |
| <b>12.0</b> | <b>Instructions for patient-collected samples. ....</b>              | <b>33</b> |
| 12.1        | Instructions for the collection of samples for specialist tests..... | 34        |
| <b>13.0</b> | <b>Specimen rejection criteria .....</b>                             | <b>34</b> |
| <b>14.0</b> | <b>Factors affecting sample results .....</b>                        | <b>35</b> |
| 14.1        | Blood sample collection technique.....                               | 35        |
| 14.2        | Pre-analytical variables – Microbiology.....                         | 35        |
| 14.3        | Pre-analytical variables in urine testing-Biochemistry.....          | 35        |
| 14.4        | Pre-analytical variables – Biochemistry.....                         | 36        |
| 14.5        | Pre-analytical variables – Haematology and coagulation.....          | 36        |
| 14.6        | Pre-analytical variables – Blood transfusion .....                   | 37        |
| 14.7        | Pre-analytical variables - Virology .....                            | 37        |
| 14.8        | Pre-analytical variables – Immunology .....                          | 38        |
| 14.9        | Pre-analytical variables – Histology.....                            | 38        |
| 14.10       | Pre-analytical variables – Cytopathology .....                       | 38        |
| 14.10.1     | Non-gynaecological samples.....                                      | 38        |

|                                                                               |                                                                            |    |
|-------------------------------------------------------------------------------|----------------------------------------------------------------------------|----|
| 14.10.2                                                                       | Cervical cytology.....                                                     | 39 |
| 14.11                                                                         | Risk Assessment.....                                                       | 39 |
| 15.0                                                                          | Clinical Advice.....                                                       | 41 |
| 16.0                                                                          | Protection of Personal Information .....                                   | 42 |
| 17.0                                                                          | Complaint Procedure.....                                                   | 42 |
| 18.0                                                                          | Measurement Uncertainty and Biological variance .....                      | 42 |
| 19.0                                                                          | Turnaround Times .....                                                     | 42 |
| 20.0                                                                          | Customer Information.....                                                  | 42 |
| Appendix 1 – Tests offered by Spire Laboratory Medicine .....                 |                                                                            | 43 |
| Appendix 2 – Test Repertoire.....                                             |                                                                            | 47 |
| 22.1                                                                          | Reference ranges for paediatric Full Blood Counts .....                    | 61 |
| Appendix 3 – Instructions for the Collection of Histology Specimens .....     |                                                                            | 67 |
| Appendix 4- Broom Like device Protocol for LBC sample collection.....         |                                                                            | 68 |
| Appendix 5 – Guide for Microbiological Investigation .....                    |                                                                            | 69 |
| 25.1                                                                          | GUIDELINES ON APPROPRIATE CLINICAL DETAILS FOR MICROBIOLOGY REQUESTS ..... | 69 |
| 25.2                                                                          | Guide to taking Specimens for Microbiological Investigation .....          | 72 |
| Ear swabs and associated specimens .....                                      |                                                                            | 72 |
| Eye swabs for bacterial infections .....                                      |                                                                            | 72 |
| Superficial mouth samples.....                                                |                                                                            | 72 |
| Nasal swabs.....                                                              |                                                                            | 73 |
| Samples for Bordatella pertussis culture.....                                 |                                                                            | 73 |
| Pernasal swabs .....                                                          |                                                                            | 73 |
| Nasopharyngeal specimens .....                                                |                                                                            | 73 |
| Throat related specimens .....                                                |                                                                            | 74 |
| Faeces for Clostridium difficile.....                                         |                                                                            | 74 |
| Investigation of swabs from skin and superficial soft tissue infections ..... |                                                                            | 74 |
| Pus and exudates .....                                                        |                                                                            | 75 |
| Investigation of Bile.....                                                    |                                                                            | 75 |
| Investigation of tissues and biopsies from deep-seated sites and organs ..... |                                                                            | 76 |

|                                                                                                |    |
|------------------------------------------------------------------------------------------------|----|
| Investigation of intravascular cannulae and associated specimens .....                         | 76 |
| Correct specimen type and method of collection: .....                                          | 76 |
| Cannulae.....                                                                                  | 76 |
| Swabs .....                                                                                    | 76 |
| Blood .....                                                                                    | 77 |
| Investigation of Cerebrospinal Fluid Shunts .....                                              | 77 |
| Investigation of Continuous Ambulatory Peritoneal Dialysis Fluid .....                         | 77 |
| Investigation of Fluids from Normally Sterile Sites.....                                       | 77 |
| Investigation of Cerebrospinal Fluid .....                                                     | 78 |
| Investigation of Genital Tract and Associated Specimens .....                                  | 78 |
| Genital tract swabs.....                                                                       | 78 |
| High vaginal swabs.....                                                                        | 79 |
| Cervical swabs .....                                                                           | 79 |
| Urethral swabs .....                                                                           | 79 |
| Intrauterine contraceptive devices (IUCDs).....                                                | 79 |
| Rectal swabs.....                                                                              | 79 |
| Throat swabs.....                                                                              | 79 |
| Fluids and pus .....                                                                           | 79 |
| Investigations for Chlamydia, Gonorrhoea and Trichomonas testing by PCR.....                   | 80 |
| Investigation of Specimens for Screening for MRSA.....                                         | 83 |
| <b>Collecting a nasal swab:</b> .....                                                          | 84 |
| <b>Collecting perianal or groin swab:</b> .....                                                | 84 |
| Investigation of Faecal Specimens for Enteric Pathogens .....                                  | 84 |
| Investigation of specimens other than blood for parasites.....                                 | 84 |
| Faeces .....                                                                                   | 85 |
| Microscopy for E. vermicularis ova .....                                                       | 85 |
| Perianal swab.....                                                                             | 85 |
| Urine (for S. haematobium).....                                                                | 85 |
| CSF .....                                                                                      | 85 |
| Tissues, biopsies, hydatid cyst and pus from abscesses, bile, duodenal/jejunal aspirates ..... | 86 |
| Sputum/bronchoalveolar lavage.....                                                             | 86 |
| Quantity and number of specimens .....                                                         | 86 |
| Faeces .....                                                                                   | 86 |
| Perianal swab for E. vermicularis ova .....                                                    | 86 |
| Urine (for S. haematobium).....                                                                | 86 |
| CSF .....                                                                                      | 86 |
| Pus .....                                                                                      | 86 |
| Tissues/biopsies .....                                                                         | 86 |
| Bile, duodenal/jejunal aspirates.....                                                          | 86 |
| Sputum/bronchoalveolar lavage.....                                                             | 86 |
| Investigation of Blood Cultures (for Organisms other than Mycobacterium species) .....         | 87 |
| Quantity .....                                                                                 | 87 |

|                                                                                  |    |
|----------------------------------------------------------------------------------|----|
| Adults .....                                                                     | 87 |
| Children and neonates.....                                                       | 87 |
| Number.....                                                                      | 87 |
| Procedure.....                                                                   | 88 |
| Preparation .....                                                                | 88 |
| Insertion of the needle .....                                                    | 88 |
| To complete the procedure .....                                                  | 89 |
| Investigation of bone marrow .....                                               | 89 |
| Investigation of Dermatological Specimens for Superficial Mycoses .....          | 90 |
| Skin .....                                                                       | 90 |
| Nail.....                                                                        | 90 |
| Hair .....                                                                       | 90 |
| Investigation of specimens for Mycobacterium species .....                       | 90 |
| Specimens other than blood .....                                                 | 91 |
| Gastric washings.....                                                            | 91 |
| Blood and bone marrow cultures.....                                              | 91 |
| Correct specimen type and method of collection.....                              | 91 |
| Sputum specimens .....                                                           | 91 |
| Bronchoalveolar lavage/bronchial washings.....                                   | 91 |
| Gastric washings.....                                                            | 92 |
| Sterile site body fluids.....                                                    | 92 |
| Urine specimens.....                                                             | 92 |
| Skin, bone, and tissue including post mortem specimens.....                      | 92 |
| Faecal samples.....                                                              | 92 |
| Pus or pus swabs.....                                                            | 93 |
| Bone marrow .....                                                                | 93 |
| Blood .....                                                                      | 93 |
| Investigation of urine.....                                                      | 93 |
| Mid-stream urine (MSU) .....                                                     | 93 |
| Clean-catch urine .....                                                          | 93 |
| Suprapubic aspirate (SPA).....                                                   | 93 |
| Catheter urine (CSU).....                                                        | 94 |
| Bag urine.....                                                                   | 94 |
| Pad urine.....                                                                   | 94 |
| Ileal conduit – urostomy urine.....                                              | 94 |
| Cystoscopy urine .....                                                           | 94 |
| Ureteric urine.....                                                              | 94 |
| Meares and Stamey localisation culture method for diagnosis of prostatitis ..... | 94 |
| Urine for S. Typhi and S. Paratyphi cultures .....                               | 94 |
| Investigation of bone and soft tissue associated with osteomyelitis .....        | 95 |
| Investigation of orthopaedic implant associated infections .....                 | 95 |
| Screening for Neisseria meningitidis .....                                       | 96 |

|                                                                                            |           |
|--------------------------------------------------------------------------------------------|-----------|
| Investigation of gastric biopsies for <i>Helicobacter pylori</i> .....                     | 96        |
| Investigation of bronchoalveolar lavage, sputum and associated specimens.....              | 96        |
| Detection of Carriage of Group B Streptococci.....                                         | 97        |
| Detection of Enterobacteriaceae producing extended spectrum $\beta$ -lactamases .....      | 97        |
| Detection of bacteria with carbapenem-hydrolysing $\beta$ -lactamases carbapenemases)..... | 97        |
| Investigation of specimens for ectoparasites .....                                         | 98        |
| <b>Appendix 6 – Form &amp; Sample labelling guidelines .....</b>                           | <b>99</b> |
| Correct labelling of Cellular Pathology.....                                               | 99        |
| Correct Labelling for Ordercomms Samples .....                                             | 100       |
| How to label Blood tube sample correctly: .....                                            | 101       |
| How to label Transfusion sample & request form correctly:.....                             | 101       |

### 1.0 Introduction

Spire Laboratory Medicine as part of Spire Healthcare, has one of the largest networks of independent laboratories in the UK. We perform more than 1.5 million tests a year for the hospitals within the Spire Healthcare group as well as external customers including both the independent and NHS sectors.

Our truly integrated network of multidisciplinary and specialist laboratories are supported by nationally renowned consultants, excellent logistics and full electronic connectivity. This has resulted in a unique clinically led, efficient customer focused pathology service. Spire Laboratory Medicine has transformed the way independent pathology is delivered to its customers, providing onsite pathology and a local presence throughout the UK allowing us to deliver cost-effective service of the highest quality and convenience.

See appendix 1 for the types of clinical services offered in the Spire Laboratory Medicine network. Most tests are tested within the network of laboratories, but esoteric providers are used for specialist tests. A list of referred tests can be found in the test repertoire.

See appendix 2 for the Test Repertoire which details the most requested tests. Enquiries for tests not on the repertoire can be made by contacting Spire Laboratory Medicine Business Services Team ([laboratorymedicine@spirehealthcare.com](mailto:laboratorymedicine@spirehealthcare.com) )

### 2.0 Laboratory Medicine Location Details

#### Contact information

To Contact Spire Laboratory Medicine please see the section on Laboratory Information, our website <https://www.spirehealthcare.com/pathology>, or email us at [laboratorymedicine@spirehealthcare.com](mailto:laboratorymedicine@spirehealthcare.com)

#### Service Delivery Overview

Our Laboratory Medicine Services are currently delivered from 11 locations across the UK. Our Elstree and Manchester locations are the central administration locations for the service providing additional tests.

UKAS accredited service number 8314

#### Laboratory Medicine Business Services Team

Spire Laboratory Medicine operates a single point of contact for supporting our users. If you require support, please contact The Pathology Business Services team. The team support all disciplines and laboratory sites and support a full range of enquiries including:

- Test and result enquire
- Add on requests
- General enquires
- New customer enquires
- Consumable enquires

The team can be contacted on:

Email: [laboratorymedicine@spirehealthcare.com](mailto:laboratorymedicine@spirehealthcare.com)

Telephone: 0161 447 6878

The Laboratory Medicine Business Services Team operating hours are:

- Monday – Friday 07:00-18:00
- Saturday 08:00-16:00
- Sunday 08:00-12:00

\*Public holidays may differ from these times.

If your enquiry is outside of these times and requires urgent action, please contact your supporting laboratory directly.

**Please note**, unfortunately this is not a patient facing service and we would ask you to contact your requestor or hospital / clinic site for further support.

### Laboratory Medicine Senior Management Team

| Laboratory Medicine Senior Management Team              |                 |                                                                                                                    |
|---------------------------------------------------------|-----------------|--------------------------------------------------------------------------------------------------------------------|
| Role                                                    | Name            | Contact Details                                                                                                    |
| Director of Diagnostics                                 | Chris Gunn      | <a href="mailto:christopher.gunn@spirehealthcare.com">christopher.gunn@spirehealthcare.com</a><br>Tel: 07874873583 |
| Regional Laboratory Medicine Operations Manager (North) | Claire Grinnell | <a href="mailto:claire.grinnell@spirehealthcare.com">claire.grinnell@spirehealthcare.com</a><br>Tel: 07770814993   |
| Regional Laboratory Medicine Operations Manager (South) | David Hall      | <a href="mailto:david.hall@spirehealthcare.com">david.hall@spirehealthcare.com</a><br>Tel: 07718565464             |
| Head of Diagnostic Governance                           | Fiona McLeman   | <a href="mailto:fiona.mcleman@spirehealthcare.com">fiona.mcleman@spirehealthcare.com</a><br>Tel: 07720736827       |
| Pathology Engagement Manager                            | Martin Phillips | <a href="mailto:martin.phillips@spirehealthcare.com">martin.phillips@spirehealthcare.com</a><br>Tel: 07718487363   |

### Service Locations with hospitals supported

Laboratory Medicine Service locations and contact details are listed on the following pages in alphabetical order and spoke sites providing analytical services are listed below them:

**Key:**

- Spire Laboratory Hub site
  - Spire laboratory Spoke site
    - Spire supported hospital
- Spire Laboratory Medicine Bristol
  - Spire Cardiff
- Spire Laboratory Medicine Centennial Park, Elstree
  - Spire Dunedin
    - Spire Thames Valley
    - Spire Harpenden

- Spire Laboratory Medicine Hartswood
  - Spire London East
  - Spire Wellesley
  - Spire Cambridge Lea
- Spire Histology Centre, Manchester (All Spire Hospitals supported)
- Spire Laboratory Medicine Leeds
  - Spire Hull and East Riding
  - Spire Washington
    - Spire Elland
    - Spire Methley Park
    - Spire Harrogate Clinic
- Spire Laboratory Medicine Manchester
  - Spire Wirral
  - Spire Cheshire
  - Spire Liverpool
  - Spire Regency
  - Spire Yale
  - Spire Fylde Coast
  - Spire Abergele Clinic
- Spire Laboratory Medicine Murrayfield Edinburgh
  - Spire Shawfair Park
- Spire Laboratory Medicine Nottingham
  - Spire Leicester
- Spire Laboratory Medicine Parkway
  - Spire Little Aston
    - Spire South Bank
- Spire Laboratory Medicine Southampton
  - Spire Portsmouth
- Spire Laboratory Medicine St Anthony's
  - Spire Alexandra
  - Spire Tunbridge Wells
  - Spire Gatwick Park
  - Spire Montefiore

## 2.4.1 Spire Laboratory Medicine Bristol



**Address:**  
Spire Bristol Hospital  
The Glen, Redland Hill  
Durdham Down  
Bristol  
BS6 6UT

Laboratory located: Floor 1 – Specimen reception halfway down hill on left hand side

Sample drop off point: Laboratory Medicine entrance (if department closed main hospital reception)

What3words location:  
also.wells.nasal

**Laboratory Opening Times:****Days**

Monday – Friday  
Saturday  
Sunday  
24 hour On-Call

**Times**

08.00 – 20.00  
08.00 – 16.00  
08.00 – 16.00  
Tel: 077 3629 0284

**Laboratory Medicine Business Services Team Single point of contact**

0161 447 6878

[laboratorymedicine@spirehealthcare.com](mailto:laboratorymedicine@spirehealthcare.com)

**Laboratory Manager:**

Rachel Ward

**Laboratory Deputy Manager:**

Hazim Elhalabi

**Laboratory Contact Details:**

Telephone: 01179 804072  
Email: [BristolPathology@spirehealthcare.com](mailto:BristolPathology@spirehealthcare.com)

**Consultant's Specialty****Consultant Name****Professional Registration****Biochemistry:**

Dr A Day

GMC 3067435

**Haematology/Transfusion:**

Dr S Robinson

GMC 3659191

**Histology:**

See SPS-QM-2800 Cellular Pathology User Guide

**Microbiology/Infection Control:**

Dr Chanaka Silva

GMC 6084058

## 2.4.1.1 Spire Laboratory Medicine Bristol – Spire Cardiff spoke site



**Address:**  
Spire Cardiff Hospital  
Croescadarn Road  
Pentwyn  
Cardiff  
CF23 8XL

Laboratory located on Level 2

Sample drop off point: Main hospital reception

What3words location:  
neon.staple.belly

**Laboratory Opening Times:****Days****Times**

Doc Ref: SPS-QM-1200

Issue No: 25

Issue Date: February 2026

Issued by: National Quality Management Team

Next Review: Managed in IQM

Page 11 of 103


**THIS IS A CONTROLLED DOCUMENT. Ensure it is the current version as managed in IQM**

|                                        |                                               |                                                              |
|----------------------------------------|-----------------------------------------------|--------------------------------------------------------------|
|                                        | Monday – Friday                               | 09.00 – 17.00<br>At all other times contact Spire<br>Bristol |
| <b>Consultant's Specialty</b>          | <b>Consultant Name</b>                        | <b>Professional Registration</b>                             |
| <b>Biochemistry:</b>                   | Dr D Datta                                    | GMC 4435387                                                  |
| <b>Haematology/Transfusion:</b>        | Dr A Al-Sabah<br>Dr A Goringe                 | GMC 4062785<br>GMC 3461314                                   |
| <b>Histology:</b>                      | See SPS-QM-2800 Cellular Pathology User Guide |                                                              |
| <b>Microbiology/Infection Control:</b> | Dr Chanaka Silva                              | GMC 6084058                                                  |


## 2.4.2 Spire Laboratory Medicine Centennial Park Elstree

|                                                                                                                                                                                   |                                                                                                                                             |                                                                                                                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
|                |                                                                                                                                             | <b>Address:</b><br>Spire Pathology Services<br>Centennial Park<br>512 Centennial Park<br>Centennial Avenue<br>Elstree, Borehamwood<br>WD6 3FG |
| The Laboratory is a purpose-built site close to Spire Bushey Hospital<br>Sample drop off point: At the laboratory, out of hours with arrange via the on-call Biomedical Scientist |                                                                                                                                             | What3words location:<br>doll.descended.mixed                                                                                                  |
| <b>Laboratory Opening Times:</b>                                                                                                                                                  | <b>Days</b><br>Monday – Friday<br>Saturday<br>Sunday<br>24 hour On-Call                                                                     | <b>Times</b><br>07.30 – 20.00<br>09.00 – 17.00<br>On Call<br>Tel: 07702 563374                                                                |
| <b>Laboratory Medicine Business Services Team Single point of contact</b>                                                                                                         | 0161 447 6878                                                                                                                               | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a>                                            |
| <b>Laboratory Manager:</b>                                                                                                                                                        | Lesley Bloom                                                                                                                                |                                                                                                                                               |
| <b>Deputy Laboratory Manager</b>                                                                                                                                                  | Judith Holt & Anca Girnetz                                                                                                                  |                                                                                                                                               |
| <b>Laboratory Contact Details:</b>                                                                                                                                                | Telephone: 020 8238 6830<br>Email: <a href="mailto:\$busheypathologyhods@spirehealthcare.com">\$busheypathologyhods@spirehealthcare.com</a> |                                                                                                                                               |
| <b>Consultant's Specialty</b>                                                                                                                                                     | <b>Consultant Name</b>                                                                                                                      | <b>Professional Registration</b>                                                                                                              |
| <b>Biochemistry:</b>                                                                                                                                                              | Dr David Sinclair<br>Dr Sophy Smith                                                                                                         | CS02067<br>CS17908                                                                                                                            |
| <b>Haematology/Transfusion:</b>                                                                                                                                                   | Dr Branislav Czako<br>Dr Parag Jasani                                                                                                       | GMC 6168735<br>GMC 6037692                                                                                                                    |
| <b>Histology:</b>                                                                                                                                                                 | See SPS-QM-2800 Cellular Pathology User Guide                                                                                               |                                                                                                                                               |
| <b>Microbiology/Infection Control:</b>                                                                                                                                            | Dr Hala Kandil                                                                                                                              | GMC 56096447                                                                                                                                  |

## 2.4.2.1 Spire Laboratory Medicine Centennial Park Elstree – Spire Dunedin Spoke site

|                                                                                                                                                                         |                                |                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|----------------------------------------------------------------------------------------------|
|   |                                | <b>Address:</b><br>Spire Dunedin Hospital<br>22 Bath Road<br>Reading<br>Berkshire<br>RG1 6NS |
| Laboratory located in a separate building.<br>Sample drop off point: Main hospital reception                                                                            |                                | What3words location:<br>prone.became.tips                                                    |
| <b>Laboratory Opening Times:</b>                                                                                                                                        | <b>Days</b><br>Monday – Friday | <b>Times</b><br>09.00 – 17.00                                                                |

|                                                                    |                                                                                                                      |                                                                                                    |
|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                                                    |                                                                                                                      | At all other times contact Spire Centennial Park                                                   |
| Laboratory Medicine Business Services Team Single point of contact | 0161 447 6878                                                                                                        | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a> |
| Laboratory Contact Details:                                        | Telephone: 0118 9553459<br>Email: <a href="mailto:dunedinpat@spirehealthcare.com">dunedinpat@spirehealthcare.com</a> |                                                                                                    |
| Consultant's Specialty                                             | Consultant Name                                                                                                      | Professional Registration                                                                          |
| Biochemistry:                                                      | Dr David Sinclair                                                                                                    | CS02067                                                                                            |
| Haematology/Transfusion:                                           | See Centennial Park                                                                                                  |                                                                                                    |


| 2.4.3 Spire Laboratory Medicine Hartswood                                           |                                                                                                              |                                                                                                    |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|   |                           | <b>Address:</b><br>Spire Hartswood Hospital<br>Eagle Way<br>Brentwood<br>Essex<br>CM13 3LE         |
| Laboratory located on First Floor<br>Sample drop off point: Main hospital reception |                                                                                                              | What3words location:<br>glaze.drips.entertainer                                                    |
| Laboratory Opening Times:                                                           | <b>Days</b><br>Monday – Friday<br>Saturday<br>Sunday<br>24 hour On-Call                                      | <b>Times</b><br>08.00 – 20.00<br>09.00 – 17.00<br>On Call<br>Tel: 07768 545955                     |
| Laboratory Medicine Business Services Team Single point of contact                  | 0161 447 6878                                                                                                | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a> |
| Laboratory Manager:                                                                 | Kirolos Gabiows                                                                                              |                                                                                                    |
| Deputy Laboratory Manager:                                                          | Glenn Owusu-Moore                                                                                            |                                                                                                    |
| Laboratory Contact Details:                                                         | Telephone: 01277 266740<br>Email: <a href="mailto:HWPATH@spirehealthcare.com">HWPATH@spirehealthcare.com</a> |                                                                                                    |
| Consultant's Specialty                                                              | Consultant Name                                                                                              | Professional Registration                                                                          |
| Biochemistry:                                                                       | Dr Catherine Street<br>Dr D Collins                                                                          | CS03441<br>CS022532                                                                                |
| Haematology/Transfusion:                                                            | Dr Parag Jasani<br>Dr Branislav Czako                                                                        | GMC 6037692<br>GMC 6168735                                                                         |
| Histology:                                                                          | See SPS-QM-2800 Cellular Pathology User Guide                                                                |                                                                                                    |
| Microbiology/Infection Control:                                                     | Dr Justin Edwards                                                                                            | GMC 4529284                                                                                        |

### 2.4.3.1 Spire Laboratory Medicine Hartswood – Spire Cambridge Lea

|                                                                                                                  |                                                                                   |                                                                                                      |
|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
|                                 |  | <b>Address:</b><br>Spire Cambridge Lea Hospital<br>30 New Road<br>Impington<br>Cambridge<br>CB24 9EL |
| Laboratory located on Lower floor at the end of the ward area.<br>Sample drop off point: Main hospital reception |                                                                                   | What3words location:<br>tape.score.party                                                             |
| <b>Laboratory Opening Times</b>                                                                                  | <b>Days</b><br>Monday – Friday<br>Saturday, Sunday and out of hours               | <b>Times</b><br>09.00 – 17.00<br>Please contact Spire Hartswood Laboratory                           |
| <b>Laboratory Medicine Business Services Team Single point of contact</b>                                        | 0161 447 6878                                                                     | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a>   |
| <b>Laboratory Contact details</b>                                                                                | Telephone: 01223 266943                                                           |                                                                                                      |

### 2.4.4 Spire Laboratory Medicine Histology Centre, Manchester


|                                                                                                |                                                                                                        |                                                                                                               |
|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
|             |                     | <b>Address:</b><br>Spire Histology Centre<br>Parkway 1 Ground floor<br>Princess Road<br>Manchester<br>M14 7LU |
| Laboratory located on Ground Floor<br>Sample drop off point: Back of the building at Parkway 1 |                                                                                                        | What3words location:<br>relax.strike.remote                                                                   |
| <b>Laboratory Opening Times:</b>                                                               | <b>Days</b><br>Monday – Friday<br>Saturday                                                             | <b>Times</b><br>07.00 – 18.00<br>07.00 – 12.00                                                                |
| <b>Laboratory Medicine Business Services Team Single point of contact</b>                      | 0161 447 6878                                                                                          | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a>            |
| <b>Laboratory Manager:</b>                                                                     | Anthony Gledhill                                                                                       |                                                                                                               |
| <b>Deputy Laboratory Manager:</b>                                                              | Ashley Annesley, Jennifer Daubney & Deborah Jane Jones                                                 |                                                                                                               |
| <b>Laboratory Contact Details:</b>                                                             | Telephone: 0161 447 6777 Option 5 or 01625 585552<br>Email: manchesterhospistology@spirehealthcare.com |                                                                                                               |
| <b>Consultant Information</b>                                                                  |                                                                                                        |                                                                                                               |
|                                                                                                | See SPS-QM-2800 Cellular Pathology User Guide                                                          |                                                                                                               |

| 2.4.5 Spire Laboratory Medicine Services Leeds                                                     |                                                                                                                                                  |                                                                                                    |
|----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                   |                                                                 | <b>Address:</b><br>Spire Leeds Hospital<br>Jackson Avenue<br>Roundhay<br>Leeds<br>LS8 1NT          |
| Laboratory located on Ground Floor Roundhay Hall<br>Sample drop off point: Main hospital reception |                                                                                                                                                  | What3words location:<br>forces.marker.sadly                                                        |
| <b>Laboratory Opening Times:</b>                                                                   | <b>Days</b><br>Monday – Friday<br>Saturday<br>Sunday<br>24 hour On-Call                                                                          | <b>Times</b><br>07.00 – 20.00<br>09.00 – 16.00<br>09.00 – 13.00<br>Tel: 01132 693939               |
| <b>Laboratory Medicine Business Services Team Single point of contact</b>                          | 0161 447 6878                                                                                                                                    | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a> |
| <b>Laboratory Manager:</b>                                                                         | Caroline Smith                                                                                                                                   |                                                                                                    |
| <b>Deputy Laboratory Manager:</b>                                                                  | Richard McBain                                                                                                                                   |                                                                                                    |
| <b>Laboratory Contact Details:</b>                                                                 | Telephone: 01132 185947<br>Email: <a href="mailto:LeedsHospsharedpathology@spirehealthcare.com">LeedsHospsharedpathology@spirehealthcare.com</a> |                                                                                                    |
| Consultant's Specialty                                                                             | Consultant Name                                                                                                                                  | Professional Registration                                                                          |
| <b>Biochemistry:</b>                                                                               | Dr David Sinclair<br>Dr Sophy Smith                                                                                                              | CS02067<br>CS17908                                                                                 |
| <b>Haematology/Transfusion:</b>                                                                    | Dr R Johnson<br>Dr Richard Kelly                                                                                                                 | GMC 3244348<br>GMC 4424781                                                                         |
| <b>Histology:</b>                                                                                  | See SPS-QM-2800 Cellular Pathology User Guide                                                                                                    |                                                                                                    |
| <b>Microbiology/Infection Control:</b>                                                             | Dr Andrew Dodgson<br>Dr Alex Peel<br>Dr Kirsty Dodgson<br>Dr K Mutton                                                                            | GMC 4193845<br>GMC 6071446<br>CS08306<br>GMC 2872595                                               |


## 2.4.5.1 Spire Laboratory Medicine Leeds – Spire Hull and East Riding spoke site

|                                                                                                                 |                                                                                   |                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                |  | <b>Address:</b><br>Lowfield Road<br>Anlaby<br>East Yorkshire<br>HU10 7AZ                           |
| Laboratory located on First floor of Lowfield Building<br>Sample drop off point: Reception at Lowfield Building |                                                                                   | What3words location:<br>will.jobs.select                                                           |
| <b>Laboratory Opening Times:</b>                                                                                | <b>Days</b><br>Monday – Friday                                                    | <b>Times</b><br>08:30 – 17:00<br>At all other times contact Spire Leeds                            |
| <b>Laboratory Medicine Business Services Team Single point of contact</b>                                       | 0161 447 6878                                                                     | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a> |
| <b>Laboratory Contact Details:</b>                                                                              | Telephone: 01482 660251                                                           |                                                                                                    |
| <b>Consultant's Specialty</b>                                                                                   | <b>Consultant Name</b>                                                            | <b>Professional Registration</b>                                                                   |
| <b>Biochemistry:</b>                                                                                            | Dr David Sinclair<br>Dr Sophy Smith                                               | CS02067<br>CS17908                                                                                 |
| <b>Haematology/Transfusion:</b>                                                                                 | Dr Richard Kelly                                                                  | GMC 4424781                                                                                        |

## 2.4.5.2 Spire Laboratory Medicine Leeds – Spire Washington spoke site

|                                                                                                                     |                                                                                     |                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                  |  | <b>Address:</b><br>Picktree Lane<br>Rickleton<br>Washington, Tyne & Wear<br>NE38 9JZ               |
| Located at the bottom of the OPD corridor Opposite Pharmacy Dept.<br>Sample drop off point: Main hospital reception |                                                                                     | What3words location:<br>code.polite.slip                                                           |
| <b>Laboratory Opening Times</b>                                                                                     | <b>Days</b><br>Monday – Friday<br>Saturday, Sunday and out of hours                 | <b>Times</b><br>08.30 – 16.30<br>Covered by QE Gateshead                                           |
| <b>Laboratory Medicine Business Services Team Single point of contact</b>                                           | 0161 447 6878                                                                       | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a> |
| <b>Laboratory Contact Details:</b>                                                                                  | Telephone: 0191 415 1182<br>Email: LeedsHospsharedpathology@spirehealthcare.com     |                                                                                                    |

| 2.4.6 Spire Laboratory Medicine Manchester                                        |                                                                                                                                                                                            |                                                                                                                               |
|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
|  |                                                                                                          | <b>Address:</b><br>Spire Manchester Hospital<br>170 Barlow Moor Road<br>Didsbury<br>Manchester<br>M20 2AF                     |
|                                                                                   |                                                                                                                                                                                            | <b>Main Laboratory and Microbiology located on the Second floor.</b><br><b>Sample drop off point: Main hospital reception</b> |
| <b>Laboratory Opening Times:</b>                                                  | <b>Days</b><br>Monday – Friday<br>Saturday<br>Sunday<br>24 hour On-Call                                                                                                                    | <b>Times</b><br>07.00 – 20.00<br>08.00 – 18.00<br>08dig.00 – 18.00<br>Tel: 0161 447 6777                                      |
| <b>Laboratory Medicine Business Services Team Single point of contact</b>         | 0161 447 6878                                                                                                                                                                              | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a>                            |
| <b>Laboratory Manager:</b>                                                        | Anthony Gledhill                                                                                                                                                                           |                                                                                                                               |
| <b>Deputy Laboratory Manager:</b>                                                 | Helen Hesketh & Mike Nicholls                                                                                                                                                              |                                                                                                                               |
| <b>Laboratory Contact Details:</b>                                                | Telephone: 0161 447 6777<br>Fax: 0161 447 6775<br>Email:<br><a href="mailto:manchesterhosppathologycustomers@spirehealthcare.com">manchesterhosppathologycustomers@spirehealthcare.com</a> |                                                                                                                               |
| Consultant's Specialty                                                            | Consultant Name                                                                                                                                                                            | Professional Registration                                                                                                     |
| <b>Biochemistry:</b>                                                              | Dr David Sinclair<br>Dr Sophy Smith                                                                                                                                                        | CS02067<br>CS17908                                                                                                            |
| <b>Haematology/Transfusion:</b>                                                   | DR Rowena Thomas-Dewing                                                                                                                                                                    | C5207050                                                                                                                      |
| <b>Histology:</b>                                                                 | See SPS-QM-2800 Cellular Pathology User Guide                                                                                                                                              |                                                                                                                               |
| <b>Microbiology/Infection Control / Virology:</b>                                 | Dr Andrew Dodgson<br>Dr Alex Peel<br>Dr Kirsty Dodgson<br>Dr K Mutton                                                                                                                      | GMC 4193845<br>GMC 6071446<br>CS08306<br>GMC 2872595                                                                          |

| 2.4.7 Spire Laboratory Medicine Murrayfield Edinburgh                                                                   |                                                                                                                         |                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
|                                        |                                        | <b>Address:</b><br>Spire Murrayfield Edinburgh Hospital<br>122 Corstorphine Road<br>Edinburgh<br>EH12 6UD |
|                                                                                                                         |                                                                                                                         | <b>What3words location:</b><br>swaps.good.shops                                                           |
| Laboratory is located left of the main reception on the ground floor.<br>Sample drop off point: Main hospital reception |                                                                                                                         |                                                                                                           |
| <b>Laboratory Opening Times:</b>                                                                                        | <b>Days</b><br>Monday – Friday<br>Saturday<br>Sunday<br>24 hour On-Call                                                 | <b>Times</b><br>08.00 – 18.00<br>09.00 – 13.00<br>On call service<br>Tel: 0131 334 0363                   |
| <b>Laboratory Medicine Business Services Team</b><br><b>Single point of contact</b>                                     | 0161 447 6878                                                                                                           | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a>        |
| <b>Laboratory Manager:</b>                                                                                              | Symon Lockhart                                                                                                          |                                                                                                           |
| <b>Deputy Laboratory Manager:</b>                                                                                       | Mark Dorrance                                                                                                           |                                                                                                           |
| <b>Laboratory Contact Details:</b>                                                                                      | Telephone: 0131 316 2521<br>Email: <a href="mailto:edpathology@spirehealthcare.com">edpathology@spirehealthcare.com</a> |                                                                                                           |
| Consultant's Specialty                                                                                                  | Consultant Name                                                                                                         | Professional Registration                                                                                 |
| <b>Biochemistry:</b>                                                                                                    | Dr Sara Jenks                                                                                                           | GMC 6160503                                                                                               |
|                                                                                                                         | Dr Jonathan Malo                                                                                                        | GMC 7134600                                                                                               |
| <b>Haematology/Transfusion:</b>                                                                                         | Dr Mark Drummond                                                                                                        | GMC 3687657                                                                                               |
|                                                                                                                         | Dr Edward Fitsimmons                                                                                                    | GMC 1349832                                                                                               |
| <b>Histology:</b>                                                                                                       | See SPS-QM-2800 Cellular Pathology User Guide                                                                           |                                                                                                           |
| <b>Microbiology/Infection Control:</b>                                                                                  | Dr David Griffiths                                                                                                      | GMC 6096477                                                                                               |
|                                                                                                                         | Dr Simon Dewar                                                                                                          | GMC 7042321                                                                                               |
|                                                                                                                         | Dr Ian Laurenson                                                                                                        | GMC 3204869                                                                                               |

## 2.4.8 Spire Laboratory Medicine Nottingham



**Address:**  
Spire Nottingham Hospital  
Pathology Department  
Tollerton Lane  
Tollerton  
Nottingham  
NG12 4GA

Laboratory located at the end of the Administration wing on the ground floor  
Sample drop off point: Pathology entrance to Spire Nottingham hospital. At the rear of the hospital, on the left-hand side of the building when looking from the road. Out of hours to main hospital reception

What3words location:  
army.could.shops

**Laboratory Opening Times:****Days**

Monday – Friday  
Saturday  
Sunday  
24 hour On-Call

**Times**

07.30 – 20.00  
09.00 – 17.00 on-call thereafter  
On call service  
Via Spire Nottingham Switchboard. 0115 937 7800

**Laboratory Medicine Business Services Team**  
Single point of contact

0161 447 6878

[laboratorymedicine@spirehealthcare.com](mailto:laboratorymedicine@spirehealthcare.com)

**Laboratory Manager:**

Priscilla Patel

**Deputy Laboratory Manager:**

Priyanka Desai

**Laboratory Contact Details:**

Telephone: 0115 937 7808  
Email: [nottinghampathology@spirehealthcare.com](mailto:nottinghampathology@spirehealthcare.com)

**Consultant's Specialty**

**Consultant Name**

**Professional Registration**

**Biochemistry:**

Dr P Prinsloo

GMC 4135474

**Haematology/Transfusion:**

Dr H Qureshi

GMC 4266493

**Histology:**


See SPS-QM-2800 Cellular Pathology User Guide

**Microbiology/Infection Control:**

Dr Nikunj Mahida

GMC 6143862

## 2.4.8.1 Spire Laboratory Medicine Nottingham – Spire Leicester spoke site




**Address:**  
Spire Leicester Hospital  
Gartree Road  
Oadby  
Leicester  
LE2 2FF

Laboratory located on first floor past Oncology  
Sample drop off point: Main hospital reception

What3words location:  
cute.person.upset


|                                                                              |                                                                                                                                        |                                                                                                    |
|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| <b>Laboratory Opening Times:</b>                                             | <b>Days</b><br>Monday – Friday                                                                                                         | <b>Times</b><br>09.00 – 17.00<br>At all other times contact Spire Nottingham                       |
| <b>Laboratory Medicine Business Services Team</b><br>Single point of contact | 0161 447 6878                                                                                                                          | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a> |
| <b>Laboratory Contact Details:</b>                                           | Telephone: 01162 653018<br>Email: <a href="mailto:nottinghampathology@spirehealthcare.com">nottinghampathology@spirehealthcare.com</a> |                                                                                                    |
| <b>Consultant's Specialty</b>                                                | <b>Consultant Name</b>                                                                                                                 | <b>Professional Registration</b>                                                                   |
| <b>Biochemistry:</b>                                                         | Dr J Falconer Smith                                                                                                                    | GMC 1480841                                                                                        |
| <b>Haematology/Transfusion:</b>                                              | Dr H Qureshi<br>Dr M Martin                                                                                                            | GMC 4266493<br>GMC 4418991                                                                         |
| <b>Histology:</b>                                                            | See SPS-QM-2800 Cellular Pathology User Guide                                                                                          |                                                                                                    |
| <b>Microbiology/Infection Control:</b>                                       | Dr D Modha<br>Dr S Bukhari                                                                                                             | GMC 3615780<br>GMC 4062802                                                                         |

| 2.4.9 Spire Laboratory Medicine Parkway                                                                                                                                  |                                                                                                                                   |                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                   | <b>Address:</b><br>Spire Parkway Hospital<br>1 Damson Parkway<br>Solihull<br>West Midlands<br>B91 2PP |
| Laboratory Location: Outpatient suite ground floor<br>Sample drop off point: Report at reception then be directed directly to Pathology                                  |                                                                                                                                   | What3words location:<br>pizza.nest.jokes                                                              |
| <b>Laboratory Opening Times</b>                                                                                                                                          | <b>Days</b><br>Monday – Friday<br>Saturday & Sunday<br>24 hour On-Call                                                            | <b>Times</b><br>08.00 – 20.00<br>09.00 – 17.00<br>Tel: 07860 895953                                   |
| <b>Laboratory Medicine Business Services Team</b><br>Single point of contact                                                                                             | 0161 447 6878                                                                                                                     | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a>    |
| <b>Laboratory Manager:</b>                                                                                                                                               | Peter Manning                                                                                                                     |                                                                                                       |
| <b>Deputy Laboratory Manager:</b>                                                                                                                                        | Afrin Mohiuddin                                                                                                                   |                                                                                                       |
| <b>Laboratory Contact Details:</b>                                                                                                                                       | Telephone: 0121 704 5564<br>Email: <a href="mailto:Parkwaypathology@spirehealthcare.com">Parkwaypathology@spirehealthcare.com</a> |                                                                                                       |
| <b>Consultant's Specialty</b>                                                                                                                                            | <b>Consultant Name</b>                                                                                                            | <b>Professional Registration</b>                                                                      |
| <b>Biochemistry:</b>                                                                                                                                                     | Dr Sinclair                                                                                                                       | CS02067                                                                                               |
| <b>Haematology /Transfusion:</b>                                                                                                                                         | Dr Kartsios                                                                                                                       | GMC 6162681                                                                                           |
| <b>Histology</b>                                                                                                                                                         | See SPS-QM-2800 Cellular Pathology User Guide                                                                                     |                                                                                                       |
| <b>Microbiology/Infection Control:</b>                                                                                                                                   | Dr Nikunj Mahida                                                                                                                  | GMC 6143862                                                                                           |

## 2.4.9.1 Spire Laboratory Medicine Parkway - Spire Little Aston spoke site


|                                                                                                              |                                                                                                                                           |                                                                                                          |
|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
|                             |                                                          | <b>Address:</b><br>Spire Little Aston Hospital<br>Little Aston Hall Drive<br>Sutton Coldfield<br>B74 3UP |
| Laboratory located on the First Floor opposite the Theatre dept.<br>Sample drop off point: At the laboratory |                                                                                                                                           | What3words location:<br>royal.maybe.wedge                                                                |
| <b>Laboratory Opening Times:</b>                                                                             | <b>Days</b><br>Monday – Friday<br>Saturday<br>Sunday<br>24 hour On-Call                                                                   | <b>Times</b><br>09.00 – 17.00<br>09:00 – 12:00<br>On call only<br>Tel: 07860 895953                      |
| <b>Laboratory Medicine Business Services Team Single point of contact</b>                                    | 0161 447 6878                                                                                                                             | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a>       |
| <b>Laboratory Contact Details:</b>                                                                           | Telephone: 0121 580 7237<br>Email: <a href="mailto:littleastonpathology@spirehealthcare.com">littleastonpathology@spirehealthcare.com</a> |                                                                                                          |
| <b>Consultant's Specialty</b>                                                                                | <b>Consultant Name</b>                                                                                                                    | <b>Professional Registration</b>                                                                         |
| <b>Haematology/Transfusion:</b>                                                                              | Dr Matthew Lumley<br>Dr Vinayak Tandon                                                                                                    | GMC 3097113<br>GMC 5198554                                                                               |
| <b>Histopathology</b>                                                                                        | See SPS-QM-2800 Cellular Pathology User Guide                                                                                             |                                                                                                          |
| <b>Microbiology</b>                                                                                          | Dr Nikunj Mahida                                                                                                                          | GMC 6143862                                                                                              |

## 2.4.10 Spire Laboratory Medicine Southampton

|                                                                                                                |                                                                                     |                                                                                               |
|----------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
|                             |  | <b>Address:</b><br>Spire Southampton Hospital<br>Chalybeate Close<br>Southampton,<br>SO16 6UY |
| Laboratory is located on the first floor next to outpatients<br>Sample drop off point: Main hospital reception |                                                                                     | What3words location:<br>hike.span.neck                                                        |
| <b>Laboratory Opening Times</b>                                                                                | <b>Days</b><br>Monday – Friday<br>Saturday<br>Sunday<br>24 hour On-Call             | <b>Times</b><br>07.00 – 22.00<br>08.00 – 16.00<br>09.00-17.00<br>Tel: 02380 775544            |

|                                                                           |                                                                                                                              |                                                                                                    |
|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| <b>Laboratory Medicine Business Services Team Single point of contact</b> | 0161 447 6878                                                                                                                | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a> |
| <b>Laboratory Manager:</b>                                                | Rosie Burns                                                                                                                  |                                                                                                    |
| <b>Deputy Laboratory Manager:</b>                                         | Vacant                                                                                                                       |                                                                                                    |
| <b>Laboratory Contact Details:</b>                                        | Telephone: 02380 914447<br>Email: <a href="mailto:spire.southamptonpathology@nhs.net">spire.southamptonpathology@nhs.net</a> |                                                                                                    |
| <b>Consultant's Specialty</b>                                             | <b>Consultant Name</b>                                                                                                       | <b>Professional Registration</b>                                                                   |
| <b>Biochemistry:</b>                                                      | Dr David Sinclair<br>Dr Sophy Smith                                                                                          | CS02067<br>CS17908                                                                                 |
| <b>Haematology/Transfusion:</b>                                           | Dr Matthew Jenner<br>Dr Rashid Kazmi<br>Dr Srin Narayanan<br>Dr Seonaid Pye                                                  | GMC 4442130<br>GMC 4496146<br>GMC 6032703<br>GMC 4200615                                           |
| <b>Histology:</b>                                                         | See SPS-QM-2800 Cellular Pathology User Guide                                                                                |                                                                                                    |
| <b>Microbiology/Infection Control:</b>                                    | Dr Matthew Dryden                                                                                                            | GMC 2847324                                                                                        |

#### 2.4.10.1 Spire Laboratory Medicine Southampton - Spire Portsmouth spoke site

|                                                                                                      |                                                           |                                                                                                    |                                                                                       |
|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
|                   |                                                           |                 | <b>Address:</b><br><br>Spire Portsmouth Hospital<br>Bartons Road<br>Havant<br>PO9 5NP |
| Laboratory located 1st floor adjacent to theatres.<br>Sample drop off point: Main hospital reception |                                                           |                                                                                                    | What3words location:<br>drove.major.play                                              |
| Laboratory Opening Times                                                                             | Days<br>Monday – Friday                                   | Times<br>09.00 – 17.00<br>At all other times contact Spire Southampton                             |                                                                                       |
| Laboratory Medicine<br>Business Services Team<br>Single point of contact                             | 0161 447 6878                                             | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a> |                                                                                       |
| Laboratory Contact Details:                                                                          | Telephone: 02392 456 030                                  |                                                                                                    |                                                                                       |
| Consultant's Specialty                                                                               | Consultant Name                                           | Professional Registration                                                                          |                                                                                       |
| Biochemistry:                                                                                        | Dr David Sinclair<br>Dr Sophy Smith                       | CS02067<br>CS17908                                                                                 |                                                                                       |
| Haematology/Transfusion:                                                                             | Dr Mary Ganczakowski<br>Dr C James<br>Dr Charles Alderman | GMC 2649193<br>GMC 2647775<br>GMC 6077560                                                          |                                                                                       |
| Histology:                                                                                           | See SPS-QM-2800 Cellular Pathology User Guide             |                                                                                                    |                                                                                       |
| Microbiology/Infection<br>Control:                                                                   | Dr H Chesterfield<br>Dr R Porter                          | GMC 4339429<br>GMC 4725987                                                                         |                                                                                       |

## 2.4.11 Spire Laboratory Medicine St Anthony's

|                                                                                                           |                                                                                    |                                                                                                         |
|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
|                          |  | <b>Address:</b><br>Spire St Anthony's Hospital<br>801 London Road<br>Cheam, Sutton<br>Surrey<br>SM3 9DW |
| Laboratory is located in the main ground floor corridor<br>Sample drop off point: Main hospital reception |                                                                                    | What3words location:<br>skips.slug.frame                                                                |
| <b>Laboratory Opening Times</b>                                                                           | Days<br>Monday – Friday<br>Saturday<br>Sunday and Bank Holidays<br>24 hour On-Call | Times<br>08.00 – 20.00<br>09.00 – 16.00<br>09:00 – 13:00<br>Tel: 07921 693673 & 07821 645617            |
| <b>Laboratory Medicine Business Services Team Single point of contact</b>                                 | 0161 447 6878                                                                      | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a>      |
| <b>Laboratory Manager:</b>                                                                                | Elke Stevenson                                                                     |                                                                                                         |
| <b>Deputy Laboratory Manager:</b>                                                                         | David Stokes                                                                       |                                                                                                         |
| <b>Laboratory Contact Details:</b>                                                                        | Telephone: 02083354520<br>Email: stanthonyspathology@spirehealthcare.com           |                                                                                                         |
| <b>Consultant's Specialty</b>                                                                             | <b>Consultant Name</b>                                                             | <b>Professional Registration</b>                                                                        |
| <b>Biochemistry:</b>                                                                                      | Dr Nikhil Johri                                                                    | C6065589                                                                                                |
| <b>Haematology/Transfusion:</b>                                                                           | Dr Simon Stern                                                                     | C3189836                                                                                                |
|                                                                                                           | Dr Pawel Kaczmarek                                                                 | C5201889                                                                                                |
|                                                                                                           | Dr Gleb Ivanov                                                                     | C5197866                                                                                                |
|                                                                                                           | Dr Caroline Ebdon                                                                  | C6078359                                                                                                |
| <b>Microbiology/Infection Control:</b>                                                                    | Dr Jim Stephenson                                                                  | C2656087                                                                                                |

## 2.4.2.2 Spire Laboratory Medicine St Anthony's – Spire Montefiore Spoke site

|                                                                                                                                                                                                                                                     |                                                                                      |                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|------------------------------------------------------------------------|
|                                                                                                                                                                  |  | <b>Address:</b><br>2 Montefiore Road<br>Hove<br>East Sussex<br>BN3 1RD |
| Located at The Montefiore Hospital, Basement<br>Sample drop off point: Use the Side Entrance in the car park of The Montefiore Hospital, Montefiore Rd. Press call point to speak to Reception/Ward; ask for Pathology and await someone to collect |                                                                                      | What3words location:<br>rises.rents.arch                               |

## LABORATORY MEDICINE SERVICE USERS GUIDE

|                                                                           |                                               |                                                                                                    |
|---------------------------------------------------------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------------------|
| <b>Laboratory Opening Times</b>                                           | <b>Days</b><br>Monday – Friday                | <b>Times</b><br>08.00 – 18.00<br>At all other times contact Spire St Anthony's                     |
| <b>Laboratory Medicine Business Services Team Single point of contact</b> | 0161 447 6878                                 | <a href="mailto:laboratorymedicine@spirehealthcare.com">laboratorymedicine@spirehealthcare.com</a> |
| <b>Laboratory Contact Details:</b>                                        | Telephone: 01273 828124                       |                                                                                                    |
| <b>Consultant's Specialty</b>                                             | <b>Consultant Name</b>                        | <b>Professional Registration</b>                                                                   |
| <b>Biochemistry:</b>                                                      | Dr David Sinclair                             | CS02067                                                                                            |
| <b>Haematology/Transfusion:</b>                                           | Dr Tim Corbett<br>Dr Tim Chevassut            | C3480290<br>C4032117                                                                               |
| <b>Histology:</b>                                                         | See SPS-QM-2800 Cellular Pathology User Guide |                                                                                                    |
| <b>Microbiology/Infection Control:</b>                                    | Dr Sunil Sharma                               | C4214623                                                                                           |

### 3.0 Laboratory Medicine Quality Policy

Spire Laboratory Medicine is committed to providing the highest quality pathology service to all our customers, across all disciplines. To this end and where applicable our laboratories are registered with UKAS (standards ISO 15189) and the Medicines and Healthcare products Regulatory Agency (MHRA). The scope of services provided by Spire Laboratory Medicine is appropriate to suit the purpose of the organisation and includes biochemistry including special chemistry, blood transfusion, coagulation, cytology, endocrinology, haematology, histology, microbiology and virology. There are contracts in place to ensure all other requests for sample testing are carried out by accredited laboratories.

- Spire Laboratory Medicine keeps the needs of our clients at the heart of all we do as measure through our user survey, internal audit and external quality assessment
- Spire Laboratory Medicine operates a quality management system to integrate the organisation's procedures, processes and resources which include a commitment to good professional practice, examinations that are fit for intended use, and are compliant with ISO15189. Quality objectives and plans are set to implement this quality policy and achieve continual quality improvement. This provides a framework for establishing and reviewing quality objectives.
- Spire Laboratory Medicine ensures that all staff are familiar with and have access to the Quality Policy, Quality Manual and Standard Operating Procedures, helping to ensure best practice. These documents undergo review to ensure continuing suitability.
- Good professional practice is also supported through appropriate staff recruitment, training and by encouraging and facilitating continuous professional development.
- Spire Laboratory Medicine is committed to ensuring the health, safety and welfare of all staff and visitors through Good Laboratory Practice
- Spire Laboratory Medicine commits to comply with relevant environmental legislation through departmental audit, management review, training and adherence to Standard Operating Procedures
- Spire Laboratory Medicine will comply with standards set by UKAS ISO 15189, CQC, HIS, HIW and The Blood Safety and Quality Regulations
- Spire Laboratory Medicine is committed to the proper procurement and maintenance of such equipment and other resources as are needed for the provision of the service.
- Spire Laboratory Medicine ensures the collection, transport and handling of all specimens in such a way as to ensure the correct performance of laboratory examinations.
- Spire Laboratory Medicine commits to the use of examination procedures that will ensure the highest achievable quality of all tests performed.
- Spire Laboratory Medicine ensures reporting results of examinations in ways which are timely, confidential, accurate and clinically useful.
- Spire Laboratory Medicine is committed to the assessment of customer satisfaction, in addition to internal audit, external quality assessment, identification and control of nonconformities to produce continual quality improvement ref: SPS-QM-0800
- Where Spire Laboratory Medicine operates split site services for a particular discipline, the responsibilities shall be documented in the quality manual

### Our vision

To be recognised as a world class healthcare business.

### Our mission

To bring together the best people who are dedicated to developing excellent clinical environments and delivering the highest quality patient care.

### Our values

Caring is our passion  
Succeeding and celebrating together  
Driving clinical excellence  
Doing the right thing  
Delivering on our promises  
Keeping it simple

### Our Purpose

Making a positive difference to people's lives through outstanding personalised care

## 4.0 Quality assurance

All Spire Laboratory Medicine departments participate in National and Local Quality Assurance Schemes. Our performance in each speciality is immediately available for inspection upon request. Each discipline is overseen professionally by a consultant who monitors both the internal and external quality control for the relevant department. The Consultant is also available to give advice on the interpretation of results and clinical recommendations. Spire Laboratory Medicine departments aim to provide a personal, high-quality service in terms of technical quality and clinical effectiveness.

## 5.0 Reports

All urgent, grossly abnormal or clinically significant results are reported by telephone in line with RCPATH guidelines. The communication of critical and unexpected pathology results v1.

All reference ranges are quoted on the printed report against each test result. Any results outside of the normal reference range are highlighted on the report.

Reference ranges are from harmonised ranges where possible. When this is not possible, they are taken from the manufacturers package inserts for Biochemistry and from Dacie and Lewis 12<sup>th</sup> Edition for Haematology.

All clinical interpretation on the report is by a named Consultant who has practicing rights for Spire Hospitals. The exception is referred samples to outside providers when clinical interpretation has been written by the referred laboratory Consultant of choice.

Any results received from a laboratory other than Spire will state where the results were received from.

Reports once validated by laboratory staff are available for viewing on the Cyberlab facility. This facility is available upon request to Spire IT services.

Unless a local agreement is in place for reports to be printed in exceptional circumstances, all reports should be accessed via Cyberlab.

## 6.0 Request forms

See box below for request form completion.

The form must be labelled as **URGENT** if required. These samples will be prioritised by the laboratory and printed results will be available as soon as possible. If results need to be telephoned, please indicate this on the request form.

| Essential                                                                                                                                                                                                                                                                                                                                                                                                  | Desirable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>• Hospital number</li> <li>• Patient's full name or unique coded identifier</li> <li>• Date of birth</li> <li>• Gender</li> <li>• Patient's location and destination for report</li> <li>• Patient's Consultant, GP or name of requesting practitioner</li> <li>• Clinical information for histology &amp; Cytology</li> <li>• Investigation(s) required</li> </ul> | <ul style="list-style-type: none"> <li>• Clinical information including relevant medication and travel history. HSE require the following to be included:               <ul style="list-style-type: none"> <li>○ recent travel history</li> <li>○ consumption of unpasteurised milk or cheese products</li> <li>○ contact with imported animals</li> <li>○ other relevant clinical symptoms or information</li> </ul> </li> <li>• Date and time sample collected (which is sometimes essential dependant on the examination being carried out)</li> <li>• Patient's address including postcode</li> <li>• Practitioners contact number (bleep or extension)</li> <li>• Type of primary sample and where relevant the anatomical site of origin (essential for histology specimens and microbiology samples also if it is left or right-if appropriate)</li> <li>• Account number</li> <li>• Identity of person taking sample</li> </ul> |

There are five different request forms:

- Collection of multiple samples from the same patient must be labelled to ensure unequivocal identification
- Histology and non-gynaecological cytology request form must also include the nature of specimen.
- Cervical cytology request form. All boxes on the request form should be completed.
- Combined request form for Haematology, Biochemistry, Endocrinology and Microbiology with a separate box for other tests.
- Transfusion request forms. All boxes must be completed, and request form signed by the requesting clinician.
- Immunology and allergy testing request form – available from any Spire Laboratory and in the Laboratory Medicine section of clinical specialities on the clinical intranet.
- Note: Some external customers may have bespoke request forms

### 6.1 Electronic requesting of pathology tests

Requests can be made electronically using Hospital Management System (HMS) Ordercoms. The guide to use this can be found in the pathology section of the Clinical Intranet <https://intranet.spirehealthcare.net/clinical-intranet/clinical-specialities/laboratory-medicine/>

## 7.0 Specimen collection

Observe any dietary requirements and any other appropriate preparatory instructions before performing investigations. Always use the correct container as specified in the test index. If in doubt as to requirements, please contact the laboratory. Never decant a specimen from a wrong tube into the correct tube. Check integrity of specimen container and expiry date, if relevant, prior to use. Gently mix blood-filled, anticoagulant tubes by inversion. All clotted samples must be centrifuged before refrigeration.

### Splitting primary patient samples

Where possible avoid having to split the primary sample, however there are instances where this may be required e.g. a urine sample for Biochemistry and Microbiology. If this is the case:

- The primary sample must not have been taken into a primary container with a preservative.
- Ensure there is sufficient material for both tests
- Where possible re-print the Ordercomms label for use on the secondary container
- When handwriting, please follow the guidance in section 8.0

### Microbiology sample collection

See Appendix 5

### Histopathology sample collection and labelling

Samples which have been collected for Histopathology must be taken into formalin, unless there has been prior discussion with the processing laboratory e.g. Lymph nodes.

All samples must be labelled as per section 8.0 below and must contain information of the site and source of the sample. Where multiple samples are taken e.g. in a series, each container must have a unique identification

See working instructions SPS-GP-WI1420 - Histology Sample Preparation

### Specimens not handled by Spire Laboratory Medicine departments

Specimens from patients who are or may be infected with the following will not be handled or referred by this laboratory:

- Simian Herpes Virus
- Lassa Fever Virus
- Marburg Virus
- Rabies Virus
- Smallpox Virus
- Ebola Virus
- Zika Virus
- MERS-CoV virus
- TBE virus (Tick-borne encephalitis virus)

If you have strong clinical suspicion of infection with any of the above agents, contact your local NHS specialist infection team and refer to an NHS hospital with appropriate care facilities.

The following genetics testing cannot be managed via Spire Laboratory Medicine

Huntington's Presymptomatic Testing (Predictive)  
 Familial adenomatous polyposis coli (FAP) and MUTYH-associated polyposis (MAP)  
 Fragile X Syndrome  
 Haemophilia A and Haemophilia B  
 Mitochondrial Disease

## 8.0 Specimen labelling

All specimens **MUST** be labelled, following collection and before leaving the patient. Samples will be rejected if they do not contain Essential information

| Essential                                                                                                                                                                                                                                                                                                                                                | Desirable                                                                                                                                                                                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>Hospital Number* (if not available the first line of the address should be included. *Needlestick injuries and Occupational Health requests are the exception to this)</li> <li>Patients full name or unique coded identifier (first name and surname counted as 2 identifiers)</li> <li>Date of Birth</li> </ul> | <ul style="list-style-type: none"> <li>Date and time of collection (essential for Transfusion specimens)</li> <li>Nature of sample, including qualifying details, e.g., left, distal etc. especially if more than one sample per request is submitted</li> <li>Signature of phlebotomist (essential for transfusion specimens)</li> </ul> |

### 8.1 Blood transfusion specimens

The patient's full name, date of birth, hospital number and date and time of collection must be given on both specimen and form. In addition, the sample must be signed by the phlebotomist. The form must be signed by a clinician and the date, and time of sampling must be completed with the name of the person taking the blood. The date and time of the operation and details of the procedure must also be given. In accordance with national guidelines, the address of the patient must be given on the request form. **DO NOT USE PRINTED LABELS ON SAMPLE**

The timing of sample collection is essential for blood product requests to conform to BCSH transfusion guidelines. This is detailed on the reverse of the transfusion request form.

### 8.2 High Risk Specimens

The following specimens are classified as "High Risk" or "Hazardous" samples. The form and sample should be marked clearly as such with a "Danger of Infection label". The sample must be contained in a plastic bag. The request must be placed in the separate pocket and not in the same compartment as the sample.

- (1) Specimens from patients known to be Hepatitis B, Hepatitis C, HIV positive or Covid-19 positive or symptomatic for Covid-19.
- (2) Specimens from renal unit patients who have not been screened for the above.
- (3) Specimens from patients with infective or suspected infective diseases of the liver.
- (4) Drug addicts.
- (5) Specimens from patients who have or may have:

Brucellosis  
Tuberculosis  
Typhoid/Paratyphoid

## 9.0 Transportation of Samples to the Laboratory

There are four ways in which samples can be sent to the laboratory

- Surface transport - Samples are brought to the laboratory by hospital employed colleagues
- Surface transport of samples between sites – internal and external courier services or taxis.
- Postal services – Royal mail, HAYs DX, or other contractors
- Pneumatic air tube

All contracts with external customers shall have an SLA which details how the samples shall be transported to the laboratory

All necessary steps shall be undertaken to ensure the integrity of the samples and the safety of personnel, irrespective of the mode of transport delivery. The WHO guidance on Regulations for the Transport of Infectious Substances 2011-2012 is implemented.

It is important that samples are sent to the laboratory within a time frame appropriate to the nature of the requested examinations. All specimens should be transported to the laboratory at the earliest opportunity to preserve the integrity of the sample. There are some samples which require special handling after collection e.g. some samples which need to be brought to the laboratory immediately, some which need to be kept at 37°C, some which need to be transported on ice and some which need to be kept in the dark (samples covered with aluminium foil). All the sample collection criteria are available in Appendix 2 – Laboratory Test repertoire.

The Spire Healthcare transport policy (WM02) is available on the clinical intranet. A guide to ordering external courier can be found here:

<https://citysprint.my.salesforce-sites.com/l?id=diFcb>

### 9.1 Classification of infectious substances for transportation

For the purpose of transportation, infectious substances are defined by the WHO and divided for the purpose of transport into two categories, Infectious substances category A and infectious substances category B.

- **Infectious substances category A** – An infectious substance which is transported in a form that, when exposure to it occurs, it can cause permanent disability, life threatening or fatal disease in otherwise healthy individuals. Should Category A infectious substances be isolated (e.g. Mycobacterium tuberculosis, Shigella dysenteriae type 1) they are immediately transported to a referral laboratory where any further work will be carried out.
- **Infectious substances category B** – An infectious sample which does not meet the criteria for inclusion in category A is assigned to category B. This category is assigned by the WHO to UN3373 Biological Substance category B. All specimens transported by Spire Laboratory Medicine departments are treated in this category.

### 9.2 Packaging and labelling for transport

The transport of all pathology specimens external to the hospital requires triple packaging which consists of three layers. Patient confidentiality must always be maintained.

- Primary container – a labelled primary watertight, leak-proof specific container, which holds the specimen e.g., blood tube, histology pot, microbiology swab etc.
- Secondary receptacle – a secondary watertight, leak-proof container to protect the primary specimen, usually in the form of a biohazard bag attached to the request form, a snap-lock plastic bag or a further screw lid container. Several primary specimens may be placed in a single secondary receptacle providing sufficient additional absorbent material is used to absorb all fluid if there is a breakage.
- Outer packaging – Secondary receptacles are placed in an outer package of adequate strength and size which must have a secure locking mechanism. Outer packaging is intended to protect the contents from physical damage during transit. The outer package must be labelled with the UN3373 BIOLOGICAL SUBSTANCE CATEGORY B labelling system.
- The outer packaging must be clearly labelled with the destination and with the name and address of the sending laboratory.
- If a referral laboratory receives specimens which have not satisfied the packaging requirements above or the sample has been incorrectly packaged which has compromised the integrity of the sample and /or the safety of the carrier, the general public and the laboratory staff. The sender shall be contacted immediately and informed about the measures to be taken to eliminate recurrence. The incident shall be reported as an adverse incident on DCIQ
- Ensure that urgent samples are not held for the next transport run but are sent straight away via another method, agreed locally

### 9.3 Pneumatic tube system

Some Spire hospitals have a pneumatic tube system installed which is used for the transport of specimens. Samples that are double packed as above and placed in the pneumatic air tube are considered to be triple packed. It is recommended that certain samples should not be sent using the pneumatic air tube system.

- If the specimen is irreplaceable e.g., CSF samples
- The specimen is in a glass container (Blood Cultures, ESR etc)
- The specimen is in a container that contains a fluid that is unsuitable e.g., histology specimens in formalin solutions.

## 10.0 Patient consent & sharing of information

Consent is required from a patient regardless of the treatment, which includes blood tests. The principle of consent is an important part of medical ethics and the international human rights law. For consent to be valid, it must be voluntary and informed, and the person who consent must have the capacity to make the decision.

Consent should be given to the healthcare professional directly responsible for the person's current treatment, such as the nurse arranging a blood test, or the surgeon planning an operation. Tacit consent can be inferred when a patient presents with a request form and submits to the procedure.

Consent may also be given:

- verbally
- non-verbally, for example, raising a hand to indicate they are happy for a nurse to take a blood sample.
- In writing, by signing a Spire Healthcare consent form (available via the supplies department, but can also be found on wards and outpatients departments)

It may be appropriate to disclose clinical information and family history to relevant healthcare professionals, where referrals are needed, which relies on the information given for diagnosis (e.g. for interpreting genetic examination results).

Note: Patient samples or material may be anonymised and used internally for the purpose of quality control, this may include verification of instrumentation.

When the laboratory is required by law or authorized by contractual arrangements to release confidential information, the patient concerned shall be notified of the information released, unless prohibited by law.

Information about the patient from a source other than the patient (e.g. complainant, regulator) shall be kept confidential by the laboratory. The identity of the source shall be kept confidential by the laboratory and shall not be shared with the patient, unless agreed by the source.

### 11.0 Instructions for the preparation of the patient

Instructions must be given to the patient by the requesting clinician or healthcare professional if the sample to be collected requires that the patient meets certain pre-collection criteria, e.g., fasting for 16 hours, medication status or sample collection at a pre-determined interval. The information must be documented on the request form to ensure the information is available to the phlebotomist or healthcare professional. It is the responsibility of the phlebotomist or healthcare professional to question the patient and to document the time of collection on the request form. Some criteria are defined in the patient information leaflets. See appendix 3.

### 12.0 Instructions for patient-collected samples.

Patient information leaflets are available on the Spire Healthcare Intranet. They can be found in the Clinical Specialities section of the Clinical Intranet under the Laboratory Medicine heading.

Leaflets available include:

Ref: SPS-GP-WI1401 – 24-hour urine collection

Ref: SPS-GP-WI1403 – Random urine collection

Ref: SPS-GP-WI1404 – Diet sheet for urinary 5-HIAA

Ref: SPS-GP-WI1405 – Diet sheet for urinary Metadrenaline / Metanephrine (Catecholamine/VMA) collection

Ref: SPS-GP-WI1407 – Collection of faecal samples for routine culture

Examples of these can be found in appendix 3. Copies can be obtained from any Spire Pathology laboratory and are available on the Clinical Intranet.

### 12.1 Instructions for the collection of samples for specialist tests.

Instructions for the collection of samples which detail the criteria of when and how samples are taken can also be found on the Spire Healthcare Clinical Intranet as above. Instructions include:

Ref: SPS-GP-WI1408 – Glucose Tolerance Test procedure (GTT)

Ref: SPS-GP-WI1409 – Growth Hormone Suppression test

Ref: SPS-GP-WI1410 – Short Synacthen test

Ref: SPS-GP-WI1420 – Histology Sample Preparation

Examples of these can be found in appendix 3. Copies can be obtained from any Spire Laboratory Medicine departments and are available on the Clinical Intranet

## 13.0 Specimen rejection criteria

Unlabelled samples will be rejected and those samples that do not have the essential points of ID as described in 8.0 above will also be rejected. Clinical staff will not be permitted to label samples retrospectively and the responsibility for ensuring that patient's samples are labelled satisfactorily always lies with the requesting clinician. Histopathology and cytology samples and some microbiology samples may be an exception due to the difficult nature of taking additional samples. Rejection of incorrectly labelled specimens can only be authorised with the consent of the respective consultant; however, the discrepancy will be noted on the specimen report.

Clotted EDTA samples are unsuitable for testing as are under filled or overfilled citrate samples for ESR and coagulation tests. Haemolysed SST samples for Biochemistry will affect some of the analytes. Some samples will deteriorate over time therefore should be sent to the laboratory without delay. Some samples may require the addition of preservatives, please refer to the test index or contact a laboratory for further information.

Samples which need to be posted to the laboratory should be packaged carefully to prevent leakage/breakage and must follow the appropriate postal regulations. Contact a laboratory for details.

Some tests require samples to be frozen. See test index. Contact laboratory for advice.

Requesting clinicians or their secretaries will be notified if the specimen has not been accepted due to the above criteria. It is therefore essential that the request forms contain the relevant contact information. Local arrangements may be in place for the phlebotomists to recall the patient for further sampling.

Spire Laboratory Medicine operates a zero tolerance for incorrect or incompletely labelled samples. They will be disposed of, and a further sample requested. To maintain patient safety, colleagues receiving samples follow a standard set of acceptance requirements, should they not be met samples are rejected and a DCIQ will be raised with the head of the requesting department as the handler.

If the sample cannot be repeated (precious samples e.g., tissue, CSF) amendment will be allowed and sample will not be rejected. Specimens return form SPS-GP-F1401 will be completed by both parties and the sample accepted into the laboratory.

If the sample is received from an external client, the client will be informed.

## 14.0 Factors affecting sample results

### 14.1 Blood sample collection technique

To prevent haemolysis the venepuncture technique is important. It is advisable, if possible, to use median cubital vein as the preferred site, clean the site with an alcohol swab from the centre of the vein in circular motions working outwards away from the vein. Allow the alcohol to air dry. Apply a tourniquet above the venepuncture site for no longer than one minute. Prolonged tourniquet time can lead to an increase in some analytes including protein, potassium and lactic acid due to haemostasis.

- Collection tubes must be in date. Expired tubes must not be used as they may have a decreased vacuum, as well as potential changes in any additive in the collection tube.
- Correct order of blood sample collection during venepuncture will ensure accurate results. The correct order of draw for plastic BD tubes is Blood cultures, Citrate samples (blue), citrate sample for ESR (black), Serum samples (red) SST tubes (yellow), Heparin (green), EDTA (pink or purple) and Fluoride (grey).
- Correct specimen volume: All blood collection tubes need to be filled to the correct volume as marked on tube. This will ensure the proper amount of blood to anticoagulant in the collection tube. See SPS-GP-SOP2400 Guide to Phlebotomy. If unable to obtain blood to the line, consult the laboratory for minimum volume requirements.
- Proper tube mixing by inversion is essential to mix the additive evenly. Do not shake vigorously as this can cause haemolysis.

### 14.2 Pre-analytical variables – Microbiology

- Urine microbiology samples should be collected into a clean Boric acid container (acts as a preservative) with the lid tightly screwed on to prevent leakage.
- Use a midstream collection (MSU) which is less likely to contain contaminants than random urine. See Section 7 for taking sample and patient information leaflet SPS-GP-WI1403.
- The collection should be aseptic to prevent contamination from skin and clothing.
- False negative results may be seen if patients are taking antibiotics.
- blood cultures must be sent to agreed testing laboratory within 4 hours of collection"
- Urine, swab and stool samples will be rejected by the laboratory if they receive more than 72 hours, postproduction of sample.

### 14.3 Pre-analytical variables in urine testing-Biochemistry

- It is important that the total urine volume collected is recorded and the time-period of collection to calculate the analyte concentrations.
- Sodium is influenced by diet. Antibiotics, cough medicines and laxatives can increase sodium results whereas diuretics decrease sodium results.
- Potassium can be influenced by diet. Diuretics, salicylates and glucocorticoids can increase potassium results.
- Chloride is falsely decreased by androgens, oestrogens, methyldopa or cortisone and increased by bicarbonates or corticosteroids.
- Creatinine is increased by gentamicin or heavy metal chemotherapy agents.

- Calcium is increased by antacids, anticonvulsants and some diuretics and decreased by adrenocorticosteroids and oral contraceptives.
- Total protein is affected by alcohol, anti-inflammatory drugs, salicylate and warfarin.
- Bilirubin can be increased with antibiotics, diuretics, oral contraceptives, sulfonamides and steroids and decreased by light and ascorbic acid.
- Amylase can be increased with aspirin, corticosteroids, codeine and oral contraceptives.
- 5-HIAA is influenced by many types of food (see patient information sheet). It is recommended that patients refrain from those listed for three days prior to sample collection.
- Porphyrins are affected by light, morphine, oral contraceptives and sulfonamides.
- Catecholamines are influenced by chocolate, cocoa, coffee, tea, bananas and vanilla. They are also affected by exercise and stress. They can be increased by lithium, insulin, tetracycline and nitroglycerine and decreased by salicylates and imipramine. These same factors also affect VMA, a metabolite of catecholamines.

#### 14.4 Pre-analytical variables – Biochemistry

- Patient preparation: Certain analytes e.g. glucose or cholesterol requires the patient to have fasted for 12 hours (no food or liquids except for water) prior to sample collection.
- Cortisol and adrenocorticotropin have diurnal variations, where the analyte is at its highest level in the morning and decrease gradually throughout the course of the day
- Haemolysis can result in the spurious elevation of some analytes e.g., potassium, lactate dehydrogenase, iron, folate and magnesium.
- Faecal Elastase samples should not reach temperatures above 40°C in these situations recommend they are transported cooled or refrigerated.
- Use of NSAIDS can produce a mildly raised Faecal Calprotectin result.
- Haemolysis may significantly increase folate values due to high concentrations of folate in red blood cells. Therefore, haemolysed samples are not suitable for use in this assay.

The following tests may be added post phlebotomy as displayed in the timeframe below.

|               |        |            |        |                     |                                                   |
|---------------|--------|------------|--------|---------------------|---------------------------------------------------|
| Glucose       | 3 days | CA 15-3    | 5 days | Pro BNP             | 6 days                                            |
| LDH           | 4 days | Cortisol   | 4 days | Progesterone        | 5 days                                            |
| Phosphate     | 4 days | Oestradiol | 2 days | Parathyroid Hormone | 2 days                                            |
| Triglycerides | 5 days | Folate     | 2 days | TPSA                | 5 days                                            |
| Uric Acid     | 5 days | FPSA       | 5 days | Vitamin B12         | 2 days                                            |
| CA 125        | 5 days | Insulin    | 2 days | Vitamin D           | 3 days RT, 7 days if separated and stored at 4 °C |

#### 14.5 Pre-analytical variables – Haematology and coagulation

- EDTA samples must be mixed by inverting gently 8-10 times to ensure the anticoagulant is mixed and the sample does not clot

- Ideally blood counts should be performed within 6 hrs of the venepuncture for optimum results, if a blood film is required it should preferably be made within 2 hours of sample collection.
- Under filled EDTA blood collection tubes can lead to erroneously low blood cell counts, haematocrits and morphological changes to RBCs, and staining alteration. White blood cell counts, and platelet counts can be affected by cryoglobulins.
- Cryoglobulins aggregate and may be falsely identified as platelets and/or WBCs by the haematology analyser. Cold agglutinins have been known to cause spurious reporting of macrocytosis and decreased RBC counts.
- Platelet satellitism is a phenomenon that only occurs in EDTA anticoagulated blood. This is due to EDTA-dependent IgG autoantibodies and occurs at room temperature. When platelet satellitism is present, there is a decrease in platelet count. In this instance a citrate sample maybe requested.
- Coagulation analysis should preferably be performed within 4 hours of collection. If this is not appropriate, the samples shall be double spun, separated from the red cells and the plasma frozen
- It is important to include any anticoagulant treatment when requesting coagulation studies as this will be needed for interpretation of results
- ESR samples collected into seditainer tubes must be tested within 4 hours of collection. If this is not possible an EDTA sample must be taken which if stored at 4°C is viable for 24hrs. The EDTA sample can be tipped into the seditainer tube for testing.

### 14.6 Pre-analytical variables – Blood transfusion

- For patients who have received a blood transfusion or who have been pregnant in the last 3 months serological studies should be performed using blood collected no more than 3 days in advance of the actual transfusion when the patient has been transfused or pregnant within the preceding 3months, or when such information is uncertain or unavailable. The 3 days includes the de-reservation period, e.g., if the sample was 1-day old, the blood would have to be transfused within 2 days.
- Requests for crossmatching may be added to the second Group and Save sample taken from a patient as the BCSH guidelines recommend that every attempt should be made to ensure that two separate samples have been fully grouped (forward and reverse groups) prior to transfusion of red cells.

### 14.7 Pre-analytical variables - Virology

- With most virology tests, samples collected during the acute phase of infection, when only IgM antibodies are present, may be negative for IgG testing. Further samples should be obtained 8 – 14 days later to determine an increase in the IgG antibody level
- Testing for VCA EBNA IgG can only be used as a guide as a diagnosis and must always be evaluated together with results of other diagnostic procedures. There is a possibility of cross reaction with samples containing E. coli antibodies.

### 14.8 Pre-analytical variables – Immunology

- Rheumatoid factor can interfere with the determination of IgM anti-Cardiolipin antibodies. It may also interfere with the determination of MPO antibodies
- In rare cases interference of the Scl-70 and Smd tests can occur due to extremely high titres of streptavidin.

### 14.9 Pre-analytical variables – Histology

- Fixation in 10 % neutral buffered formalin is a critical step in the preparation of histological sections. If it is not carried out under optimal conditions or if fixation is delayed, a tissue specimen can be irreversibly damaged. Routine tissue samples undergo fixation within 24 hours from the sampling time, larger specimens e.g., resection specimens or those that require slicing must be fixed for a further 24 hours (48 hours in total)
- Samples must be placed in sufficiently large containers to ensure the sample is completely submerged in 10% neutral buffered formalin. Container should be large enough so the sample can move freely within it to prevent damage and preserve the integrity of the tissue. See Appendix 3

### 14.10 Pre-analytical variables – Cytopathology

#### 14.10.1 Non-gynaecological samples

##### Urine Cytology

- For Urine Cytology requests when the specimen is collected off site, patients will be supplied with a unisex specimen container called “URICYTE+ BASIC KIT 120ml – FOR BLADDER CYTOLOGY” that holds 120 mls (Manufacturer CellPath Ltd) and the patient information sheet.
- Fresh Urine Cytology samples that are collected on site can be received in universal containers following guidance below.
- The first voiding of the day is unsuitable for cytological examination. A mid-morning or random specimen is recommended for urine cytology. After a small quantity of the initial urine flow is released into the toilet, fill the specimen container containing the UriCyte preservative until the container is 2/3 to 3/4 full.
- The container and Pathology request form should be placed in the specimen bag provided.
- Pass the firmly closed urine container and the request form to the responsible medical person as soon as possible.

##### Aspirates

- Fluid samples should be taken into either a sterile universal container or a container containing Cytolyt.
- Fluid aspirate samples taken directly onto slides are not acceptable and should be taken into Cytolyt.
- Non-Gynae (Diagnostic Cytology) - Air-dried FNA on glass slides are accepted by the Laboratory

**Body cavity fluids**

- These should be taken into a while-topped universal container. Sample should be sent in Cytolyt if not arriving at the laboratory on the same day.

**14.10.2 Cervical cytology**

- The test can only be performed by trained sample takers using the Thinprep PAP test-based Cytology (LBC) system.
- Specimen collection is a key factor in obtaining adequate and representative samples for analysis. Therefore, when collecting specimens, it is important to use appropriate devices and techniques, such as avoiding the use of lubricants, or if they are used, using them sparingly.
- The Broom-Like device protocol is the recommended method of collection available at Spire Hospitals. See work instruction SPS-GP-WI1422 (Appendix 4)

**14.11 Risk Assessment**

Spire Laboratory Medicine have considered the risks which affect the patient in the pre-analytical, analytical and post-analytical phases and these are documented as below.

Please contact [spirehealthcarepathologyqualityteam@spirehealthcare.com](mailto:spirehealthcarepathologyqualityteam@spirehealthcare.com) for further information of risk if required.

| <b>A. Hospital/Unit</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                | Laboratory Medicine     |                 | <b>Dept</b>      | All Laboratories |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | <b>Ref No</b> | SPS-GP-RA0027                 |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------------------|-----------------|------------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-------------------------------|----------------------|------------|-------------|----------------|---------|--------|-------------|---|---|---|---|-----|--------|-----|-------|--------------|---|---|---|---|-------|----------|-------|-------|-------|---|---|---|---|---|----------|---|---|---|---|---|---|---|---|------|---|---|---|---|---|---|---|---|--|-----|--|--|--------|--|--|------|--|
| <b>B. Assessment performed by</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                | Quality Management Team |                 | <b>Date</b>      | 21.06.2023       | <b>HOD name</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Fiona McLeman |                               | <b>Date approved</b> | 21.06.2023 |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
| <b>Subsequent reviews</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                | <b>Date</b>             | 22.01.2026 (v5) | <b>By (name)</b> | Fiona McLeman    | <b>Date</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |               | <b>By (name)</b>              |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                | <b>Date</b>             |                 | <b>By (name)</b> |                  | <b>Date</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |               | <b>By (name)</b>              |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
| <b>C. State the Risk Title</b><br>Unavailability of results due to pre-analytical errors and/or having to attend for a retake of sample                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                |                         |                 |                  |                  | <table border="1"> <tr> <th rowspan="2">Risk rating</th> <th rowspan="2">Initial</th> <th rowspan="2">Current</th> <th rowspan="2">Target</th> <th colspan="5">Consequence</th> </tr> <tr> <th>Neg</th> <th>Minor</th> <th>Mod</th> <th>Major</th> <th>Catastrophic</th> </tr> <tr> <td></td> <td></td> <td></td> <td></td> <td>□ □ □</td> <td>□ □ □</td> <td>□ □ □</td> <td>□ □ □</td> <td>□ □ □</td> </tr> </table>                                                                                                                                                                                                                                                                                                                                                    |               |                               |                      |            | Risk rating | Initial        | Current | Target | Consequence |   |   |   |   | Neg | Minor  | Mod | Major | Catastrophic |   |   |   |   | □ □ □ | □ □ □    | □ □ □ | □ □ □ | □ □ □ |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
| Risk rating                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Initial        | Current                 | Target          | Consequence      |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |               |                               |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                |                         |                 | Neg              | Minor            | Mod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Major         | Catastrophic                  |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                |                         |                 | □ □ □            | □ □ □            | □ □ □                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | □ □ □         | □ □ □                         |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
| <b>D. State the Risk Description (include the: cause, effect/risk and impact)</b><br>1. Specimens are not taken correctly from the patient<br>a. Incorrect venepuncture technique resulting in haemolysis<br>b. Incorrect post venepuncture management resulting in clotting or haemolysis<br>c. Wrong sample container selected resulting in incorrect result or sample rejection<br>d. Incorrect storage prior to transport resulting in incorrect results<br>e. Sample containers are mis-labelled resulting in rejection<br>f. Sample containers are labelled with another patient ID resulting in Wrong Blood (or sample) in tube event, causing patient to have a mis-diagnosis<br>g. Specimen container underfilled – resulting in incorrect results or sample rejection<br>h. Sample container used past expiry date – resulting in incorrect results or sample rejection<br>i. Incorrect sample container or preservative used – resulting in incorrect results or sample rejection<br>2. Specimens are not transported correctly to the testing laboratory<br>a. Samples may leak in transit – resulting in incorrect results or sample rejection and risk to colleagues<br>b. Samples not packaged correctly – resulting risk to colleagues<br>c. There is no electronic sample tracking facility – resulting in lost samples<br>d. There is no sample temperature monitoring for samples in transit – samples may be unknowingly out of stability and deliver inaccurate results<br>e. Transport colleagues or third-party drivers may have no training or competency to transport samples resulting in the samples not being handled correctly and inaccurate results |                |                         |                 |                  |                  | <table border="1"> <tr> <th rowspan="6">Likelihood</th> <th>Almost certain</th> <td>□</td> <td>□</td> <td>□</td> <td>L</td> <td>M</td> <td>H</td> <td>H</td> <td>H</td> </tr> <tr> <th>Likely</th> <td>□</td> <td>□</td> <td>□</td> <td>L</td> <td>M</td> <td>M</td> <td>H</td> <td>H</td> </tr> <tr> <th>Possible</th> <td>□</td> <td>□</td> <td>□</td> <td>L</td> <td>L</td> <td>M</td> <td>M</td> <td>H</td> </tr> <tr> <th>Unlikely</th> <td>□</td> <td>□</td> <td>□</td> <td>L</td> <td>L</td> <td>L</td> <td>M</td> <td>M</td> </tr> <tr> <th>Rare</th> <td>□</td> <td>□</td> <td>□</td> <td>L</td> <td>L</td> <td>L</td> <td>L</td> <td>L</td> </tr> <tr> <th></th> <td colspan="3">Low</td> <td colspan="3">Medium</td> <td colspan="2">High</td> </tr> </table> |               |                               |                      |            | Likelihood  | Almost certain | □       | □      | □           | L | M | H | H | H   | Likely | □   | □     | □            | L | M | M | H | H     | Possible | □     | □     | □     | L | L | M | M | H | Unlikely | □ | □ | □ | L | L | L | M | M | Rare | □ | □ | □ | L | L | L | L | L |  | Low |  |  | Medium |  |  | High |  |
| Likelihood                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Almost certain | □                       | □               | □                | L                | M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | H             | H                             | H                    |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Likely         | □                       | □               | □                | L                | M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | M             | H                             | H                    |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Possible       | □                       | □               | □                | L                | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | M             | M                             | H                    |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Unlikely       | □                       | □               | □                | L                | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | L             | M                             | M                    |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Rare           | □                       | □               | □                | L                | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | L             | L                             | L                    |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                | Low                     |                 |                  | Medium           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |               | High                          |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
| <b>F. Risk before controls</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                |                         |                 |                  |                  | <b>Medium</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |               | <b>H. Risk after controls</b> |                      | <b>Low</b> |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
| <b>F. Risk Target</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                |                         |                 |                  |                  | <b>Low</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |               |                               |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
| <b>E. Who may be harmed?</b> Staff <input type="checkbox"/> Patients <input checked="" type="checkbox"/> Contractors <input type="checkbox"/> Visitors/public <input checked="" type="checkbox"/> Young workers <input type="checkbox"/> Trainees <input type="checkbox"/> Others (specify)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                |                         |                 |                  |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |               |                               |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |
| <b>G. What controls are in place to reduce the risk?</b> Consider in order; elimination, substitution, isolation, engineering/re-design, training, PPE.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                |                         |                 |                  |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |               |                               |                      |            |             |                |         |        |             |   |   |   |   |     |        |     |       |              |   |   |   |   |       |          |       |       |       |   |   |   |   |   |          |   |   |   |   |   |   |   |   |      |   |   |   |   |   |   |   |   |  |     |  |  |        |  |  |      |  |

## LABORATORY MEDICINE SERVICE USERS GUIDE

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <ol style="list-style-type: none"> <li>1. Laboratory Medicine User guide</li> <li>2. Guide to phlebotomy</li> <li>3. Working instructions available on clinical intranet including use of the centrifuge, Histology sample preparation, urine cytology collection &amp; transportation of specimens</li> <li>4. Ordercomms (with sample taking instructions) – users guide on clinical intranet</li> <li>5. Haemolysis report for Director of Clinical Service</li> <li>6. Communication of rejected sample as per SPS-GP-SOP1400</li> </ol> | <ol style="list-style-type: none"> <li>7. Incident reporting via DCIQ</li> <li>8. Spire clinical competencies for sample taking</li> <li>9. Pre-analytical training delivered to Pre-Assessment leads, DoCS, ward managers and out-patient leads</li> <li>10. Transportation policy (WM02) including driver competencies</li> <li>11. QI package and information disseminated via Ops comms to all sites</li> <li>12. SLA with City Sprint which gives assurance around driver competency</li> </ol> |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

### H. What further actions are required to control the risk? Please specify target completion dates

| Action | Target date | Action | Target date |
|--------|-------------|--------|-------------|
|        |             |        |             |

Has risk been reduced as far as possible? (Low or Very Low Risk Rating following application of control measures)

Yes ☒ No ☐

| A. Responsibility                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                      | Laboratory Medicine                                                        |                                                                                       | Groups                                                                     |                                                                            | All Laboratories                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            | Version (self create) |               | Approval/Signature |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|---------------|--------------------|------------|--------|--|------------------------|--|-----|--|--|--|--|-----|-------|-----|-------|--------------|--|--|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|------------|------------------------------------------------------------------------------------------------------|---|---|---|---|---|-------------------------------------------------------------------------------------|---|---|---|---|---|-------------------------------------------------------------------------------------|---|---|---|---|---|-------------------------------------------------------------------------------------|---|---|---|---|---|---------------------------------------------------------------------------------|---|---|---|---|---|-----|--|--------|--|--|--|------|
| B. Assessment performed by                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                      | Quality Management Team                                                    |                                                                                       | Date                                                                       | 21.06.2023                                                                 | HOD name                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            | Fiona McLeman         |               | Date approved      | 21.06.2023 |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| Subsequent reviews                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                      | Date                                                                       | 16.08.2023                                                                            | By (name)                                                                  | Fiona McLeman                                                              | Date                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 31.11.2024 | By (name)             | Fiona McLeman |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                      | Date                                                                       | 18.11.2025                                                                            | By (name)                                                                  | Fiona McLeman                                                              | Date                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            | By (name)             |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| C. State the Risk Title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                      |                                                                            |                                                                                       |                                                                            |                                                                            | Risk rating                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| Risks to patient safety and satisfaction related to analytical activities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                      |                                                                            |                                                                                       |                                                                            |                                                                            | <table border="1"> <thead> <tr> <th colspan="2"></th> <th colspan="5">Consequence</th> </tr> <tr> <th colspan="2"></th> <th>Neg</th> <th>Minor</th> <th>Mod</th> <th>Major</th> <th>Catastrophic</th> </tr> <tr> <th colspan="2"></th> <th><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></th> <th><input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/></th> <th><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></th> <th><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></th> <th><input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></th> </tr> </thead> <tbody> <tr> <td rowspan="5">Likelihood</td> <td>Almost certain <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></td> <td>L</td> <td>M</td> <td>H</td> <td>H</td> <td>H</td> </tr> <tr> <td>Unlikely <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></td> <td>L</td> <td>M</td> <td>M</td> <td>H</td> <td>H</td> </tr> <tr> <td>Possible <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></td> <td>L</td> <td>L</td> <td>M</td> <td>M</td> <td>H</td> </tr> <tr> <td>Unlikely <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></td> <td>L</td> <td>L</td> <td>L</td> <td>M</td> <td>M</td> </tr> <tr> <td>Rare <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></td> <td>L</td> <td>L</td> <td>L</td> <td>L</td> <td>L</td> </tr> <tr> <td colspan="2">Low</td> <td colspan="4">Medium</td> <td>High</td> </tr> </tbody> </table> |            |                       |               |                    |            |        |  | Consequence            |  |     |  |  |  |  | Neg | Minor | Mod | Major | Catastrophic |  |  | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | Likelihood | Almost certain <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | L | M | H | H | H | Unlikely <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | L | M | M | H | H | Possible <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | L | L | M | M | H | Unlikely <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | L | L | L | M | M | Rare <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | L | L | L | L | L | Low |  | Medium |  |  |  | High |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                      | Consequence                                                                |                                                                                       |                                                                            |                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                      | Neg                                                                        | Minor                                                                                 | Mod                                                                        | Major                                                                      | Catastrophic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                      | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| Likelihood                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Almost certain <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | L                                                                          | M                                                                                     | H                                                                          | H                                                                          | H                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Unlikely <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>                  | L                                                                          | M                                                                                     | M                                                                          | H                                                                          | H                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Possible <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>                  | L                                                                          | L                                                                                     | M                                                                          | M                                                                          | H                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Unlikely <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>                  | L                                                                          | L                                                                                     | L                                                                          | M                                                                          | M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Rare <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>                      | L                                                                          | L                                                                                     | L                                                                          | L                                                                          | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| Low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                      | Medium                                                                     |                                                                                       |                                                                            |                                                                            | High                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| D. State the Risk Description (include the: cause, effect/risk and impact)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                      |                                                                            |                                                                                       |                                                                            |                                                                            | F. Risk before controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| <ol style="list-style-type: none"> <li>1. Colleagues not trained or assessed as competent to perform testing of patients samples</li> <li>2. Tests performed not subject to control (EQA / IQC/ILC)</li> <li>3. Results have no clinical input</li> <li>4. Laboratory Medicine is not subject to correct governance or central support</li> <li>5. Internal assurance of compliance to UKAS and MHRA standards not assessed</li> <li>6. Instrumentation not subject to regular assessment and checking</li> <li>7. Health and Safety of Laboratory Medicine colleagues not managed</li> </ol>                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                      |                                                                            |                                                                                       |                                                                            |                                                                            | <table border="1"> <tr> <td colspan="2">Medium</td> <td colspan="2">H. Risk after controls</td> <td>Low</td> </tr> </table>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |                       |               |                    |            | Medium |  | H. Risk after controls |  | Low |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| Medium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                      | H. Risk after controls                                                     |                                                                                       | Low                                                                        |                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| E. Who may be harmed? Staff <input checked="" type="checkbox"/> Patients <input checked="" type="checkbox"/> Contractors <input type="checkbox"/> Visitors/public <input type="checkbox"/> Young workers <input type="checkbox"/> Trainees <input type="checkbox"/> Others (specify)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                      |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| G. What controls are in place to reduce the risk? Consider in order; elimination, substitution, isolation, engineering/re-design, training, PPE.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| <ol style="list-style-type: none"> <li>1. Target operating model in place for staffing and skill mix across all sites</li> <li>2. Standard Operating procedures for all analytical platforms including operation &amp; maintenance</li> <li>3. Standard Training and Competency documentation for all analytical tests &amp; processes performed within Spire Pathology</li> <li>4. Analytical tests are covered by Internal Quality Controls and External Quality assurance, which are trended monthly, those which are not covered are individually risk assessed.</li> <li>5. External Quality assurance reviewed monthly at Laboratory Medicine Performance review and by Discipline consultants at each site</li> <li>6. Support structure in place; Laboratory Medicine SMT, Laboratory Medicine Quality Team and Discipline groups.</li> <li>7. Clinically led service with regular documented meetings with Discipline consultants at each site</li> <li>8. Scope of practice at each site is audited annually</li> </ol> |                                                                                                      |                                                                            |                                                                                       |                                                                            |                                                                            | <ol style="list-style-type: none"> <li>9. All sites are UKAS accredited and MHRA (where applicable) compliant</li> <li>10. All DCIQ events raised are reviewed monthly and discussed at Laboratory Medicine Governance meetings</li> <li>11. Ordercomms for electronic ordering</li> <li>12. BCP in place at all sites and nationally.</li> <li>13. Annual re-verification assessment of tests and equipment</li> <li>14. Maintenance contracts in place</li> <li>15. Supplier review meetings</li> <li>16. BCP and Major Haemorrhage scenarios performed annually</li> <li>17. Staff receive spills training and there is an associated work instruction</li> <li>18. Interfaces between instrumentation and WinPath Enterprise act as a holding mechanism to prevent incorrect results release</li> <li>19. Incompletes list in LIMS used as a control for missing tests</li> </ol>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| H. What further actions are required to control the risk? Please specify target completion dates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                      |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
| Action                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                      |                                                                            |                                                                                       | Target date                                                                |                                                                            | Action                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |                       |               | Target date        |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                      |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |                       |               |                    |            |        |  |                        |  |     |  |  |  |  |     |       |     |       |              |  |  |                                                                            |                                                                                       |                                                                            |                                                                            |                                                                            |            |                                                                                                      |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                     |   |   |   |   |   |                                                                                 |   |   |   |   |   |     |  |        |  |  |  |      |

Has risk been reduced as far as possible? (Low or Very Low Risk Rating following application of control measures)

Yes ☒ No ☐

| <b>A. Hospital/Unit</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                | Laboratory Medicine                 |                                     | Dept                                | All Laboratories                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Ref No<br>(self create) | SPS-GP-RA0029 |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|-------------------------------------|-------------------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|---------------|---------------|-------------------------|--|--|-------------|--|------------------------|--|-----|--|---------|---------|--------|-----|-------|-----|-------|--------------|------------|----------------|-------------------------------------|-------------------------------------|-------------------------------------|---|---|---|---|---|--------|--------------------------|--------------------------|--------------------------|---|---|---|---|---|----------|--------------------------|--------------------------|--------------------------|---|---|---|---|---|----------|--------------------------|--------------------------|--------------------------|---|---|---|---|---|------|--------------------------|--------------------------|--------------------------|---|---|---|---|---|--|--|--|--|-----|--|--|--------|--|------|
| <b>B. Assessment performed by</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                | Quality Management Team             |                                     | Date                                | 21.06.2023                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | HOD name                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Fiona McLeman           |               | Date approved |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| <b>Subsequent reviews</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                | Date                                | 22.01.2026 (v3)                     | By (name)                           | Fiona McLeman                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Date                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         | By (name)     |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                | Date                                |                                     | By (name)                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Date                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         | By (name)     |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| <b>C. State the Risk Title</b><br>Post-analytical activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                |                                     |                                     |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <table border="1"> <tr> <th colspan="3">Risk rating</th> <th colspan="5">Consequence</th> </tr> <tr> <th></th> <th>Initial</th> <th>Current</th> <th>Target</th> <th>Neg</th> <th>Minor</th> <th>Mod</th> <th>Major</th> <th>Catastrophic</th> </tr> <tr> <td rowspan="5">Likelihood</td> <td>Almost certain</td> <td><input checked="" type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> <td>L</td> <td>M</td> <td>H</td> <td>H</td> <td>H</td> </tr> <tr> <td>Likely</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>L</td> <td>M</td> <td>M</td> <td>H</td> <td>H</td> </tr> <tr> <td>Possible</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>L</td> <td>L</td> <td>M</td> <td>M</td> <td>H</td> </tr> <tr> <td>Unlikely</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>L</td> <td>L</td> <td>L</td> <td>M</td> <td>M</td> </tr> <tr> <td>Rare</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td>L</td> <td>L</td> <td>L</td> <td>L</td> <td>L</td> </tr> <tr> <td colspan="3"></td> <td></td> <td colspan="3">Low</td> <td colspan="2">Medium</td> <td>High</td> </tr> </table> |                         |               |               | Risk rating             |  |  | Consequence |  |                        |  |     |  | Initial | Current | Target | Neg | Minor | Mod | Major | Catastrophic | Likelihood | Almost certain | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | L | M | H | H | H | Likely | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | L | M | M | H | H | Possible | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | L | L | M | M | H | Unlikely | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | L | L | L | M | M | Rare | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | L | L | L | L | L |  |  |  |  | Low |  |  | Medium |  | High |
| Risk rating                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                |                                     | Consequence                         |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                         |               |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Initial        | Current                             | Target                              | Neg                                 | Minor                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Mod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Major                   | Catastrophic  |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| Likelihood                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Almost certain | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | H                       | H             | H             |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Likely         | <input type="checkbox"/>            | <input type="checkbox"/>            | <input type="checkbox"/>            | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | M                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | M                       | H             | H             |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Possible       | <input type="checkbox"/>            | <input type="checkbox"/>            | <input type="checkbox"/>            | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | M                       | M             | H             |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Unlikely       | <input type="checkbox"/>            | <input type="checkbox"/>            | <input type="checkbox"/>            | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | L                       | M             | M             |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Rare           | <input type="checkbox"/>            | <input type="checkbox"/>            | <input type="checkbox"/>            | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | L                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | L                       | L             | L             |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                |                                     |                                     | Low                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Medium                  |               | High          |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| <b>D. State the Risk Description (include the: cause, effect/risk and impact)</b><br>Risks to patient safety and satisfaction related to post-analytical activities.<br>1. Results transcribed incorrectly leading to misdiagnosis and treatment<br>2. Delay or non-communication of critical results leading to delayed critical treatment<br>3. Result released by non-competent colleagues leading to patient receiving incorrect result<br>4. Reputational risk<br>5. Financial risk due to compensation being sought<br>Risk to consultant satisfaction due to the above post-analytical activities |                |                                     |                                     |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | <table border="1"> <tr> <td colspan="3">F. Risk before controls</td> <td colspan="2">Medium</td> <td colspan="2">H. Risk after controls</td> <td colspan="2">Low</td> </tr> </table>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                         |               |               | F. Risk before controls |  |  | Medium      |  | H. Risk after controls |  | Low |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| F. Risk before controls                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                |                                     | Medium                              |                                     | H. Risk after controls                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Low                     |               |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| <b>F. Risk Target</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                |                                     |                                     |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Low                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                         |               |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| <b>E. Who may be harmed?</b> Staff <input type="checkbox"/> Patients <input checked="" type="checkbox"/> Contractors <input type="checkbox"/> Visitors/public <input type="checkbox"/> Young workers <input type="checkbox"/> Trainees <input type="checkbox"/> Others (specify)                                                                                                                                                                                                                                                                                                                         |                |                                     |                                     |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                         |               |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| <b>G. What controls are in place to reduce the risk?</b> Consider in order; elimination, substitution, isolation, engineering/re-design, training, PPE.                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                |                                     |                                     |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                         |               |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| 1. Standard operating procedures in place for Pathology LIMS system & Post analytical procedures<br>2. Standard Training and Competency documentation<br>3. All test requests are entered onto the Pathology LIMS system and available electronically to consultants<br>4. NPEx in place for 3 <sup>rd</sup> party referrals<br>5. Abnormal results requiring escalation/communication are held in LIMS for action by a BMS<br>6. Results can be referred within the LIMS for consultant review &/or comment                                                                                             |                |                                     |                                     |                                     | 7. LIMS audit trail for telephoning results in place<br>8. Support structure in place; Pathology SMT, Pathology Quality Team and Discipline<br>9. All Datix events raised are reviewed monthly and discussed at Pathology Governance meetings<br>10. Consultant Handbook available (MED 02)<br>11. Practising privileges policy (MED 03)<br>12. Communication of abnormal or unexpected histology results (CLINI 95)<br>13. Surveillance for HCI organisms Policy (CLINI 83) |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                         |               |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| <b>H. What further actions are required to control the risk? Please specify target completion dates</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                |                                     |                                     |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                         |               |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| Action<br>Further development of NPEx                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                |                                     |                                     | Target date<br>Ongoing              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Action                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                         | Target date   |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |
| <b>Has risk been reduced as far as possible?</b> (Low or Very Low Risk Rating following application of control measures)<br>Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>                                                                                                                                                                                                                                                                                                                                                                                                          |                |                                     |                                     |                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                         |               |               |                         |  |  |             |  |                        |  |     |  |         |         |        |     |       |     |       |              |            |                |                                     |                                     |                                     |   |   |   |   |   |        |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |          |                          |                          |                          |   |   |   |   |   |      |                          |                          |                          |   |   |   |   |   |  |  |  |  |     |  |  |        |  |      |

## 15.0 Clinical Advice

Spire Laboratory Medicine departments have consultant advisors for each discipline. Each Consultant has signed a service level agreement and shall provide evidence on an annual basis to assure the Pathology Manager and Hospital Senior Management team that they remain competent for the applicable scope of practice within the department they are working in.

The names of the Consultants for each laboratory are documented in section 2.4

The scope of their responsibilities includes

- Available to give professional judgments on interpretation of results.
  - In Histopathology, the interpretative comments based on observations constitute the professional judgment of the Consultant Histopathologist's that is the basis of the report.
  - In other disciplines interpretative comments are added to reports to aid clinicians.
- Available to offer clinical advice. Their contact details are available at the relevant Spire Laboratory Medicine department
- To promote the effective utilization of the laboratory services
- To be involved in consultation on scientific and logistic matters such as sample suitability.

## 16.0 Protection of Personal Information

Confidentiality of medical information relies on access to information being made only by those who have legitimate reasons to do so, as part of that person's medical care.

Breaches of confidentiality are contrary to the General Data Protection Regulation and are considered disciplinary offences by Spire Healthcare.

The laboratory is responsible, through legally enforceable agreements, for the management of all patient information obtained or created during the performance of laboratory activities.

Management of patient information includes privacy and confidentiality. The laboratory will inform the user and/or the patient in advance, of the information it intends to place in the public domain.

Except for information that the user and/or the patient makes publicly available, or when agreed between the laboratory and the patient (e.g., for the purpose of responding to complaints), all other information is considered proprietary information and shall be regarded as confidential.

Personnel, including any committee members, contractors, personnel of external bodies, or individuals with access to laboratory information acting on the laboratory's behalf, shall keep confidential all information obtained or created during the performance of laboratory activities.

## 17.0 Complaint Procedure

Spire Laboratory Medicine abides by the Spire Healthcare Complaints Policy (HOP2) The purpose of this policy (which is based on the Independent Sector Complaints Adjudication Service Members Code of Practice for Managing Complaints, May 2013('ISCAS Code')) is to establish a clear framework within which complaints will be managed by Spire Healthcare. Co-operation with the ISCAS Code is a condition of Spire Healthcare's membership of ISCAS.

Complaints should be directed to the local Pathology Manager or Hospital Director. Written complaints are dealt with in a timely manner. A written acknowledgement must ordinarily be made within 2 working days of receipt of the complaint (unless a full reply can be sent within 5 working days). A full response will normally be made within 20 working days of receipt of the complaint.

Where the investigation is still in progress, a letter explaining the reason for the delay must be sent to the patient and a full response made within 5 working days of completion of the investigation.

## 18.0 Measurement Uncertainty and Biological variance

Measurement Uncertainty and Biological variance (Biochemistry only) for each measured parameter is available on request.

## 19.0 Turnaround Times

Stated turnaround times are measured from time received into the testing laboratory in working days. It should be noted that some samples are received as postal samples and therefore turnaround time may be elongated due to this process.

## 20.0 Customer Information

Users of Spire Laboratory Medicine services may obtain information on the cost of tests to patients from the local hospital Financial Directors or Business administration teams. If this information is required, it should be sought prior to having any tests undertaken.

Assistance may also be sought by hospital teams from the Laboratory Medicine Business Service team at [Laboratorymedicine@spirehealthcare.com](mailto:Laboratorymedicine@spirehealthcare.com) in relation to test codes.

## Appendix 1 – Tests offered by Spire Laboratory Medicine

|                                                                                                                                               | Bristol | Centennial Park | Dunedin | Edinburgh | Hartwood | Leeds | Leicester | Little Aston | Manchester | Montefiore | Nottingham | Parkway | Portsmouth | Southampton | St Anthony's | Histology Centre |
|-----------------------------------------------------------------------------------------------------------------------------------------------|---------|-----------------|---------|-----------|----------|-------|-----------|--------------|------------|------------|------------|---------|------------|-------------|--------------|------------------|
| <b>Biochemistry</b>                                                                                                                           |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| AFP                                                                                                                                           |         | X               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| AMH                                                                                                                                           |         |                 |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| Amylase                                                                                                                                       | X       | X               |         | X         | X        | X     |           |              | X          | X          | X          | X       |            | X           | X            |                  |
| Angiotensin converting enzyme (ACE)                                                                                                           |         | X               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Apolipoprotein A                                                                                                                              |         |                 |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| Apolipoprotein B                                                                                                                              |         |                 |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| Aspartate Aminotransferase (AST)                                                                                                              | X       | X               |         | X         |          | X     |           |              | X          | X          |            |         |            |             |              |                  |
| Bicarbonate                                                                                                                                   | X       | X               |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| Bone (Total protein, Albumin, Globulin (calculation), Calcium, Adjusted calcium (calculation), Phosphate, Alkaline Phosphatase and Uric acid) | X       | X               |         | X         | X        | X     |           |              | X          | X          | X          | X       |            | X           | X            |                  |
| C125                                                                                                                                          | X       | X               |         | X         | X        | X     |           |              | X          |            | X          | X       |            | X           | X            |                  |
| C153                                                                                                                                          |         | X               |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| C199                                                                                                                                          |         | X               |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| CEA                                                                                                                                           | X       | X               |         | X         | X        | X     |           |              | X          |            | X          | X       |            | X           | X            |                  |
| Chloride                                                                                                                                      | X       | X               |         |           |          |       |           |              | X          |            |            |         |            | X           |              |                  |
| Cortisol                                                                                                                                      |         | X               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Creatinine Kinase                                                                                                                             | X       | X               |         | X         | X        | X     |           |              | X          | X          | X          | X       |            | X           | X            |                  |
| CRP                                                                                                                                           | X       | X               |         | X         | X        | X     |           |              | X          | X          | X          | X       |            | X           | X            |                  |
| Direct Bilirubin                                                                                                                              |         | X               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Faecal Calprotectin                                                                                                                           |         |                 |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| Faecal Elastase                                                                                                                               |         |                 |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| Faecal immunochemical testing                                                                                                                 |         |                 |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| Ferritin                                                                                                                                      | X       | X               |         | X         | X        | X     |           |              | X          |            | X          | X       |            | X           | X            |                  |
| Fibrosis-4                                                                                                                                    | X       | X               |         | X         | X        | X     |           |              | X          |            | X          | X       |            | X           | X            |                  |
| Free Androgen Index                                                                                                                           |         | X               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Folate                                                                                                                                        | X       | X               |         | X         | X        | X     |           |              | X          |            | X          | X       |            | X           | X            |                  |
| Free PSA                                                                                                                                      | X       | X               |         | X         | X        | X     |           |              | X          |            | X          | X       |            | X           | X            |                  |
| Free calculated testosterone                                                                                                                  |         | X               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Free PSA Ratio                                                                                                                                | X       | X               |         | X         | X        | X     |           |              | X          |            | X          | X       |            | X           | X            |                  |
| FSH                                                                                                                                           |         | X               |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |
| FT3                                                                                                                                           |         | X               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| FT4                                                                                                                                           | X       | X               |         | X         | X        | X     |           |              | X          |            | X          | X       |            | X           | X            |                  |
| Gentamicin                                                                                                                                    |         | X               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Glucose                                                                                                                                       | X       | X               |         | X         | X        | X     |           |              | X          | X          | X          | X       |            | X           | X            |                  |
| HbA1c                                                                                                                                         |         | X               |         |           |          |       |           |              | X          |            |            |         |            |             |              |                  |

## LABORATORY MEDICINE SERVICE USERS GUIDE

|                                                                                                               | Bristol | Centennial Park | Dunedin | Edinburgh | Hartwood | Leeds | Leicester | Little Aston | Manchester | Montefiore | Nottingham | Parkway | Portsmouth | Southampton | St Anthony's | Histology Centre |
|---------------------------------------------------------------------------------------------------------------|---------|-----------------|---------|-----------|----------|-------|-----------|--------------|------------|------------|------------|---------|------------|-------------|--------------|------------------|
| HCG- beta                                                                                                     |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| IgA                                                                                                           |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| IgG                                                                                                           |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| IgM                                                                                                           |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Immunofixation                                                                                                |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Insulin                                                                                                       |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Iron and TIBC                                                                                                 |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Lactate                                                                                                       |         |                 |         |           |          |       |           |              |            |            |            | x       |            |             |              |                  |
| LDH                                                                                                           | x       | x               |         | x         | x        | x     |           |              | x          | x          | x          | x       |            | x           | x            |                  |
| LH                                                                                                            |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Lipid (Cholesterol, Triglycerides, HDL, Non-HDL cholesterol, LDL and a Cholesterol/HDL ratio (calculation))   | x       | x               |         | x         | x        | x     |           |              | x          | x          | x          | x       |            | x           | x            |                  |
| Lipoprotein a                                                                                                 |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Lithium                                                                                                       |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Liver function tests (Total bilirubin, Alk Phos, ALT, GGT, Total Protein, Albumin and Globulin (calculation)) | x       | x               |         | x         | x        | x     |           |              | x          | x          | x          | x       |            | x           | x            |                  |
| Magnesium                                                                                                     | x       | x               |         | x         | x        | x     |           |              | x          | x          | x          | x       |            | x           | x            |                  |
| Oestradiol                                                                                                    |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| proBNP                                                                                                        |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Progesterone                                                                                                  |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Prolactin                                                                                                     |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Protein electrophoresis                                                                                       |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| PSA (Total)                                                                                                   | x       | x               |         | x         | x        | x     |           |              | x          |            | x          | x       |            | x           | x            |                  |
| PTH                                                                                                           | x       | x               |         |           | x        | x     |           |              | x          |            |            | x       |            | x           | x            |                  |
| SHBG                                                                                                          |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Testosterone                                                                                                  |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Transferrin saturation                                                                                        |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Troponin T                                                                                                    | x       | x               |         |           | x        |       |           |              | x          |            | x          |         |            |             | x            |                  |
| TSH                                                                                                           | x       | x               |         | x         | x        | x     |           |              | x          |            | x          | x       |            | x           | x            |                  |
| Unsaturated Iron Binding Capacity (UIBC)                                                                      |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Urea and Electrolytes (Sodium, Potassium, Urea, Creatinine, eGFR (calculation) and AKI (calculation))         | x       | x               |         | x         | x        | x     |           |              | x          | x          | x          | x       |            | x           | x            |                  |
| Urine Amylase                                                                                                 |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Calcium                                                                                                 |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Calcium / Creatinine Ratio                                                                              |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Calcium / Creatinine Clearance Ratio                                                                    |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine 24-hour Creatinine Clearance                                                                            |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |

## LABORATORY MEDICINE SERVICE USERS GUIDE

|                                                         | Bristol | Centennial Park | Dunedin | Edinburgh | Hartwood | Leeds | Leicester | Little Aston | Manchester | Montefiore | Nottingham | Parkway | Portsmouth | Southampton | St Anthony's | Histology Centre |
|---------------------------------------------------------|---------|-----------------|---------|-----------|----------|-------|-----------|--------------|------------|------------|------------|---------|------------|-------------|--------------|------------------|
| Urine Chloride                                          |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Creatinine                                        |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Glucose                                           |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Magnesium                                         |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Phosphate                                         |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Potassium                                         |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Protein                                           |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Protein / Creatinine Ratio                        |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Sodium                                            |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Urea                                              |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Urine Uric Acid                                         |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Valproate                                               |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Vitamin B12                                             | x       | x               |         | x         | x        | x     |           |              | x          |            | x          | x       |            | x           | x            |                  |
| <b>Haematology</b>                                      |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Activated Partial Thromboplastin Ratio (APTR)           |         |                 |         |           |          |       |           |              |            |            |            |         |            | x           | x            |                  |
| Activated partial thromboplastin time (APTT)            | x       | x               |         | x         | x        | x     |           |              | x          |            | x          | x       |            | x           | x            |                  |
| Blood Films                                             | x       | x               |         | x         | x        | x     |           |              | x          | x          | x          | x       |            | x           | x            |                  |
| D Dimer                                                 |         | x               |         | x         | x        |       |           |              | x          |            |            |         |            |             | x            |                  |
| ESR                                                     | x       | x               |         | x         | x        | x     |           |              | x          | x          | x          | x       |            | x           | x            |                  |
| Fibrinogen                                              |         |                 |         |           |          |       |           |              | x          |            | x          |         |            | x           | x            |                  |
| Full Blood Count                                        | x       | x               | x       | x         | x        | x     | x         | x            | x          | x          | x          | x       | x          | x           | x            |                  |
| International Normalised Ratio (INR)                    | x       | x               |         | x         | x        | x     |           |              | x          |            | x          | x       |            | x           | x            |                  |
| Prothrombin time (PT)                                   | x       | x               |         | x         | x        | x     |           |              | x          |            | x          | x       |            | x           | x            |                  |
| Reticulocytes                                           |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| <b>Microbiology</b>                                     |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Blood culture screening                                 |         | x               |         | x         |          | x     |           |              | x          |            | x          |         |            | x           | x            |                  |
| C Difficile GDH A/B                                     |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Chlamydia/Gonorrhoea/Trichomonas PCR                    |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Clinical bacteriology (NOT incl. Category 3 organisms)  |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| CMV IgG/ IgM                                            |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgM |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Epstein-Barr Virus Nuclear Antigen (EBNA)               |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Faecal Helicobacter Antigen                             |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Hep A IgM                                               |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |

## LABORATORY MEDICINE SERVICE USERS GUIDE

|                                                                                                         | Bristol | Centennial Park | Dunedin | Edinburgh | Hartwood | Leeds | Leicester | Little Aston | Manchester | Montefiore | Nottingham | Parkway | Portsmouth | Southampton | St Anthony's | Histology Centre |
|---------------------------------------------------------------------------------------------------------|---------|-----------------|---------|-----------|----------|-------|-----------|--------------|------------|------------|------------|---------|------------|-------------|--------------|------------------|
| Hep B Ab                                                                                                |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Hep B S Ag                                                                                              |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Hep C Ab                                                                                                |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Hepatitis B Core Total Antibody                                                                         |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| HIV Ag and Ab                                                                                           |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| HSV type I & II IgG                                                                                     |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Measles IgG                                                                                             |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| CPE bacterial screening                                                                                 |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| MRSA Screening                                                                                          |         | x               |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Mumps IgG                                                                                               |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Mycology                                                                                                |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Parasitology                                                                                            |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Rubella IgG                                                                                             |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| SARS-CoV-2 (N1 and N2)<br>Influenza A and Influenza B<br>Human Respiratory Syncytial Virus<br>A/B (RSV) |         | x               |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Syphilis IgG/IgM                                                                                        |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| TB Quantiferon                                                                                          |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Toxoplasma IgG / IgM                                                                                    |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| Varicella Zoster IgG                                                                                    |         |                 |         |           |          |       |           |              | x          |            |            |         |            |             |              |                  |
| <b>Blood Transfusion</b>                                                                                |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Antibody Identification                                                                                 | x       |                 |         | x         | x        | x     |           |              | x          |            |            |         |            | x           | x            |                  |
| Antibody Screens                                                                                        | x       | x               |         | x         | x        | x     |           |              | x          |            | x          | x       |            | x           | x            |                  |
| Blood Groups                                                                                            | x       | x               |         | x         | x        | x     |           |              | x          |            | x          | x       |            | x           | x            |                  |
| Crossmatching                                                                                           | x       | x               |         | x         | x        | x     |           |              | x          |            | x          | x       |            | x           | x            |                  |
| RhK Phenotyping                                                                                         |         |                 |         | x         |          | x     |           |              | x          |            |            |         |            |             | x            |                  |
| <b>Cellular Pathology</b>                                                                               |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              |                  |
| Histology H&E                                                                                           |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              | x                |
| Histology Molecular Testing                                                                             |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              | x                |
| Immunohisto-chemistry                                                                                   |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              | x                |
| Non Gynae Cytology                                                                                      |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              | x                |
| Special stains                                                                                          |         |                 |         |           |          |       |           |              |            |            |            |         |            |             |              | x                |

## Appendix 2 – Test Repertoire

### Key to Vacutainers

| Vacutainer | Anticoagulant    | Capacity   | Sample Types |
|------------|------------------|------------|--------------|
| Lavender   | EDTA             | 4ml        | ●            |
| Gold       | SST/Gel          | 3.5ml, 5ml | ●            |
| Blue       | Citrate          | 4.5ml      | ●            |
| Red        | None             | 6ml        | ●            |
| Black      | Sodium Citrate   | 5 ml       | ●            |
| Green      | Lithium heparin  | 6ml        | ●            |
| Pink       | EDTA             | 6ml        | ●            |
| Grey       | Fluoride oxalate | 2ml        | ●            |

Paediatric age definitions: Neonate < 4 weeks, Infant 4 weeks to 1 year. Child 1 to 16 years

Location of testing – some will be site dependant

IH – Most Spire laboratories will carry out this testing on-site

SR – These tests are carried out within Spire Laboratory Medicine

EXT – These tests are generally referred out of the Spire Network and the location of testing performed will be indicated on the final report. Any tests which are sent externally may have an extended turnaround time.

| Description                                     | Sample      | Notes / Instruction Ref | TAT     | Reference Range               |                    | Units | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|-------------------------------------------------|-------------|-------------------------|---------|-------------------------------|--------------------|-------|------------------------------------------------------------------|
| <b>A</b>                                        |             |                         |         |                               |                    |       |                                                                  |
| Adrenocorticotrophic hormone (ACTH)             | ●           | 52                      | 14 days | < 46 @ 09:00 am               |                    | ng/L  | EXT                                                              |
| AKI                                             | ● or ●      |                         | 4 hrs   | See report for interpretation |                    |       | IH                                                               |
| Albumin                                         | ● or ●      |                         | 4 hrs   | Adult                         | 35 - 50            | g/L   | IH                                                               |
|                                                 |             |                         |         | Neonate                       | 30 - 45            |       |                                                                  |
|                                                 |             |                         |         | Infant 1 - 16 yrs             | 30 - 45<br>30 - 50 |       |                                                                  |
| Alkaline Phosphatase (ALP)                      | ● or ●      |                         | 4 hrs   | Adult                         | 30 - 130           | IU/L  | IH                                                               |
|                                                 |             |                         |         | Neonate                       | 70 - 380           |       |                                                                  |
|                                                 |             |                         |         | Infant - 16 yrs               | 60 - 425           |       |                                                                  |
| Allergy Screen (See Total and Specific IgE)     | ●           | 33                      |         |                               |                    |       | EXT                                                              |
| Alpha 1 Anti-trypsin (Faeces)                   | Solid Stool | 1, 2, 3                 | 14 days | See report                    |                    |       | EXT                                                              |
| Alpha 1 Anti-trypsin Genotype (S and Z variant) | ●           | 4                       | 45 days | See Report                    |                    |       | EXT                                                              |
| Alpha 1 Anti-trypsin Phenotype                  | ●           | 4                       | 16 days | See Report                    |                    |       | EXT                                                              |

| Description                                                                                               | Sample       | Notes / Instruction Ref                                                              | TAT                                                             | Reference Range                                                                                                                            |                          | Units  | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|-----------------------------------------------------------------------------------------------------------|--------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------|------------------------------------------------------------------|
| Alpha 1 Anti-trypsin (serum)                                                                              | ●            | 4                                                                                    | 5 days                                                          | Adults                                                                                                                                     | 1.1 - 2.1                | g/L    | EXT                                                              |
|                                                                                                           |              |                                                                                      |                                                                 | Children                                                                                                                                   | Age related – see report |        |                                                                  |
| Alpha Feto Protein (AFP)                                                                                  | ●            |                                                                                      | 2 days                                                          | 0 - 5.8                                                                                                                                    |                          | KU/L   | EXT                                                              |
| Alanine Aminotransferase (ALT)                                                                            | ● or ●       | 68                                                                                   | 4 hrs                                                           | See Report                                                                                                                                 |                          | IU/L   | IH                                                               |
| Amylase                                                                                                   | ● or ●       |                                                                                      | 4 hrs                                                           | 28 - 100                                                                                                                                   |                          | IU/L   | IH                                                               |
| Amylase (Fluid)                                                                                           | Fluid        | 5                                                                                    | 2 days                                                          | See Report                                                                                                                                 |                          | IU/L   | SR                                                               |
| Amylase (Urine)                                                                                           | Random Urine | 5                                                                                    | 2 days                                                          | See report                                                                                                                                 |                          | U/L    | SR                                                               |
| Angiotensin Converting Enzyme                                                                             | ●            |                                                                                      | 2 days                                                          | Up to age 17                                                                                                                               | 29 - 112                 | U/L    | SR                                                               |
|                                                                                                           |              |                                                                                      |                                                                 | Adult                                                                                                                                      | 20 - 70                  |        |                                                                  |
| Antibody identification (blood transfusion)                                                               | ● x2         |                                                                                      | Depends on nature of antibodies, may indicate need for referral | N/A                                                                                                                                        |                          | N/A    | IH/ SR/EXT                                                       |
| Anti DNA                                                                                                  | ●            |                                                                                      | 10 days                                                         | Negative <10<br>Equivocal 10 - 15<br>Positive >5                                                                                           |                          | IU/mL  | EXT                                                              |
| Anti Extractable Nuclear Antibodies (Anti ENA) (includes Anti-Jo-1, La,RNP, Ro, Scl-70 and Sm Antibodies) | ●            |                                                                                      | 5 days                                                          | Screen negative: Negative<br>Screen positive or equivocal: individual antigens will be tested separately                                   |                          |        | EXT                                                              |
| Anti Mullerian Hormone                                                                                    | ●            |                                                                                      | 3 days                                                          | See report                                                                                                                                 |                          | pmol/L | SR                                                               |
| Anti Neutrophil Cytoplasmic Antibodies (ANCA)                                                             | ●            |                                                                                      | 4 days                                                          | <b>MPO</b><br>Negative <3.5<br>Equivocal 3.5 - 5.0<br>Positive >5.0<br><b>PR3</b><br>Negative <2.0<br>Equivocal 2.0 - 3.0<br>Positive >3.0 |                          | IU/mL  | EXT                                                              |
| Antinuclear Antibodies (ANA)                                                                              | ●            |                                                                                      | 7 days                                                          | Positive/Negative/ Cytoplasmic staining seen. If positive, titre is reflexed - reported as titre and pattern                               |                          |        | EXT                                                              |
| Anti Streptolysin O Titre                                                                                 | ●            |                                                                                      | 4 days                                                          | See report                                                                                                                                 |                          |        | EXT                                                              |
| Apolipoprotein A                                                                                          | ●            | Stable for up to 8 hours at RT<br>8-48hrs – refrigerated<br>>48 hrs require freezing | 2 days                                                          | Male > 1.0<br>Female >1.0                                                                                                                  |                          | g/L    | SR                                                               |
| Apolipoprotein B                                                                                          | ●            |                                                                                      | 2 days                                                          | Male 0.65 – 1.30<br>Female 0.60 – 1.20                                                                                                     |                          | g/L    | SR                                                               |
| APTT                                                                                                      | ●            | 1, 7, 8, 59                                                                          | 4 hrs                                                           | See report                                                                                                                                 |                          | secs   | IH                                                               |
| Aspartate Transaminase (AST)                                                                              | ● or ●       | 68                                                                                   | 4 hrs                                                           | See report                                                                                                                                 |                          | IU/L   | IH                                                               |

## LABORATORY MEDICINE SERVICE USERS GUIDE

| Description                                    | Sample                                                                 | Notes / Instruction Ref | TAT                                  | Reference Range                                                                                                                                     | Units  | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|------------------------------------------------|------------------------------------------------------------------------|-------------------------|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------------------------------------------|
| Autoimmune Antibody Screen                     | ●                                                                      |                         | 9 days                               | Positive/Negative<br>If Positive for smooth muscle or mitochondrial antibodies - reflex test. These reflex tests are reported as a titre.           |        | EXT                                                              |
| <b>B</b>                                       |                                                                        |                         |                                      |                                                                                                                                                     |        |                                                                  |
| Bordatella pertussis culture (Whooping cough)  | Pernasal swab (contact lab)                                            | 64                      | 12 days                              |                                                                                                                                                     |        | EXT                                                              |
| Borrelia Burgdorferi Antibodies (Lyme disease) | ●                                                                      | 9, 10                   | 8 days (Confirmatory test 21 days)   | See Report                                                                                                                                          |        | EXT                                                              |
| Bence Jones Protein                            | Fresh Early Morning Urine in white top container                       | 5                       | 7 days                               | Qualitative.<br>Please note urinary free light chain quantification is not available. Please request serum free light chain quantification instead. |        | EXT                                                              |
| Beta HCG                                       | ●                                                                      |                         | 2 days                               | 0 - 5                                                                                                                                               | IU/L   | SR                                                               |
| Bicarbonate                                    | ●                                                                      |                         | 2 days                               | Neonate 19 - 28<br>Child 19 - 28<br>Adult 22 - 29                                                                                                   | mmol/L | SR / IH                                                          |
| Bile culture                                   | Bile                                                                   | 5                       | 2-4 days                             |                                                                                                                                                     |        | IH                                                               |
| Bilirubin (Total)                              | ● or ●                                                                 |                         | 4 hrs                                | Age range: from 14 days < 21                                                                                                                        | μmol/L | IH                                                               |
| Blood Culture                                  | IH *Set of 1x aerobic and 1x anaerobic BD Bactec blood culture bottles | 1,11                    | Up to 7 days                         | Not applicable                                                                                                                                      |        | IH/EXT/SR                                                        |
| Blood Culture (septic patient)                 | 2 x anaerobic and 2 x aerobic bottles                                  | 1,11                    | Up to 7 days                         | Not applicable                                                                                                                                      |        | IH/EXT/SR                                                        |
| Blood Films                                    | ●                                                                      |                         | Contact local laboratory             | Not applicable                                                                                                                                      |        | IH/EXT                                                           |
| Blood Group (ABO/Rh)                           | ●                                                                      | 12                      | 1 - 2 days                           | Not applicable                                                                                                                                      |        | IH/SR/EXT                                                        |
| Blood Group and antibody screen                | ●                                                                      | 12                      | 1 – 2 days                           | Not applicable                                                                                                                                      |        | IH/SR/EXT                                                        |
| Bone profile                                   | ● or ●                                                                 |                         | 4 hrs                                | See Report                                                                                                                                          |        | IH                                                               |
| Bordetella Pertussis Antibodies                | ●                                                                      | 9, 10                   | 7 days                               | Not applicable                                                                                                                                      |        | EXT                                                              |
| Bronchial Washing/BAL/NPA for Culture          | Bronchial Washings                                                     | 5                       | 2-4 days                             | Not applicable                                                                                                                                      |        | IH/SR                                                            |
| Bronchial Washing for TB Culture               | Bronchial Washing                                                      | 5                       | Microscopy 48 hours<br>Final 6 Weeks | Not applicable                                                                                                                                      |        | EXT                                                              |
| <b>C</b>                                       |                                                                        |                         |                                      |                                                                                                                                                     |        |                                                                  |
| C Reactive Protein (CRP)                       | ● or ●                                                                 |                         | 4 hrs                                | 0 - 5                                                                                                                                               | mg/L   | IH                                                               |

## LABORATORY MEDICINE SERVICE USERS GUIDE

| Description                                                  | Sample                                   | Notes / Instruction Ref | TAT        | Reference Range                                               |           | Units       | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|--------------------------------------------------------------|------------------------------------------|-------------------------|------------|---------------------------------------------------------------|-----------|-------------|------------------------------------------------------------------|
| CA 125                                                       | ●                                        | 56                      | 2 days     | <35                                                           |           | kU/L        | SR                                                               |
| CA 15-3                                                      | ●                                        | 56                      | 2 days     | <26.4                                                         |           | kU/L        | SR                                                               |
| CA 19-9                                                      | ●                                        |                         | 2 days     | <27                                                           |           | kU/L        | SR                                                               |
| Caeruloplasmin                                               | ●                                        |                         | 9 days     | 0.2 - 0.6                                                     |           | g/L         | EXT                                                              |
| Calcium (Adjusted)                                           | ● or ●                                   | Avoid venestasis        | 4 hrs      | 2.2 - 2.6                                                     |           | mmol/L      | IH                                                               |
| Paediatric Calcium, not adjusted                             | ●                                        | Avoid venestasis        | 4 hrs      | Neonate                                                       | 2.0 – 2.7 | mmol/L      | IH                                                               |
|                                                              |                                          |                         |            | Infant – 16 yrs                                               | 2.2 – 2.7 |             |                                                                  |
| Calcium (24 hr Urine)                                        | 24 hr Urine (Acidified)                  | 13, 18                  | 2 days     | 2.5 - 7.5                                                     |           | mmol/24 hrs | SR                                                               |
| Carcino Embryonic Antigen                                    | ●                                        |                         | 2 days     | Age 20-69 <4.7<br>Age 40-69 <5.2                              |           | µg/L        | SR                                                               |
| Cardiac Enzymes                                              | ● or ●                                   |                         | 4 hrs      | See Report                                                    |           |             | IH                                                               |
| Cardiolipin Antibodies (IgG)                                 | ●                                        |                         | 12 days    | Negative: < 10<br>Weak Positive: 10 – 40<br>Positive: > 40    |           | GPL-U/ml    | EXT                                                              |
| Cardiolipin Antibodies (IgM)                                 | ●                                        |                         | 12 days    | Negative: < 10<br>Weak Positive: 10 – 40<br>Positive: > 40    |           | MPL-U/ml    | EXT                                                              |
| Cervical Cytology (HPV)                                      | LBC container                            |                         | 5 - 7 days | See Report                                                    |           |             | EXT                                                              |
| Chlamydia, Eye Swab                                          | Dry PCR swab                             |                         | 2-3 days   | Negative or Positive by PCR                                   |           |             | EXT                                                              |
| Chlamydia Genital Swab (endocervical and vaginal swabs only) | BD swab collection kit<br>Chlamydia swab | 14                      | 2-3 days   | Negative or Positive by PCR                                   |           |             | SR                                                               |
| Chlamydia, Urine                                             | BD urine collection kit                  | 5                       | 2-3 days   | Negative or Positive by PCR                                   |           |             | SR                                                               |
| Chloride                                                     | ●                                        |                         | 2 days     | 98 - 107                                                      |           | mmol/L      | IH                                                               |
| Cholesterol                                                  | ● or ●                                   |                         | 4 hrs      | <5.0                                                          |           | mmol/L      | IH                                                               |
| Chromium (MOM Hip Investigation)                             | ●                                        | 15                      | 7 days     | See report                                                    |           | nmol/L      | EXT                                                              |
| Citrulline Antibodies (Anti-CCP)                             | ●                                        |                         | 5 days     | Negative: 0 - 7.0<br>Equivocal: 7.0 - 10.0<br>Positive: >10.0 |           | Elia U/mL   | EXT                                                              |
| CKMB                                                         | ●                                        |                         | 2 days     | <25                                                           |           | IU/L        | SR                                                               |
| Clostridium Difficile GDH and Toxin (C. Diff)                | Faeces                                   | 16, 17                  | 1-2 days   | Positive or Negative                                          |           |             | SR                                                               |
| CMV (Cytomegalovirus) IgG Antibodies                         | ●                                        |                         | 5 days     | Detected or Not Detected                                      |           |             | SR                                                               |
| CMV (Cytomegalovirus) IgM Antibodies                         | ●                                        |                         | 5 days     | Detected or Not Detected                                      |           |             | SR                                                               |
| Coagulation Screen (PT/APTT)                                 | ●                                        | 1, 7, 8                 | 4 hrs      | PT: 12.2 – 15.3<br>APTT: 22.2 – 34.7                          |           | secs        | IH                                                               |
| Cobalt (Metal on Metal)                                      | ●                                        | 15                      | 7 days     | See Report                                                    |           | nmol/L      | EXT                                                              |
| Coeliac Screen (see TTG and Endomysial Antibodies)           | ●                                        |                         | 10 days    |                                                               |           |             | EXT                                                              |
| Complement C3                                                | ●                                        |                         | 5 days     | 0.75 – 1.65                                                   |           | g/L         | EXT                                                              |
| Complement C4                                                | ●                                        |                         | 5 days     | 0.14 – 0.54                                                   |           | g/L         | EXT                                                              |
| Copper (Serum)                                               | ●                                        | 70                      | 7 days     | <4 mths                                                       | 1.4 - 7.2 | µmol/l      | EXT                                                              |

## LABORATORY MEDICINE SERVICE USERS GUIDE

| Description                                                                            | Sample                                                          | Notes / Instruction Ref | TAT                                                     | Reference Range                                                                     |                                   | Units        | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|----------------------------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------|---------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------|--------------|------------------------------------------------------------------|
|                                                                                        |                                                                 |                         |                                                         | 4-<6mths                                                                            | 3.9 – 17.3                        |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 6m-<9yrs                                                                            | 11.1 – 27.4                       |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 9-<13 yrs                                                                           | 11.2 – 23.7                       |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 13-19 yrs                                                                           | 11.0 – 22.5                       |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | >19 yrs                                                                             | 11.0 – 25.1                       |              |                                                                  |
| Copper (24 hr urine)                                                                   | 24 hr Urine                                                     | 13, 18, 19              | 7 days                                                  | Normal <0.7<br>Wilscons disease >1.8                                                |                                   | µmol/2 4hrs  | EXT                                                              |
| Cortisol                                                                               | ●                                                               | 56                      | 2 days                                                  | 6-10am 166-507<br>4-8pm 73.8-291.0                                                  |                                   | nmol/L       | SR                                                               |
| Cortisol (24 hr Urine)                                                                 | 24 hr Urine                                                     | 13, 19                  | 9 days                                                  | < 486                                                                               |                                   | nmol/2 4 hr  | EXT                                                              |
| Covid-19 Antigen SARS-Cov-2 PCR (swabbing maybe undertaken at any Spire Hospital site) | Viral swab                                                      | 62                      | 2 days                                                  | Detected / Not detected                                                             |                                   |              | SR                                                               |
| CPE Screening by Culture (Carbapenemase Producing Enterobacteriaceae)                  | Blue top Rectal Swab with visible faecal matter or stool sample |                         | 2-4 days, if positive confirmatory test may take longer | Detected or Not Detected                                                            |                                   |              | SR                                                               |
| Creatine phosphokinase                                                                 | ● or ●                                                          |                         | 4 hrs                                                   | Female: 25 – 200<br>Male: 40 - 320                                                  |                                   | IU/L         | IH                                                               |
| Creatinine                                                                             | ● or ●                                                          |                         | 4 hrs                                                   | Neonates                                                                            | 27 - 77                           | µmol/L       | IH                                                               |
|                                                                                        |                                                                 |                         |                                                         | 2 – 12 months                                                                       | 14 - 34                           |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 1 – 3 years                                                                         | 15 - 31                           |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 3 – 5 years                                                                         | 23 - 37                           |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 5 – 7 years                                                                         | 25 - 42                           |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 7 – 9 years                                                                         | 30 - 47                           |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 9 – 11 years                                                                        | 29 - 56                           |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 11 – 13 years                                                                       | 39 - 60                           |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | 13 – 15 years                                                                       | 40 - 68                           |              |                                                                  |
|                                                                                        |                                                                 |                         |                                                         | Adult                                                                               | Female: 45 – 84<br>Male: 59 - 104 |              |                                                                  |
| Creatinine Clearance Test                                                              | ● +24 hr Urine                                                  | 13, 19, 20              | 2 days                                                  | 66 - 143                                                                            |                                   | ml/min       | SR                                                               |
| Creatinine (Random Urine)                                                              | Random Urine                                                    |                         | 2 days                                                  | Not applicable                                                                      |                                   | mmol/L       | SR                                                               |
| Creatinine (24 hr Urine)                                                               | 24 hr Urine                                                     | 13                      | 2 days                                                  | Female: 6 - 13<br>Male: 9 - 19                                                      |                                   | mmol/2 4 hrs | SR                                                               |
| Crossmatch request                                                                     | ●                                                               | 12, 43                  | 1 – 2 days                                              | Not applicable                                                                      |                                   |              | IH / SR / EXT                                                    |
| Cryptosporidium microscopy                                                             | Stool                                                           |                         | 2-3 days                                                |                                                                                     |                                   |              | SR                                                               |
| Cryoglobulin                                                                           | ●                                                               | 63                      | 10 days                                                 | Not applicable                                                                      |                                   |              | EXT                                                              |
| Crystals in Fluid                                                                      | Fluid                                                           | 5                       | 1-2 days                                                | Not applicable                                                                      |                                   |              | SR                                                               |
| Crystals in Fluid and Culture                                                          | Fluid                                                           | 5                       | Interim 2-3 days<br>Final up to 7 days                  | Not applicable                                                                      |                                   |              | SR                                                               |
| CSF Culture and Cell Count                                                             | CSF                                                             | 1, 5                    | 1-3 days                                                | Not applicable                                                                      |                                   |              | SR                                                               |
| CSF Glucose                                                                            | ● CSF (min 150 µl)                                              | 5                       | 3 days                                                  | Interpret with serum glucose result<br>Paed (<16 yr): 3.3 – 4.4<br>Adult: 2.2 – 3.9 |                                   | mmol/L       | EXT                                                              |
| CSF Protein                                                                            | CSF                                                             | 5                       | 3 days                                                  | 0.15 - 0.40                                                                         |                                   | g/L          | SR                                                               |

| Description                                  | Sample                                                  | Notes / Instruction Ref | TAT         | Reference Range                                                                                     | Units           | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|----------------------------------------------|---------------------------------------------------------|-------------------------|-------------|-----------------------------------------------------------------------------------------------------|-----------------|------------------------------------------------------------------|
| Cytology, Fine Needle Aspirate               | Aspirate                                                | 1, 5                    | 7 days      | Not applicable                                                                                      |                 | IH/SR/ EXT                                                       |
| Cytology, Fluid                              | LBC container or universal                              | 1                       | 7 days      | Not applicable                                                                                      |                 | IH/SR/EXT                                                        |
| Cytology, Smear (HPV)                        | LBC container                                           |                         | 5 - 7 days  | Not applicable                                                                                      |                 | EXT                                                              |
| Cytology, Urine                              | Urine                                                   | 1, 5                    | 7 days      | Not applicable                                                                                      |                 | IH/SR/EXT                                                        |
| <b>D</b>                                     |                                                         |                         |             |                                                                                                     |                 |                                                                  |
| D-Dimer                                      | Contact Laboratory                                      | 7, 8                    | Contact lab | Defined locally – see report                                                                        | Defined locally | IH / EXT                                                         |
| Digoxin                                      | ●                                                       | 23                      | 3 days      | 0.5 – 2.0<br>Target range in heart failure is 0.5 – 1.0                                             | mg/L            | EXT                                                              |
| <b>E</b>                                     |                                                         |                         |             |                                                                                                     |                 |                                                                  |
| eGFR                                         | ● or ●                                                  |                         | 4 hrs       | See report for interpretation                                                                       |                 | IH                                                               |
| Ear swab                                     | Orange top charcoal swab                                |                         | 3 days      | 5 days for fungal culture                                                                           |                 | SR                                                               |
| Endocervical swab                            | Black top Charcoal swab                                 | 50                      | 2-4 days    | Growth detected / Not detected                                                                      |                 | SR                                                               |
| Endomysial Antibodies (IgA)                  | ●                                                       |                         | 10 days     | Positive/Negative/ Equivocal                                                                        |                 | EXT                                                              |
| Epstein Barr virus (EBV) Antibodies          | ●                                                       |                         | 5 days      | Detected / Not detected/ Equivocal                                                                  |                 | IH/SR                                                            |
| Erythrocyte Sedimentation Rate (ESR)         | ●                                                       | 51                      | 4 hrs       | Age (yrs) M F<br>10-50 ≤10 ≤12<br>51-60 ≤12 ≤19<br>61-70 ≤14 ≤20<br>>70 ≤30 ≤35                     | mm/hr           | IH                                                               |
| Eye swab                                     | Swab                                                    |                         | 2-4 days    |                                                                                                     |                 | SR                                                               |
| Expressed prostatic secretions (EPS) culture | EPS                                                     | 5                       | 2-4 days    |                                                                                                     |                 | SR                                                               |
| <b>F</b>                                     |                                                         |                         |             |                                                                                                     |                 |                                                                  |
| Faecal Calprotectin                          | Stool                                                   | 16                      | 5 days      | Normal: < 50<br>Median: 25<br>>50 regarded as positive                                              | µg/g faeces     | SR                                                               |
| Faeces Culture                               | Stool                                                   | 16                      | 2 - 4 days  | Not applicable                                                                                      |                 | SR                                                               |
| Faecal Elastase                              | Stool                                                   | 16                      | 5 days      | Normal: >200<br>Moderate Pancreatic Insufficiency: 100-200<br>Severe Pancreatic Insufficiency: <100 | µg/g faeces     | SR                                                               |
| Faecal Immunochemical testing (FIT)          | Stool collected in EXTEL HEMO-AUTO MC Collection Picker |                         | 7 days      | Positive / Negative                                                                                 | µg Hb/g         | SR                                                               |

| Description                                                                                                                   | Sample                                                                                         | Notes / Instruction Ref | TAT                                                      | Reference Range                                                                                                                                 |             |             | Units     | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------|-----------|------------------------------------------------------------------|
| Ferritin                                                                                                                      | ●                                                                                              |                         | 2 days                                                   | Female: 13 – 150<br>Male: 30 - 400                                                                                                              |             |             | µg/L      | SR                                                               |
| Fibrinogen                                                                                                                    | ●                                                                                              | 1, 7, 8                 | 24 hrs                                                   | Generally, between 1.5 – 4.0.<br>See individual reports for specific reference range                                                            |             |             | g/L       | IH / EXT                                                         |
| Fluid /aspirate/Pus culture from non-sterile sites                                                                            | State site                                                                                     | 5                       | Interim 2-4 days                                         |                                                                                                                                                 |             |             |           | SR                                                               |
| Fluid /aspirate/Pus culture from sterile sites                                                                                | State site                                                                                     | 5                       | Interim 2-4 days                                         |                                                                                                                                                 |             |             |           | SR                                                               |
| Fluid Or Aspirate for Culture<br><br>Orthopaedic culture                                                                      | State Site                                                                                     | 5, 58                   | Interim 2-3 days<br>Final up to 7 days<br>21 days        | Not applicable                                                                                                                                  |             |             |           | SR                                                               |
| Fluid (from sterile sites) in blood culture bottles                                                                           | A minimum of 3ml and max of 10ml to be put into each of an anaerobic bottle and aerobic bottle |                         | Interim 2-4 days                                         |                                                                                                                                                 |             |             |           | SR                                                               |
| Fluid Or Aspirate for Culture with TB Culture                                                                                 | State Site                                                                                     | 5, 57, 58               | Interim 2-3 days<br>Final up to 7 days (routine culture) | Not applicable                                                                                                                                  |             |             |           | EXT                                                              |
| Fluid Or Aspirate for TB Culture                                                                                              | State Site                                                                                     | 5,                      | Microscopy 2-3 days<br>Culture up to 8 Weeks             | Not applicable                                                                                                                                  |             |             |           | EXT                                                              |
| Folate (Serum)                                                                                                                | ●                                                                                              | 1, 6, 36, 56            | 2 days                                                   | 3.89 – 26.8                                                                                                                                     |             |             | µg/L      | SR                                                               |
| Follicle Stimulating Hormone                                                                                                  | ●                                                                                              |                         | 2 days                                                   | Follicular: 3.5 - 12.5<br>Ovulation: 4.7 - 21.5<br>Luteal: 1.7 - 7.7<br>Post Menopause: 25.8 – 134.8<br>Male: 1.5 – 12.4                        |             |             | mIU/ml    | SR                                                               |
| Free Androgen Index                                                                                                           | ●                                                                                              | 67                      | 2 days                                                   | Male aged 20 - 49:<br>35.0 - 92.6<br>Male aged >=50:<br>24.3 - 72.1<br>Female aged 20-49:<br>0.297 - 5.62<br>Female aged >= 50:<br>0.187 - 3.63 |             |             | %         | SR                                                               |
| Free T3                                                                                                                       | ●                                                                                              |                         | 2 days                                                   | 3.1 - 6.8                                                                                                                                       |             |             | pmol/L    | SR                                                               |
| Free T4                                                                                                                       | ●                                                                                              |                         | 2 days                                                   | 12 - 22                                                                                                                                         |             |             | pmol/L    | SR                                                               |
| Full Blood Count (FBC including Differential)<br>For paediatric reference ranges please see tables at the end of this section | ●                                                                                              |                         | 4 hrs                                                    |                                                                                                                                                 | Male        | Female      |           | IH                                                               |
|                                                                                                                               |                                                                                                |                         |                                                          | WBC                                                                                                                                             | 4.0 – 10.0  | 4.0 – 10.0  | x10^9/L   |                                                                  |
|                                                                                                                               |                                                                                                |                         |                                                          | RBC                                                                                                                                             | 4.5 – 5.5   | 3.8 – 4.8   | X10^12/ L |                                                                  |
|                                                                                                                               |                                                                                                |                         |                                                          | Hb                                                                                                                                              | 130 - 170   | 120 - 150   | g/L       |                                                                  |
|                                                                                                                               |                                                                                                |                         |                                                          | HCT                                                                                                                                             | 0.4 – 0.5   | 0.36 – 0.46 | ratio     |                                                                  |
|                                                                                                                               |                                                                                                |                         |                                                          | MCV                                                                                                                                             | 83 - 101    | 83 - 101    | fL        |                                                                  |
|                                                                                                                               |                                                                                                |                         |                                                          | MCH                                                                                                                                             | 27.0 – 32.0 | 27.0 – 32.0 | pg        |                                                                  |

| Description                                                      | Sample                                                                        | Notes / Instruction Ref | TAT          | Reference Range                                  |            |            | Units   | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------|--------------|--------------------------------------------------|------------|------------|---------|------------------------------------------------------------------|
|                                                                  |                                                                               |                         |              | MCHC                                             | 315 - 345  | 315 - 345  | g/L     |                                                                  |
|                                                                  |                                                                               |                         |              | Platelets                                        | 150 - 410  | 150 - 410  | X10^9/L |                                                                  |
|                                                                  |                                                                               |                         |              | RDW                                              | 11.6-14.0  | 11.6-14.0  | CV%     |                                                                  |
|                                                                  |                                                                               |                         |              | Neutrophil Abs                                   | 2.0 – 7.0  | 2.0 – 7.0  | X10^9/L |                                                                  |
|                                                                  |                                                                               |                         |              | Lymphocytes abs                                  | 1.0 – 3.0  | 1.0 – 3.0  | X10^9/L |                                                                  |
|                                                                  |                                                                               |                         |              | Monocytes abs                                    | 0.2 – 1.0  | 0.2 – 1.0  | X10^9/L |                                                                  |
|                                                                  |                                                                               |                         |              | Eosinophils abs                                  | 0.02 – 0.5 | 0.02 – 0.5 | X10^9/L |                                                                  |
|                                                                  |                                                                               |                         |              | Basophils abs                                    | 0.02 – 0.1 | 0.02 – 0.1 | X10^9/L |                                                                  |
| G                                                                |                                                                               |                         |              |                                                  |            |            |         |                                                                  |
| Gamma Glutamyl Transaminase                                      | ● or ●                                                                        |                         | 4 hrs        | Female: 1 - 40<br>Male: 1 - 60                   |            |            | IU/L    | IH                                                               |
| Gentamicin                                                       | ●                                                                             | 24                      | 1 day        | Defined locally                                  |            |            |         | EXT                                                              |
| Glucose (Serum)                                                  | ● or ●                                                                        | 56, 68                  | 4 hrs        | See Report                                       |            |            | mmol/L  | IH                                                               |
| Glucose Tolerance Test                                           | ●                                                                             | By arrangement with OPD | 4 hrs        | See Report                                       |            |            | mmol/L  | IH                                                               |
| Glycated Haemoglobin / Haemoglobin A1c (HbA1c)                   | ●                                                                             |                         | 2 days       | See Report                                       |            |            | %       | SR                                                               |
| Gonorrhoea culture                                               | Black top Charcoal swab                                                       | 50                      | 2 - 4 days   | Growth detected / not detected                   |            |            |         | SR                                                               |
| Gonorrhoea, PCR (Urine sample, endocervical or vaginal swab only | BD swab collection kit or random urine collected in "BD" urine collection kit | 14                      | 2 - 3 days   | Negative or Positive by PCR                      |            |            |         | SR                                                               |
| H                                                                |                                                                               |                         |              |                                                  |            |            |         |                                                                  |
| Harmony (Non-Invasive Paternity Test)                            | Contact Lab                                                                   | 9,25                    | 14 days      | See Report                                       |            |            |         | EXT                                                              |
| HDL Cholesterol                                                  | ● or ●                                                                        |                         | 4 hrs        | Desirable Ranges<br>Female: > 1.2<br>Male: > 1.0 |            |            | mmol/L  | IH                                                               |
| Helicobacter Pylori Culture and susceptibility testing           | Gastric Biopsy in Dents transport media (contact lab)                         | 26                      | 15 - 18 Days | Not applicable                                   |            |            |         | SR                                                               |
| Helicobacter Pylori Faecal Antigen                               | Stool                                                                         | 16                      | 2 days       | Detected or Not Detected                         |            |            |         | SR                                                               |
| Hepatitis A Antibodies (IgM)                                     | ●                                                                             |                         | 3 days       | Detected or Not Detected                         |            |            |         | SR                                                               |
| Hepatitis B Total Core Antibodies (IgM/IgG)                      | ●                                                                             |                         | 2 days       | Detected or Not Detected                         |            |            |         | SR                                                               |
| Hepatitis B (e) Status                                           | ●                                                                             |                         | 10 days      | Detected or Not Detected                         |            |            |         | SR                                                               |
| Hepatitis B Surface Antibodies                                   | ●                                                                             |                         | 2 days       | See Report                                       |            |            | IU/L    | SR                                                               |

| Description                                              | Sample                                         | Notes / Instruction Ref             | TAT                   | Reference Range                      | Units  | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|----------------------------------------------------------|------------------------------------------------|-------------------------------------|-----------------------|--------------------------------------|--------|------------------------------------------------------------------|
| Hepatitis B Surface Antigen (HbsAg)                      | ●                                              |                                     | 2 days                | Detected or Not Detected             |        | SR                                                               |
| Hepatitis C Antibodies                                   | ●                                              |                                     | 2 days                | Detected or Not Detected             |        | SR                                                               |
| Herpes Simplex type I IgG                                | ●                                              |                                     | 5 days                | Detected / Not detected/ Equivocal   |        | IH                                                               |
| Herpes Simplex type II IgG                               | ●                                              |                                     | 5 days                | Detected / Not detected/ Equivocal   |        | IH                                                               |
| Histology – diagnostic biopsy                            | See Note 27                                    | 27, 61                              | 7 days                | See Report                           |        | IH/SR/EXT                                                        |
| Histology – samples which are non-diagnostic             | See Note 27                                    | 61                                  | 10 days               | See Report                           |        | IH/SR/EXT                                                        |
| Histology Frozen section                                 | Fresh sterile universal container              | Please contact lab before arranging | Tissue type dependant | See Report                           |        | EXT                                                              |
| Histology Molecular testing (BRAF, MSI, KRAS, NRAS-BRAF) | formalin fixed paraffin-embedded (FFPE) tissue |                                     | 5 days                | Detected or Not Detected             |        | IH                                                               |
| HIV 1, 2 Antibodies and p24 Antigen                      | ●                                              |                                     | 2 days                | Detected or Not Detected             |        | SR                                                               |
| High Vaginal Swab                                        | See Note 28                                    | 28                                  | 3-5 days              | Not applicable                       |        | SR                                                               |
| <b>I</b>                                                 |                                                |                                     |                       |                                      |        |                                                                  |
| IGF1 (Somatomedin)also known as Insulin like GF1         | ●                                              | 29                                  | 9 days                | Age and gender related<br>See report | nmol/L | EXT                                                              |
| Immunoglobulins (IgG, IgM, IgA)                          | ●                                              |                                     | 2 days                | See report – age related             |        | SR                                                               |
| Immunohistochemistry                                     | Fixed tissue on slide                          | 49                                  | Tissue type dependant |                                      |        | IH                                                               |
| Insulin                                                  | ●                                              | 56                                  | 2 days                | 17.8 – 173.0                         | pmol/L | SR                                                               |
| INR                                                      | ●                                              | 1, 7, 8                             | 4 hrs                 | Normal 0.8 – 1.2                     | ratio  | IH                                                               |
|                                                          |                                                |                                     |                       | Anticoagulation therapy below        |        |                                                                  |
|                                                          |                                                |                                     |                       | Target INR 2.5 (2.0 – 3.0)           |        |                                                                  |
|                                                          |                                                |                                     |                       | Target INR 3.5 (3.0 – 4.0)           |        |                                                                  |
| Iron                                                     | ●                                              |                                     | 2 days                | 5.83 – 34.5                          | µmol/L | SR                                                               |
| Iron and TIBC                                            | ●                                              |                                     | 2 days                | See Report                           |        | SR                                                               |
| IUCD                                                     | Device in sterile pot                          |                                     | 2-4 days              |                                      |        | SR                                                               |
| IV Tip culture                                           | 5cm portion of tip                             |                                     | 2-4 days              |                                      |        | SR                                                               |
| <b>J</b>                                                 |                                                |                                     |                       |                                      |        |                                                                  |
| JAK2 Mutation                                            | ●●                                             |                                     | 12 days               |                                      |        | EXT                                                              |
| <b>K</b>                                                 |                                                |                                     |                       |                                      |        |                                                                  |
| Karyotyping (X/Y)                                        | ●                                              | 1, 4, 30, 42                        | 45 days               |                                      |        | EXT                                                              |
| <b>L</b>                                                 |                                                |                                     |                       |                                      |        |                                                                  |

| Description                               | Sample                    | Notes / Instruction Ref | TAT                                    | Reference Range                                                                                     | Units       | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|-------------------------------------------|---------------------------|-------------------------|----------------------------------------|-----------------------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------|
| Lactate                                   | ●                         |                         | 4 hours                                | <16 years 0.6 - 2.5<br>>16 years 0.5 - 2.2                                                          | mmol/L      | IH / EXT                                                         |
| Lactate Dehydrogenase                     | ● or ●                    | 56                      | 4 hrs                                  | Female: 135 - 214<br>Male: 135 - 225                                                                | IU/L        | IH                                                               |
| LDL Cholesterol (Low Density Lipoprotein) | ● or ●                    |                         | 4 hrs                                  | <3.0                                                                                                | mmol/L      | IH                                                               |
| Legionella Antigen                        | Urine                     | 65                      | 4 days                                 | Detected / Not detected                                                                             |             | EXT                                                              |
| Lipid Profile                             | ● or ●                    |                         | 4 hrs                                  | See Report                                                                                          |             | IH                                                               |
| Lipoprotein (a)                           | ●                         | 3                       | 2 days                                 | Desirable range <50 in non-Hispanic Caucasians                                                      | nmol/L      | SR                                                               |
| Lithium                                   | ●                         | 4, 31                   | 2 days                                 | See report                                                                                          | See report  | IH/SR/ EXT                                                       |
| Liver Function Tests                      | ● or ●                    |                         | 4 hrs                                  | See Report                                                                                          |             | IH                                                               |
| Lupus Anticoagulant Screen                | ●●●●                      | 1, 3, 6, 7, 8, 25, 34   | 7 days                                 | Contact lab for Interpretation of results.                                                          |             | SR                                                               |
| Luteinising Hormone                       | ●                         |                         | 2 days                                 | Follicular: 2.4 -12.6<br>Ovulation: 14.0 - 95.6<br>Luteal: 1.0 - 11.4<br>Post Menopause: 7.7 - 58.5 | U/L         | SR                                                               |
| <b>M</b>                                  |                           |                         |                                        |                                                                                                     |             |                                                                  |
| Magnesium (Serum)                         | ● or ●                    |                         | 4 hrs                                  | Adult 0.7 – 1.0<br>Neonate 0.6 – 1.0<br>Infant – 16 yr 0.7 – 1.0                                    | mmol/L      | IH                                                               |
| Magnesium (Red Cell)                      | ●●                        | 40                      | 7 days                                 | See report                                                                                          |             | EXT                                                              |
| Magnesium (Urine)                         | Random Urine              | 5                       | 2 days                                 | Ref Range only quoted for 24hr collection                                                           | mmol/L      | SR                                                               |
| Magnesium (24 hr Urine)                   | 24 hr Urine (Acidified)   | 13                      | 2 days                                 | See report                                                                                          | mmol/24 hrs | SR                                                               |
| Malarial Parasites                        | ●                         | 48                      | 4 hours                                | Detected or Not Detected                                                                            |             | IH / EXT                                                         |
| Measles Antibodies (IgG)                  | ●                         |                         | 5 days                                 | Detected or Not Detected                                                                            |             | SR                                                               |
| Measles Antibodies (IgM)                  | ●                         |                         | 10 days                                | Detected or Not Detected                                                                            |             | EXT                                                              |
| Metadrenalin (Urine)                      | 24 hr Urine (Acidified)   | 13, 18                  | 12 days                                | See Report                                                                                          |             | EXT                                                              |
| Metal work for culture                    | Metal work in sterile pot |                         | 2-4 interim, up to 16 days final       |                                                                                                     |             | SR                                                               |
| Metanephrines (plasma)                    | 2x ●                      | 1, 3                    | 15 days                                | Normetanephrine: <170<br>Metanephrine <100                                                          | ng/L        | EXT                                                              |
| Mouth swab                                | Blue top swab             |                         | 2-4 days                               |                                                                                                     |             | SR                                                               |
| MRSA swab                                 | Blue top swab             |                         | Negative 1-2 days<br>Positive 2-3 days | Not Isolated or See Report                                                                          |             | SR                                                               |
| MSSA swab                                 | Blue top swab             |                         | Negative 1-2 days<br>Positive 2-3 days | Not Isolated or See Report                                                                          |             | SR                                                               |
| Mumps IgG Antibodies                      | ●                         |                         | 5 days                                 | Detected or Not Detected                                                                            |             | SR                                                               |

| Description                                 | Sample                                                            | Notes / Instruction Ref | TAT             | Reference Range                                                                                                          | Units       | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|---------------------------------------------|-------------------------------------------------------------------|-------------------------|-----------------|--------------------------------------------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------|
| Mumps IgM Antibodies                        | ●                                                                 |                         | 10 days         | Detected or Not Detected                                                                                                 |             | EXT                                                              |
| Mycoplasma genitalium and Ureaplasma by PCR | Urine with white top container                                    |                         | 12 days         |                                                                                                                          |             | EXT                                                              |
| Mycology                                    | Skin scrapings, hair or nails ONLY                                | 25                      | Minimum 21 days | Not applicable                                                                                                           |             | SR                                                               |
| <b>N</b>                                    |                                                                   |                         |                 |                                                                                                                          |             |                                                                  |
| Norovirus Screening                         | Faeces                                                            | 16, 17                  | 2 - 3 days      | Detected or Not Detected                                                                                                 |             | EXT                                                              |
| Nose swab                                   | Blue top swab                                                     |                         | 2 – 4 days      |                                                                                                                          |             | SR                                                               |
| <b>O</b>                                    |                                                                   |                         |                 |                                                                                                                          |             |                                                                  |
| Oestradiol                                  | ●                                                                 | 56                      | 2 days          | Follicular: 114 - 332<br>Ovulation: 222 - 1959<br>Luteal: 222 - 854<br>Post Menopause: < 18.4 - 505<br>MALES: 41.4 - 159 | mol/L       | SR                                                               |
| Oligoclonal bands                           | ● +CSF in white top container<br><br>0.2 ml paired serum required | 5, 22                   | 9 days          | See Report                                                                                                               |             | EXT                                                              |
| Ova, cysts and parasites (Faeces)           | Faeces                                                            | 9, 10, 16               | 3 days          | Not applicable                                                                                                           |             | SR                                                               |
| <b>P</b>                                    |                                                                   |                         |                 |                                                                                                                          |             |                                                                  |
| Parathyroid Hormone (Intact)                | ●                                                                 | 56                      | 2 days          | 17.3 – 74.1<br>See report for associated comment                                                                         | pg/mL       | SR                                                               |
| Pemphigoid Antibodies                       | ●                                                                 |                         | 8 days          | Positive/ Negative                                                                                                       |             | EXT                                                              |
| Pemphigus Antibodies                        | ●                                                                 |                         | 8 days          | Positive/ Negative                                                                                                       |             | EXT                                                              |
| Penile swab                                 | Blue top swab                                                     |                         | 2 – 4 days      |                                                                                                                          |             | SR                                                               |
| Phosphate                                   | ● or ●                                                            | 56                      | 4 hrs           | Adult 0.80 - 1.50<br>Neonate 1.3 – 2.6<br>Infant 1.3 – 2.4<br>1 – 16 yrs 0.9 – 1.8                                       | mmol/L      | IH                                                               |
| Phosphate (Random Urine)                    | Random Urine                                                      | 5                       | 2 days          | Ref Range only quoted for 24hr collection                                                                                | mmol/L      | IH                                                               |
| Phosphate (24 hr Urine)                     | 24 hr Urine (Acidified)                                           | 13, 18, 19              | 2 days          | 13 - 44                                                                                                                  | mmol/24 hrs | SR                                                               |
| Potassium                                   | ● or ●                                                            |                         | 4 hrs           | Adult 3.5 - 5.3<br>Neonate 3.4 – 6.0<br>Infant 3.5 - 5.7<br>1 – 16 yr 3.5 – 5.0                                          | mmol/L      | IH                                                               |
| Potassium (Random Urine)                    | Random Urine                                                      | 5                       | 2 days          | Ref Range only quoted for 24hr collection                                                                                | mmol/L      | SR                                                               |
| Potassium (24 hr Urine)                     | 24 hr Urine                                                       | 13                      | 2 days          | 25 - 125                                                                                                                 | mmol/24 hrs | SR                                                               |

## LABORATORY MEDICINE SERVICE USERS GUIDE

| Description                           | Sample       | Notes / Instruction Ref | TAT           | Reference Range                                                                                                                              | Units    | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|---------------------------------------|--------------|-------------------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------|----------|------------------------------------------------------------------|
| Pregnancy Test (Urine)                | Random Urine | 5                       | 4 hrs         | Negative/Positive                                                                                                                            |          | IH                                                               |
| proBNP                                | ●            | 4, 56                   | 3 days        | 0 - 400                                                                                                                                      | ng/L     | SR                                                               |
| Progesterone                          | ●            | 56                      | 2 days        | Follicular: <0.159-0.616<br>Ovulation phase: 0.175-13.2<br>Luteal phase: 13.1-46.3<br>Post Menopause: <0.159 – 0.401<br>MALE: <0.159 – 0.474 | nmol/L   | SR                                                               |
| Prolactin                             | ●            |                         | 2 days        | Woman (not pregnant): 102-496<br>MALE: 86 - 324                                                                                              | mU/L     | SR                                                               |
| Prostate Specific Antigen             | ●            | 56                      | 2 days        | Age specific<br>See Report                                                                                                                   | ng/ml    | SR                                                               |
| Protein (Fluid)                       | Fluid        | 5                       | 2 days        | See Report                                                                                                                                   | g/L      | SR                                                               |
| Protein (Random Urine)                | Random Urine | 5                       | 2 days        | Ref Range only quoted for 24hr collection                                                                                                    | g/L      | SR                                                               |
| Protein (24 hour Urine)               | 24 hr Urine  | 13                      | 2 days        | < 0.15                                                                                                                                       | g/24 hrs | SR                                                               |
| Protein Electrophoresis               | ●            |                         | 5 days        | See Report                                                                                                                                   |          | SR                                                               |
| Prothrombin Time                      | ●            | 1, 7, 8, 59             | 4 hrs         | See report                                                                                                                                   | sec      | IH                                                               |
| Pus swab from sterile site            | Swab         |                         | 5 - 7 days    |                                                                                                                                              |          | SR                                                               |
| <b>Q</b>                              |              |                         |               |                                                                                                                                              |          |                                                                  |
| Quantiferon TB Gold                   | Contact Lab  | 25                      | 5 days        | Negative, Intermediate or Positive                                                                                                           |          | SR                                                               |
| <b>R</b>                              |              |                         |               |                                                                                                                                              |          |                                                                  |
| RAST<br>See Total IgE or Specific IgE | ●            | 33                      |               |                                                                                                                                              |          | EXT                                                              |
| Red Cell Folate                       | ●            | 36                      | 3 days        | 200-650                                                                                                                                      | ug/L     | EXT                                                              |
| Rheumatoid Factor                     | ●            |                         | 5 days        | <15 Negative<br>15 – 20 Weak Positive<br>>20 Positive                                                                                        | IU/ml    | EXT                                                              |
| Rotavirus                             | Faeces       |                         | 5 days        |                                                                                                                                              |          | EXT                                                              |
| Rubella (IgG)                         | ●            |                         | 3 days        | See Report                                                                                                                                   | IU/mL    | SR                                                               |
| Rubella (IgM)                         | ●            |                         | 3 days        | See Report                                                                                                                                   | U/L      | SR                                                               |
| <b>S</b>                              |              |                         |               |                                                                                                                                              |          |                                                                  |
| Serotonin                             | 2x ●         | 3                       | 15 days       | See report                                                                                                                                   |          | EXT                                                              |
| Serum Free Light Chains               | ●            |                         | 7 days        | Kappa: 3.30 - 19.4<br>Lambda: 5.71 - 26.3<br>Ratio: 0.26 - 1.65                                                                              | mg/L     | EXT                                                              |
| Sex Hormone Binding Globulin          | ●            |                         | Up to 10 days | Age related – see report                                                                                                                     | nmol/L   | SR                                                               |
| Sickle Cell Screen                    | ●            |                         | 2 days        | See Report                                                                                                                                   |          | SR/EXT                                                           |
| Sodium                                | ● or ●       |                         | 4 hrs         | 133 - 146                                                                                                                                    | mmol/L   | IH                                                               |
| Sodium (Fluid)                        | Fluid        | 5                       | 2 days        |                                                                                                                                              | mmol/L   | SR                                                               |

## LABORATORY MEDICINE SERVICE USERS GUIDE

| Description                                       | Sample                                                       | Notes / Instruction Ref | TAT                                           | Reference Range                                                                                                                                       | Units       | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|---------------------------------------------------|--------------------------------------------------------------|-------------------------|-----------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------|
| Sodium (Random Urine)                             | Urine                                                        | 5                       | 2 days                                        | Ref Range only quoted for 24hr collection                                                                                                             | mmol/L      | SR                                                               |
| Sodium (24-hour Urine)                            | 24 hr Urine                                                  | 13                      | 2 days                                        | 40 - 220                                                                                                                                              | mmol/24 hrs | SR                                                               |
| Specific IgE (Individual Allergens or components) | ●                                                            | 33                      | 7 days                                        | See report                                                                                                                                            | kU/L        | EXT                                                              |
| Sputum For Culture                                | Sputum                                                       | 5                       | 2-4 days                                      | Not applicable                                                                                                                                        |             | SR                                                               |
| Sputum For Culture including TB Culture           | Sputum – preferably first sputum of the day                  | 5, 57                   | 3-5 days (routine culture)                    | Not applicable                                                                                                                                        |             | EXT                                                              |
| Sputum For TB Culture                             | Sputum - preferably first sputum of the day                  | 5, 57                   | Microscopy 2-3 days<br>Culture up to 8 Weeks  | Not applicable                                                                                                                                        |             | EXT                                                              |
| Stone (Calculi) Analysis                          | Stone                                                        | 5                       | 9 days                                        | Not applicable                                                                                                                                        |             | EXT                                                              |
| Syphilis (RPR, VDRL, TPHA)                        | ●                                                            |                         | 3 days                                        | Detected or Not Detected                                                                                                                              |             | SR                                                               |
| Synacthen Test                                    | ●                                                            |                         | Up to 3 days                                  | See Report                                                                                                                                            |             | SR                                                               |
| <b>T</b>                                          |                                                              |                         |                                               |                                                                                                                                                       |             |                                                                  |
| TB Culture (Sputum, Fluid, Aspirate or Tissue)    | Sputum /Fluid / Tissue/ ASP                                  | 5, 57                   | Microscopy 2-3 days,<br>Culture up to 8 Weeks | Not applicable                                                                                                                                        |             | EXT                                                              |
| TB Culture (Early morning urine)                  | Whole bladder Early morning urine (EMU) x 3 consecutive days | 44, 57                  | Up to 8 weeks                                 | Not applicable                                                                                                                                        |             | EXT                                                              |
| Testosterone                                      | ●                                                            |                         | 2 days                                        | Sex and age related<br>See Report                                                                                                                     | nmol/l      | SR                                                               |
| Testosterone (Free)                               | ●                                                            | 66                      | 2 days                                        | Male aged 20 -49:<br>0.198 – 0.619<br>Male aged >= 50:<br>0.163 - 0.473<br>Female aged 20-49:<br>0.003 – 0.033<br>Female aged >= 50:<br>0.001 – 0.020 | nmol/L      | SR                                                               |
| Tip/line culture                                  | 5cm portion of tip                                           |                         | 2-4 days                                      |                                                                                                                                                       |             | SR                                                               |
| Tissue/biopsy routine culture from sterile sites  | Tissue in sterile pot                                        | 58                      | 2-4 days interim, up to 16 days for final     |                                                                                                                                                       |             | SR                                                               |
| Throat swab                                       | Blue top swab                                                |                         | 2-4 days                                      |                                                                                                                                                       |             | SR                                                               |
| Thrombin Time                                     | ●                                                            | 1, 7, 8                 | 2 days                                        | 11.0 - 17.8                                                                                                                                           | sec         | SR                                                               |
| Thrombophilia screen                              | ●●●●●●                                                       | 1, 6, 7, 8, 34          | 10 days                                       | Contact Lab for Interpretation                                                                                                                        |             | SR                                                               |
| Thyroglobulin Antibodies                          | ●                                                            |                         | 9 days                                        | < 20<br>Post thyroid ablation: <0.1L                                                                                                                  | kU/L        | EXT                                                              |

| Description                                  | Sample                                                                                                   | Notes / Instruction Ref | TAT                                     | Reference Range                                      | Units       | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|----------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------|-----------------------------------------|------------------------------------------------------|-------------|------------------------------------------------------------------|
| Thyroid Peroxidase Antibodies                | ●                                                                                                        |                         | 9 days                                  | 0 – 24                                               | IU/mL       | EXT                                                              |
| Thyroid Receptor Antibodies                  | ●                                                                                                        | 3                       | 17 days                                 | < 1.0                                                | IU/L        | EXT                                                              |
| Thyroid Stimulating Hormone (TSH)            | ●                                                                                                        |                         | 2 days                                  | 0.27 -4.20                                           | mU/L        | SR                                                               |
| Tissue for Culture                           | State Site                                                                                               | 5                       | Interim 2-3 days<br>Final up to 16 days | See Report                                           |             | SR                                                               |
| Orthopaedic tissue                           |                                                                                                          |                         | 21 days                                 |                                                      |             |                                                                  |
| Tissue For Culture with TB Culture           | State Site                                                                                               | 5, 57, 58               | See individual tests                    | See Report                                           |             | EXT                                                              |
| Tissue Transglutaminase (TTG) Antibodies IgA | ●                                                                                                        |                         | 10 days                                 | Negative: < 7<br>Equivocal: 7 - 10<br>Positive: > 10 | Elia u/ml   | EXT                                                              |
| Trichomonas, PCR                             | BD swab collection kit for endocervical or vaginal, or random urine collected in BD urine collection kit | 14                      | 3 days                                  | Negative or positive by PCR                          |             | SR                                                               |
| Total IgE                                    | ●                                                                                                        | 33                      | 7 days                                  | Age dependant – see report                           | KU/L        | EXT                                                              |
| Total Protein                                | ● or ●                                                                                                   |                         | 4 hrs                                   | 60 - 80                                              | g/L         | IH                                                               |
| Total Protein (24 hr Urine)                  | 24 hr Urine                                                                                              | 5, 13                   | 2 days                                  | < 0.15                                               | g/24 hrs    | SR                                                               |
| Triglycerides                                | ● or ●                                                                                                   | 56                      | 4 hrs                                   | <1.7                                                 | mmol/L      | IH                                                               |
| Troponin T                                   | Contact laboratory                                                                                       | 1, 42                   | Up to 1 day                             | See report                                           | See report  | IH / EXT                                                         |
| Toxoplasma IgG / IgM                         | ●                                                                                                        |                         | 5 days                                  | Detected / Not detected/<br>Equivocal                |             | IH                                                               |
| <b>U</b>                                     |                                                                                                          |                         |                                         |                                                      |             |                                                                  |
| Urea                                         | ● or ●                                                                                                   |                         | 4 hrs                                   | Adult                                                | 2.5 - 7.8   | mmol/l                                                           |
|                                              |                                                                                                          |                         |                                         | Neonate                                              | 0.8 – 5.5   |                                                                  |
|                                              |                                                                                                          |                         |                                         | Infant                                               | 1.0 – 5.5   |                                                                  |
|                                              |                                                                                                          |                         |                                         | 1 – 16 yr                                            | 2.5 – 6.5   |                                                                  |
| Urea (Random Urine)                          | Random Urine                                                                                             | 5                       | 2 days                                  | Ref Range only quoted for 24hr collection            | mmol/L      | SR                                                               |
| Urea (24 hr Urine)                           | 24 hr Urine                                                                                              | 13                      | 2 days                                  | 428 - 714                                            | mmol/24 hrs | SR                                                               |
| Urea and Electrolytes (U&E)                  | ● or ●                                                                                                   |                         | 4 hrs                                   | See Report                                           |             | IH                                                               |
| Urea and electrolytes (24 hr Urine)          | 24 hr Urine                                                                                              | 13, 19                  | 2 days                                  | See Report                                           |             | SR                                                               |
| Urethral swab                                | Black top Charcoal swab                                                                                  | 50                      | 2 - 4 days                              | Growth detected / Not detected                       |             | SR                                                               |
| Uric Acid (Serum)                            | ● or ●                                                                                                   | 56                      | 4 hrs                                   | Female: 140 - 360<br>Male: 200 - 430                 | µmol/L      | IH                                                               |

| Description                                 | Sample                                                                                  | Notes / Instruction Ref | TAT          | Reference Range                                                                                                    | Units           | In-House (IH)/ Spire In-House Referred (SR) /External Test (EXT) |
|---------------------------------------------|-----------------------------------------------------------------------------------------|-------------------------|--------------|--------------------------------------------------------------------------------------------------------------------|-----------------|------------------------------------------------------------------|
| Uric Acid (Fluid)                           | Fluid                                                                                   | 5                       | 2 days       |                                                                                                                    |                 | SR                                                               |
| Uric Acid Random (Urine)                    | Random Urine                                                                            | 5                       | 2 days       | Ref Range only quoted for 24hr collection                                                                          | mmol/L          | SR                                                               |
| Uric Acid (24 hr Urine)                     | 24 hr Urine                                                                             | 13, 19                  | 2 days       | 1.5 - 4.5                                                                                                          | mmol/24 hrs     | SR                                                               |
| Urinary Telopectides (NTx)                  | fasting, 2nd void morning sample (collected between 8 – 10am).                          | 69                      | 10 days      | See report                                                                                                         | See report      | EXT                                                              |
| Urine for microscopy and culture            | Mid-stream Urine collected in Boric acid container filled to 20 mls (red top universal) | 21                      | 2-4 days     | Not applicable                                                                                                     |                 | SR                                                               |
| <b>V</b>                                    |                                                                                         |                         |              |                                                                                                                    |                 |                                                                  |
| Vaginal Swab                                | Black top charcoal swab                                                                 | 28                      | 2-4 days     |                                                                                                                    |                 | SR                                                               |
| Varicella Zoster IgG                        | ●                                                                                       |                         | 5 days       | Detected or Not Detected                                                                                           |                 | SR                                                               |
| Varicella Zoster IgM                        | ●                                                                                       |                         | 10 days      | Detected or Not Detected                                                                                           |                 | EXT                                                              |
| Viral Screening                             | ●●                                                                                      | 9                       | Up to 7 days | Detected or Not Detected                                                                                           |                 | SR                                                               |
| Viral swab PCR for Herpes, VZV, Enterovirus | Green viral swab (contact lab) State which virus to be tested on request form           |                         | 5 days       |                                                                                                                    |                 | EXT                                                              |
| Vitamin B12                                 | ●                                                                                       | 3, 56 Avoid Haemolysis  | 4 days       | 197 - 771                                                                                                          | ng/l            | SR                                                               |
| Vitamin D (1,25 Dihydroxycholecalciferol)   | ●                                                                                       | 1, 35, 36, 56           | 14 days      | 48 - 192                                                                                                           | pmol/l          | EXT                                                              |
| Vitamin D (25 Hydroxy)                      | ●                                                                                       | 1, 56, 60               | 7 days       | < 25 Vitamin D deficiency<br>25 – 50 May be inadequate<br>51 – 250 Sufficient<br>> 250 Possible vitamin D toxicity | nmol/l          | EXT                                                              |
| Vulval culture                              | Blue top Swab                                                                           |                         | 2-4 days     |                                                                                                                    |                 | SR                                                               |
| <b>W</b>                                    |                                                                                         |                         |              |                                                                                                                    |                 |                                                                  |
| Wound swab - all sites                      | Blue top Swab                                                                           |                         | 2-4 days     |                                                                                                                    |                 | SR                                                               |
| <b>Y</b>                                    |                                                                                         |                         |              |                                                                                                                    |                 |                                                                  |
| Y Microdeletion                             | ●●                                                                                      | 26,30                   | 35 days      | See Report                                                                                                         |                 | EXT                                                              |
| <b>Z</b>                                    |                                                                                         |                         |              |                                                                                                                    |                 |                                                                  |
| Zinc (Serum)                                | ●                                                                                       | 70                      | 7 days       | –See report – age related                                                                                          | µmol/l          | EXT                                                              |
| Zinc (Urine)                                | Random Urine                                                                            | 5                       | 7 days       | < 1.1                                                                                                              | µmol/mmol creat | EXT                                                              |

## 22.1 Reference ranges for paediatric Full Blood Counts

| Parameter                         | Birth       | Day 3       | Day 7       | Day 14      | 1 Month     | 2 Months    |
|-----------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| RBC (x 10 <sup>12</sup> /L)       | 6.0 ± 1.0   | 5.3 ± 1.3   | 5.1 ± 1.2   | 4.9 ± 1.3   | 4.2 ± 1.2   | 3.7 ± 0.6   |
| HB (g/L)                          | 180 ± 40    | 180 ± 30    | 175 ± 40    | 165 ± 40    | 140 ± 25    | 112 ± 18    |
| HCT (L/L)                         | 0.60 ± 0.15 | 0.56 ± 0.11 | 0.54 ± 0.12 | 0.51 ± 0.20 | 0.43 ± 0.10 | 0.35 ± 0.07 |
| MCV (fl)                          | 110 ± 10    | 105 ± 13    | 107 ± 19    | 105 ± 19    | 104 ± 12    | 95 ± 8      |
| MCH (pg)                          | 34 ± 3      | 34 ± 3      | 34 ± 3      | 34 ± 3      | 33 ± 3      | 30 ± 3      |
| MCHC (g/L)                        | 330 ± 30    | 330 ± 40    | 330 ± 50    | 330 ± 50    | 330 ± 40    | 320 ± 35    |
| WBC (x10 <sup>9</sup> /L)         | 18 ± 8      | 15 ± 8      | 14 ± 8      | 14 ± 8      | 12 ± 7      | 10 ± 5      |
| Platelets (x10 <sup>9</sup> /L)   | 100-450     | 210-500     | 160-500     | 170-500     | 200-500     | 210-650     |
| Neutrophils (x10 <sup>9</sup> /L) | 4-14        | 3-5         | 3-6         | 3-7         | 3-9         | 1-5         |
| Lymphocytes (x10 <sup>9</sup> /L) | 3-8         | 2-8         | 3-9         | 3-9         | 3-16        | 4-10        |
| Monocytes (x10 <sup>9</sup> /L)   | 0.5-2.0     | 0.5-1.0     | 0.1-1.7     | 0.1-1.7     | 0.3-1.0     | 0.4-1.2     |
| Eosinophils (x10 <sup>9</sup> /L) | 0.1-1.0     | 0.1-2.0     | 0.1-0.8     | 0.1-0.9     | 0.2-1.0     | 0.1-1.0     |

| Parameter                         | 3-6 Months  | 1 Year       | 2-6 Years    | 6-12 Years  |
|-----------------------------------|-------------|--------------|--------------|-------------|
| RBC (x 10 <sup>12</sup> /L)       | 4.7 ± 0.6   | 4.5 ± 0.6    | 4.6 ± 0.6    | 4.6 ± 0.6   |
| HB (g/L)                          | 126 ± 15    | 126 ± 15     | 125 ± 15     | 135 ± 20    |
| HCT (L/L)                         | 0.35 ± 0.05 | 0.340 ± 0.04 | 0.370 ± 0.03 | 0.40 ± 0.05 |
| MCV (fl)                          | 76 ± 8      | 78 ± 6       | 81 ± 6       | 86 ± 9      |
| MCH (pg)                          | 27 ± 3      | 27 ± 2       | 27 ± 3       | 29 ± 4      |
| MCHC (g/L)                        | 330 ± 30    | 340 ± 20     | 340 ± 30     | 340 ± 30    |
| WBC (x10 <sup>9</sup> /L)         | 12 ± 6      | 11 ± 5       | 10 ± 5       | 9 ± 4       |
| Platelets (x10 <sup>9</sup> /L)   | 200-550     | 200-550      | 200-490      | 170-450     |
| Neutrophils (x10 <sup>9</sup> /L) | 1-6         | 1-7          | 1.5-8        | 2-8         |
| Lymphocytes (x10 <sup>9</sup> /L) | 4-12        | 3.5-11.0     | 6.0-9.0      | 1.0-5.0     |
| Monocytes (x10 <sup>9</sup> /L)   | 0.2-1.2     | 0.2-1.0      | 0.2-1.0      | 0.2-1.0     |
| Eosinophils (x10 <sup>9</sup> /L) | 0.1-1.0     | 0.1-1.0      | 0.1-1.0      | 0.1-1.0     |

## Key to Notes

- 1 Send to lab immediately.
- 2 Labile - must reach lab on same day as sample collected. Bean sized volume of faeces required in sputum/faeces pot.
- 3 Send frozen (**by laboratory**)
- 4 Store between 2 - 8°C
- 5 30ml sterile White top Universal container.
- 6 Sample should be separated and frozen within 2 hours of being taken. If a delay is expected with transportation to the testing laboratory samples must be transported frozen.

- 7 If collecting using Butterfly system discard initial blue bottle.
- 8 If possible, it is preferable to collect blood WITHOUT using tourniquet. Citrate (Blue bottles) MUST always be taken before other coloured bottles and filled to the line.
- 9 Clinical history and any medication information must be provided. Date of onset if microbiology or virology test.
- 10 Provide details of patient travel history.
- 11 bottles must be filled accurately with 8-10ml blood in each and must be sent to agreed testing laboratory to arrive within 4 hours of collection. This is to ensure optimal recovery of organisms.
- 12 Large PINK bottle. Sample must be labelled clearly by HAND with first name, surname, date of birth and either patient number or postal code. The sample MUST be signed by the person taking the blood.
- 13 Provide volume/date/time for all 24-hour samples.
- 14 Use BDMax specimen kits available from the NDC.
- 15 To avoid external contamination, take two EDTA samples and discard the first. Min 2mls blood.
- 16 Faeces in sterile blue top stool pot.
- 17 Formed faeces will not be tested
- 18 24-hour Urine container must be acid washed or contain acid, contact lab. store acid containers in a COSHH cupboard
- 19 **Laboratory advice:** 20ml aliquot. Give 24-hour volume in ml. Store aliquot at 2-8°C.
- 20 Blood sample must be collected during 24-hour Urine collection time.
- 21 State whether CSU, MSU or specific type on sample bottle and request form. Use Red top (Boric Acid) urine bottle. DO NOT use sputum pots.
- 22 Min 1 ml CSF and min 2ml serum. Paired CSF and serum required (max 5 days apart). Store at 4°C.
- 23 Sample must be taken 6 - 10 hours post dose  
State dose and time of dose  
Minimum volume 125 µL of serum  
Digibind affects results, state if patient is on Digibind therapy
- 24 State if pre or post dose sample, give last time of dose, state dose and other medication.
- 25 Contact the laboratory for special sample tubes/containers/kit and/or instructions.
- 26 Collect Monday to Thursday only. Must arrive at laboratory before noon.
- 27 Sample codes are applied at the discretion of the Histopathology staff. All patient demographics and sample description must be on both the sample container and the request form. Relevant clinical history should be provided. Samples must be completely immersed in formaldehyde.

- 28 **Black** swab preferred will accept **blue** swab. State region swabbed on both sample and request form. For genital swabs from patients with clinical details: Trichomonas vaginalis, Sexually transmitted disease (STD/ STI) or if the patient is pregnant. Please also send a BDMAX PCR swab for CT/GC/TV PCR testing
- 29 Minimum 0.2ml. Freeze until dispatch if >24 hours
- 30 Special Genetics form must be sent with sample, available on the Clinical Intranet, Pathology page.
- 31 Collect blood a minimum of 12 hours post last dose of Lithium.
- 32 **GOLD** top sample only when processed on the same day (this is only applied when the sample will arrive at Spire Laboratory Centennial Park on the same day). If the sample is transported overnight – need **EDTA** sample spun, separated and frozen.
- 33 Include copy of allergy referral form with sample
- 34 Citrated tubes should be double centrifuged
- 35 **Laboratory advice:** Sample should be separated and frozen within 4 hours.
- 36 Protect from light, wrap completely in foil and transport to lab immediately.
- 37 10 mls required
- 38 Full blood count must be performed prior to carrying out the analysis
- 39 Sample should not be more than 7 days old
- 40 Send Mg serum result and haematocrit from FBC
- 41 Stable for 2 - 4 hours at 20 - 25 °C, for 24 hours at 2 - 8 °C and at -20°C for one month. Sample should be frozen if a delay is expected with transportation to the testing laboratory, samples must be transported frozen.
- 42 Do **NOT** spin.
- 43 Samples from patients who have not had a transfusion or been pregnant in the last 3 months are able to be cross matched from this sample up to 7 days before transfusion; otherwise, sample must be taken within 72 hours of the transfusion. Please ensure the laboratory is aware if this is an urgent request. A second sample may be required if there is no historic group available for the patient.
- 44 3 consecutive early morning whole bladder urine specimens to be collected in large 250ml containers.
- 46 Treatment of DVT, PE, AF, recurrent DVT off warfarin, symptomatic inherited thrombophilia, cardiomyopathy, mural thrombus, cardioversion.
- 47 Recurrent DVT while on warfarin, mechanical prosthetic heart valves, antiphospholipid syndrome (some cases)

- 48 Negative smears will be confirmed by an alternative method
- 49 ER, PR and Her-2 are reported at SHC
- 50 Swab must reach the laboratory within 24 hours of being taken otherwise detection of Gonorrhoeae may be compromised. Do not refrigerate.
- 51 If a black topped ESR seditainer sample cannot reach the laboratory within 4 hours of collection an **EDTA** sample should be taken.
- 52 Avoid patient stress. Transport immediately on ice as required to be separated within 30 minutes. **Laboratory advice:** Freeze plasma in less than 2 hours. Send plasma frozen. Visible haemolysis will invalidate test. Minimum 3 mL plasma.
- 53 Sample stable for 7 days from time of sample collection to testing at referral laboratory.
- 56 The addition of the following tests can be made in the timeframe displayed post phlebotomy. Additional biochemistry tests may be requested up to 7 days from sample receipt, with the exception of those listed in the table below and only if the laboratory has capacity to store these

|               |         |            |         |                     |                                                   |
|---------------|---------|------------|---------|---------------------|---------------------------------------------------|
| Glucose       | 3 days  | CA 15-3    | 5 days  | Pro BNP             | 6 days                                            |
| LDH           | 4 days  | Cortisol   | 4 days  | Progesterone        | 5 days                                            |
| Phosphate     | 4 days  | Oestradiol | 2 days  | Parathyroid Hormone | 2 days                                            |
| Triglycerides | 5 days  | Folate     | 2 days  | TPSA                | 3 days                                            |
| Uric Acid     | 5 days  | FPSA       | 3 days  | Vitamin B12         | 2 days                                            |
| CA 125        | 5 days  | Insulin    | 2 days  | Vitamin D           | 3 days RT, 7 days if separated and stored at 4 oC |
| Sodium        | 14 days | Potassium  | 14 days | Chloride            | 7 days                                            |

- 57 Atypical Mycobacteria may take up to 10 weeks. If fast track TB PCR is required on primary samples; note that the primary sample is only retained for 48 hours after processing. Therefore, the request must be relayed to the microbiology lab immediately to ensure the sample is still available to action the request.
- 58 Orthopaedic samples may take up to 16 days. 14-day extended enrichment culture can be requested for sterile site samples. Please add this request in the clinical details where required.
- 59 Reference range dependent upon analyser type. Please contact local laboratory
- 60 **Laboratory advice:** If there will be a delay before sending, store serum frozen and send thawed
- 61 Excluded tests include Her 2 FISH (not Her ICC) and molecular tests, and decalcified whole specimens
- 62 Single swabs used for throat then nose into one pot of viral transport medium. Bacterial or charcoal swabs are not suitable.
- 63 **Hospital advice:** Take with a Prewarmed syringe, ensure vacutainer and transport equipment are prewarmed. Samples for cryoglobulin testing must be taken and transported to the laboratory at 37 degrees using an appropriate kit to obtain valid results. If this procedure is not followed when collecting the sample, it can lead to a false negative result.

**Laboratory advice:** samples must be incubated at 37 degrees and centrifuged prior to sending.

- 64 Collect PERNASAL Swab from upper naso pharynx, the swab should be inserted gently down the nose as far as "gag" reflex allows.  
Please clearly state relevant clinical details pertaining to the reasons behind taking the sample i.e. hot/pain/red. Samples without relevant clinical details may be rejected.  
Please state on form if the patient has had recent foreign travel or if there is a strong suspicion of high-risk pathogens as these pose a risk to laboratory staff.
- 65 Please clearly state relevant clinical details pertaining to the reasons behind taking the sample i.e. hot/pain/red. Samples without relevant clinical details may be rejected.  
Please state on form if the patient has had recent foreign travel or if there is a strong suspicion of high-risk pathogens as these pose a risk to laboratory staff.
- 66 Calculated tests based on Albumin, Testosterone and SHBG levels
- 67 A ratio based on the Testosterone and SHBG results
- 68 Spire Laboratory Medicine is currently undergoing a Biochemistry analyser replacement programme. Please see report for reference ranges.
- 69 NTx can be measured on a random urine sample but suggested that where clinical teams are looking to monitor patient treatment with serial measurements to ensure that either a morning or afternoon clinic samples are consistently collected.  
Minimum volume: 1mL in case repeat analyses are required.  
Storage:  
Sensitive to direct sunlight: avoid samples being exposed (ambient/artificial light is fine). Samples not sent immediately can be stored short term in a fridge at 4°C or longer term (more than a week) at -20°C.
- 70 Laboratory colleagues only: Spin and separate prior to referral to testing laboratory

## Appendix 3 – Instructions for the Collection of Histology Specimens



### WORK INSTRUCTION HISTOLOGY SAMPLE PREPARATION

How to manage Spire Healthcare samples that require histological examination by Spire Pathology Services. If your histology samples are sent outside of Spire Pathology, then please check the sample preparation criteria required by your pathology supplier.

#### Histology Samples

Specimens requiring histological examination may come from a number of different sources. They range from very large specimens or whole organs to tiny fragments of tissue. For example, the following are some of the specimen-types commonly sent to a histopathology lab.

- Excision specimens (surgical biopsies), where whole organs or affected areas are removed at operation
- Incisional biopsy specimens, where tissue is removed for diagnosis from within an affected area
- Punch biopsies, where punches are used to remove a small piece of suspicious tissue for examination (often from the skin)
- Shave biopsies, where small fragments of tissue are "shaved" from a surface (usually skin)
- Curettings, where tissue is removed in small pieces from the lining of the uterus or cervix
- Core biopsies, where a small tissue sample is removed using a special needle sometimes through the skin (percutaneously).

Specimens are usually received in fixative (preservative) but sometimes arrive fresh and must be immediately fixed. Before specimens are accepted by a laboratory the identification (labelling) and accompanying documentation will be carefully checked, all details recorded and "specimen tracking" commenced.

#### Fixation

Fixation is a crucial step in preparing specimens for microscopic examination. Its objective is to prevent decay and preserve cells and tissues in a "life-like" state. It does this by stopping enzyme activity, killing microorganisms and hardening the specimen while maintaining sufficient amount of the molecular structure to enable appropriate staining methods to be applied. The sooner fixation is initiated following separation of a specimen from its blood supply the better the result will be. The most popular fixing agent is formaldehyde, usually in the form of a phosphate-buffered solution (often referred to as "formalin"). Ideally specimens should be fixed by immersion in formalin for six to twelve hours before they are processed by the pathology department




Sample management to be carried out at the time the sample is taken from the patient.

- Fixation in 10 % neutral buffered formalin is a critical step in the preparation of histological sections. If it is not carried out under optimal conditions or if fixation is delayed, a tissue specimen can be irreversibly damaged
- Samples must be placed in sufficiently large containers to ensure the sample is completely submerged in 10% neutral buffered formalin. Container should be large enough so the sample can move freely within it in order to prevent damage and preserve the integrity of the tissue
- All samples and request forms are to be completed with patient surname, first name, date of birth, hospital number and anatomical site
- Details of the sample type, location, number of biopsies should be recorded on the request form and include as much detail as possible to aid in the processing and diagnostic management of the sample as possible
- All histology samples must be delivered to the pathology department as soon as possible after collection
- All histology samples must be stored at room temperature, they must NOT be placed in a fridge or incubator

|   | Histology pot containing 10% neutral buffered formalin | Quantity of pots | Formalin volume in pre-filled pot | NSV SAP ordering Code |
|---|--------------------------------------------------------|------------------|-----------------------------------|-----------------------|
| 1 | Pre-filled formalin biopsy pots                        | Box of 25 pots   | 60 mls                            | 2STA2557              |
| 2 | Pre-filled formalin pots                               | Box of 10 pots   | 250 mls                           | 4KCP0577              |
| 3 | Pre-filled formalin pots                               | Box of 10 pots   | 350 mls                           | 4KCP0269              |
| 4 | Pre-filled formalin pots                               | Box of 8 pots    | 500 mls                           | 4KCP0001              |
| 5 | Pre-filled formalin pots                               | Box of 6 pots    | 1 litre                           | 4KCP0002              |
| 6 | Pre-filled formalin pots                               | Box of 4 pots    | 2.5 litre                         | 4KCL0036              |
| 7 | Pre-filled formalin pots                               | 1 pot            | 5 litre                           | 4KCL0034              |
| 8 | Pre-filled formalin pots                               | 1 large pot      | 10 Litre                          | 4KCL0033              |

## Appendix 4- Broom Like device Protocol for LBC sample collection

## COLLECTING A SAMPLE FOR THIN PREP LIQUID BASED CYTOLOGY USING THE BROOM LIKE DEVICE PROTOCOL

**Obtain...**

...an adequate sampling from the cervix using a broom-like device. If desired, use lukewarm water to warm and lubricate the speculum. Water-soluble gel lubricant sparingly applied to the posterior blade of the speculum can be used if necessary.<sup>1</sup> Insert the central bristles of the broom into the endocervical canal deep enough to allow the shorter bristles to fully contact the ectocervix. Push gently, and rotate the broom in a clockwise direction five times.

**Rinse...**

...the broom as quickly as possible into the PreservCyt solution vial by pushing the broom into the bottom of the vial 10 times, forcing the bristles apart. As a final step, swirl the broom vigorously to further release material. Discard the collection device.

**Tighten...**

...the cap so that the torque line on the cap passes the torque line on the vial.

**Record...**

...the patient's name and ID number on the vial, and the patient information and medical history on the cytology requisition form.

**Place...**

...the vial and requisition in a specimen bag for transport to the laboratory.

|                                                  |                                 |                                                                                       |             |
|--------------------------------------------------|---------------------------------|---------------------------------------------------------------------------------------|-------------|
| Doc Ref: SPS-GP-WI1422                           | Version No: 2                   | Issue Date: April 2025                                                                | Page 1 of 1 |
| Issued by: National Pathology Compliance Manager | Next Review: Managed in Q-Pulse | THIS IS A CONTROLLED DOCUMENT. Ensure it is the current version as managed in Q-Pulse |             |

## Appendix 5 – Guide for Microbiological Investigation

### 25.1 GUIDELINES ON APPROPRIATE CLINICAL DETAILS FOR MICROBIOLOGY REQUESTS

The microbiology laboratory is committed to providing the highest quality results, as quickly as possible, to facilitate good clinical care. The microbiology laboratory requires brief but pertinent clinical details on all diagnostic microbiology sample requests. This is to ensure the most appropriate processing of samples, correct assessment of the clinical relevance of results and adequate protection of laboratory staff from potentially hazardous organisms. We also believe that such an approach will have positive effects on antimicrobial stewardship.

Microbiology is a more subjective laboratory discipline than others. The rationale for clinical details can be split into three areas of the testing process: pre-analytical, analytical and post-analytical. There will however be overlap between the three areas:

**Pre-analytical:** Clinical details allow us to decide if the test is appropriate for a given clinical situation, and whether extra or alternative testing may be indicated.

**Analytical:** This area is particularly important for samples which are processed for bacterial culture. Clinical details can (and often do) affect any of the following steps in the bacteriology culture process:

- Whether additional tests in addition to culture are indicated.
- What incubation conditions are used (aerobic/CO<sub>2</sub>/anaerobic) for the culture plates.
- Which culture media are set up on the sample.
- Ascertaining the relative significance of different culture isolates and deciding further workup.
- Whether susceptibility testing should be performed, and what antimicrobials to test against.
- Which culture isolates should be reported to the requestor.
- Which antimicrobial susceptibilities are released to the requestor.
- Whether an interpretative comment is added to the final report.

**Post-analytical:** This allows us to decide whether the culture findings are consistent with the clinical details, which antibiotics should be reported, if any, and which interpretative or management comments should be added.

This document offers a guide to what the laboratory considers useful clinical information on various sample types. This is not an exhaustive list.

#### Health and Safety of Staff in the Laboratory

There is a risk to staff associated with the omission of clinical details, such as suspicion of high-risk pathogens, foreign travel and high-risk occupational information. This risk has been picked up by Health and Safety Executive (HSE) as a trend back in 2011 and they produced this safety bulletin in response to that trend and risk to laboratory staff. See link below.

<https://www.hse.gov.uk/safetybulletins/clinicalinformation.htm>

#### Urine Samples

A brief summary of the patient's specific symptoms, accompanied by any other useful information such as pregnancy, immunocompromising conditions, current antibiotics, allergies, etc.

| Acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Not acceptable                                                                                                                                                                                                                  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Symptoms</b> <ul style="list-style-type: none"> <li>• Dysuria/Frequency</li> <li>• Incontinence</li> <li>• Fever</li> <li>• Confusion (increased or new)</li> <li>• Flank pain</li> <li>• Suprapubic pain</li> <li>• Abdominal pain</li> <li>• Haematuria</li> <li>• Falls (non-mechanical)</li> </ul> <b>Diagnoses/Clinical Scenarios</b> <ul style="list-style-type: none"> <li>• Cystitis</li> <li>• Pyelonephritis</li> <li>• Sepsis</li> <li>• Delirium</li> <li>• ↑PSA</li> <li>• Prostatitis</li> <li>• Pelvic inflammatory disease (PID)</li> <li>• Pregnant</li> <li>• Urology pre-op</li> <li>• Gynae pre-op</li> <li>• Post-renal transplant</li> <li>• Epididymitis/orchitis</li> <li>• Pre-BCG treatment</li> <li>• Renal calculus (kidney stone)</li> </ul> | <ul style="list-style-type: none"> <li>• No clinical details</li> <li>• Monitoring</li> <li>• Review</li> <li>• Annual review</li> <li>• Screening</li> <li>• MSU /CSU (without clinical indication of an infection)</li> </ul> |

“? UTI”/” UTI” or similar will be accepted for testing. However, this is essentially a diagnosis as opposed to relevant clinical details, and we strongly discourage this practice.

The patient's specific symptoms should be stated as detailed above. This helps the laboratory decide between an uncomplicated and complicated UTI and whether the upper renal tract may be involved. These decisions affect which antibiotics are tested, whether an antibiotic is interpreted as susceptible or resistant and which susceptibility results are reported back to the requestor.

### Superficial Wound/Skin swabs

The diagnosis of wound infection is essentially a clinical diagnosis, with laboratory testing used to provide further information to guide management, particularly when the use of systemic antibiotics is deemed appropriate.

Please note: The body site the swab is taken from is a critical part of the information required for Microbiology to process the swab.

| Acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Not acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Symptoms</b> <ul style="list-style-type: none"> <li>• New or increased pain</li> <li>• Swelling</li> <li>• Erythema</li> <li>• Purulent exudate</li> <li>• Localised warmth</li> <li>• Systemic signs (fever, tachycardia, etc.)</li> </ul> <b>Diagnoses/Clinical Scenarios</b> <ul style="list-style-type: none"> <li>• Infected post-surgical wound</li> <li>• Bite wounds</li> <li>• Superficial burns</li> <li>• Penetrating wounds</li> <li>• Diabetic foot infections</li> <li>• Skin grafts</li> <li>• Extensive eczema</li> <li>• Extensive impetigo</li> <li>• Cellulitis (only if associated skin break/wound)</li> <li>• Infected wounds that have not responded to standard management</li> </ul> | <ul style="list-style-type: none"> <li>• No clinical details (i.e. blank or just test request)</li> <li>• Cut</li> <li>• wound</li> <li>• Surgical site</li> <li>• site of wound</li> </ul> <p><b>FURTHER NOTES:</b></p> <ul style="list-style-type: none"> <li>• Chronic wounds/pressure sore/ulcers –<br/>These chronic lesions are inevitably colonised with bacteria, so the positive predictive value of the culture result is low.</li> <li>• Peri-anal and groin wounds<br/>These are also low yield due to high contamination rate with enteric flora</li> </ul> |

“? infection”/“infection” or similar will be accepted for testing. However, this is essentially a clinical diagnosis as opposed to relevant clinical details, and we strongly discourage this practice. A positive microbiological culture report does not indicate infection in the absence of clinical signs as growth will likely represent the patient’s own colonising flora.

### Sputum Samples

Bacterial culture of sputum samples suffers from both poor sensitivity and specificity, leading to sub-optimal antimicrobial stewardship.

| Acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Not acceptable                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>• Infective exacerbation of COPD (recommended only if failing empiric therapy or resistant organism suspected)</li> <li>• Exacerbation of bronchiectasis</li> <li>• Bronchiectasis monitoring (no more than every 6 months)</li> <li>• Immunocompromised patient</li> <li>• Failure to respond to initial antibiotic therapy</li> <li>• Pneumonia (guidelines suggest moderate to severe cases only)</li> <li>• LRTI</li> <li>• Haemoptysis</li> <li>• Specialist request</li> <li>• CXR changes</li> <li>• Increasing SOB/dyspnoea</li> </ul> | <ul style="list-style-type: none"> <li>• No clinical details</li> <li>• Sputum</li> <li>• Screening</li> <li>• Monitoring</li> </ul> |

### Faeces Samples

#### Infective Gastroenteritis testing

Clinical details are important to indicate when specific culture plates should be added to the routine testing as well as the clinical follow up

| Acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Not acceptable                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>• Food handler</li> <li>• Childcare attendance</li> <li>• Rural (including camping trips, farm visits, untreated water supply)</li> <li>• Raw seafood</li> <li>• Overseas travel (specify countries visited)</li> <li>• Recent antibiotics or chemotherapy</li> <li>• Bloody diarrhoea</li> <li>• Immunocompromised (includes pregnancy)</li> <li>• Persistent diarrhoea (&gt;1 week)</li> <li>• Public Health request in outbreak situation</li> </ul> | <ul style="list-style-type: none"> <li>• No clinical details</li> </ul> |

### Vaginal Swabs

| Acceptable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Not acceptable                                                                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Symptoms</b> <ul style="list-style-type: none"> <li>• Discharge</li> <li>• Itch</li> <li>• Genital irritation/Vaginal soreness</li> <li>• Lower abdominal/pelvic pain</li> </ul> <b>Diagnoses/Clinical Scenarios</b> <ul style="list-style-type: none"> <li>• Post-partum</li> <li>• Miscarriage/RPOC</li> <li>• TOP</li> <li>• Post TOP</li> <li>• Post-operative, post colposcopy</li> <li>• Cancer of genital tract</li> <li>• Sexual abuse/assault</li> <li>• Bacterial vaginosis (BV)</li> <li>• PROM/SROM</li> <li>• Irregular bleeding</li> <li>• Endometritis</li> <li>• PID/? PID</li> <li>• Thrush/Yeast *</li> </ul> | <ul style="list-style-type: none"> <li>• No clinical details</li> <li>• Review</li> <li>• Monitoring</li> <li>• Only the swab site</li> </ul> |

**\*NOTE:** in cases of recurrent thrush where the requestor requires the isolate to be tested to antifungals – please indicate this on the request form

*Reproduced and locally adapted by Spire Laboratory Medicine with permission from Microbiology at BSPS: Berkshire and Surrey Pathology Services. (2024). BSPS Guidelines on Appropriate Clinical Details for Microbiology Requests.*

### 25.2 Guide to taking Specimens for Microbiological Investigation

**When taking a swab specimen ensure it has been fully rotated over the area being swabbed**

#### Ear swabs and associated specimens

Unless otherwise stated, swabs for bacterial and fungal culture should then be placed in appropriate transport medium

Swab any pus or exudates can be submitted for examination. Pus or exudate is preferred. For investigation of fungal infection, scrapings of material from the ear canal are preferred although swabs can also be used.

Collect specimens other than swabs into appropriate CE marked leakproof containers and place in sealed plastic bags.

#### Eye swabs for bacterial infections

Unless otherwise stated, swabs for bacterial and fungal culture should be placed in appropriate transport medium.

Collect specimens other than swabs into appropriate CE marked leakproof containers and place in sealed plastic bags.

Collect specimens before antimicrobial therapy where possible.

Corneal scrapings and intraocular fluids will be collected by an ophthalmic surgeon. Because of the small amounts of material involved, inoculation of plates and preparation of slides may need to be done at the patients' side. Laboratories should agree a protocol for the collection of specimens, inoculation of media, and transport to the laboratory with their local ophthalmologists, and supply kits for this purpose when required.

Under appropriate agreed protocols consider issuing corneal scrape kits to the ophthalmologists. They would scrape the cornea and send the blade in 1mL BHI broth in a bijou (inside an appropriate CE marked leakproof containers and placed in sealed plastic bags) and this is cultured.

Any available pus should be sampled as well as the lesion of interest.

It may also be useful to sample the contact lens itself and the contact lens case if still available and cleaning solutions.

Separate samples must be collected into appropriate transport media for detection of viruses or chlamydiae

#### Superficial mouth samples

Collect specimens before starting antimicrobial therapy where possible.

To assure that the preconditions of the sampling for oral infections are comparable it is advised that patients should not:

1. eat or drink within 2 hours
2. brush their teeth within 2 hours
3. use any mouth rinse or disinfectant within 2 hours prior to sampling

If possible, samples should be taken in the morning under fasting conditions.

Unless otherwise indicated collect each swab for bacterial and/or fungal culture and place in appropriate transport medium.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Sample any lesions or inflamed areas using cotton tipped swabs. Samples of denture fitting surfaces should also be swabbed as these are more sensitive sites than the palatal mucosa to recover *Candida* species. The use of a tongue depressor or spatula may be helpful. Oral rinses can be useful to follow up level of colonisation. These are collected by rinsing with 10mL of sterile saline for one minute.

### Nasal swabs

Collect specimens before antimicrobial therapy where possible.

Unless otherwise stated, swabs for bacterial and fungal culture should then be placed in appropriate transport medium.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

The washout or swab specimen will be collected by a specialist ENT surgeon.

### Samples for *Bordetella pertussis* culture

Collect specimens before antimicrobial therapy where possible.

Swabs should be collected and transported in charcoal-based transport medium such as Regan-Lowe.

### Pernasal swabs

A pernasal swab (Dacron or rayon with flexible ultrafine wire shaft) is inserted through a nostril and advanced along the floor of the nose until it reaches the nasopharynx. It has been suggested that the swab is held against the posterior nasopharynx for up to 30s or until the patient coughs. In practice, it is more likely that a patient will only be able to tolerate this for a few seconds.

### Nasopharyngeal specimens

Sampling of nasopharyngeal secretions in patients with whooping cough may precipitate a paroxysm of coughing and cause obstruction of the airways. Resuscitation equipment must be available if whooping cough is suspected. The specimen collector should avoid exposure to direct coughs from the patient.

Nasopharyngeal exudate may be obtained using a suction catheter (No.8 French) inserted through the nose. The exudate is collected in a sterile plastic trap in which the specimen is transported to the laboratory, or in a sterile clear plastic universal container (30mL or 60mL, to BS 5213).

**Note:** Cough plates are not recommended.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Unless otherwise stated, swabs for bacterial and fungal culture should then be placed in appropriate transport medium.

### Throat related specimens

Collect specimens before antimicrobial therapy where possible.

Unless otherwise stated, swabs for bacterial and fungal culture should be placed in appropriate transport medium.

Throat swabs should be taken from the tonsillar area and/or posterior pharynx, avoiding the tongue and uvula.

Throat culture should not be taken if the epiglottis is inflamed as sampling may cause serious respiratory obstruction.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Specimens should be transported and processed as soon as possible.

If processing is delayed, refrigeration is preferable to storage at ambient temperature.

Ideally, inoculation of specimens for *N. gonorrhoeae* should be made directly on to culture media at the time of collection and these should be incubated without delay. Transport time should be as short as possible. Samples should not be refrigerated if *N. gonorrhoeae* is suspected.

### Faeces for *Clostridium difficile*

Collect specimens before antimicrobial therapy where possible.

Specimens from children <2 years old will be rejected

Specimen may be passed into a clean, dry, disposable bedpan or similar container, and transferred into a CE marked leak proof container. The specimen is unsatisfactory if any residual soap, detergent or disinfectant remains in the pan.

Formed stools are unsuitable for investigation for *C. difficile*. These should be rejected with the appropriate comment appended to the report.

A liquid specimen of 1-2ml is sufficient for culture and toxin detection. Repeat testing of samples if there is no indication within a 28-day period. This applies to repeat testing positive results. On the contrary, a negative test, if symptoms persist, should be re-tested as it is known that a one-off negative can occur.

### Investigation of swabs from skin and superficial soft tissue infections

Collect specimens before starting antimicrobial therapy where possible.

Unless otherwise stated, swabs for bacterial and fungal culture should then be placed in appropriate transport medium.

Samples of pus/exudate, if present, are preferred to swabs. If only a minute amount of pus or exudate is available, it is preferable to send a pus/exudate swab in transport medium to minimise the risk of desiccation during transport.

Sample a representative part of the lesion. Swabbing dry crusted areas is unlikely to yield the causative pathogen.

If specimens are taken from ulcers, the debris on the ulcer should be removed and the ulcer should be cleaned with saline. A biopsy or, preferably, a needle aspiration of the edge of the wound should be taken.

A less invasive irrigation-aspiration method may be preferred. Place the tip of a small needleless syringe under the ulcer margin and irrigate gently with at least 1mL sterile 0.85% NaCl without preservative. After massaging the ulcer margin, repeat the irrigation with a further 1mL sterile saline. Massage the ulcer margin again, aspirate approximately 0.25mL of the fluid and place in a CE marked leak proof container.

### Pus and exudates

Collect specimens before antimicrobial therapy where possible.

Samples of pus are preferred to swabs. However, pus swabs are often received. When using a swab disinfect the superficial areas first. The deepest part of the wound should be sampled, avoiding the superficial microflora.

The specimen will usually be collected by a medical practitioner. Cleaning the site with sterile saline or 70% alcohol is recommended by some sources.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Unless otherwise stated, swabs for bacterial and fungal culture should then be placed in appropriate transport medium.

Ideally, a minimum volume of 1mL of pus should be submitted.

Swabs are not the optimal sample type. However, if received, swabs should be well soaked in pus.

Numbers and frequency of specimen collection are dependent on clinical condition of patient.

### Investigation of Bile

Collect specimens before antimicrobial therapy where possible.

Unless otherwise stated, swabs for bacterial and fungal culture should be placed in appropriate transport medium.

Bile may be collected in theatre or from a closed drainage system by aspiration with a needle and syringe.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Ideally, a minimum volume of 1mL.

### Investigation of tissues and biopsies from deep-seated sites and organs

Collect specimens before antimicrobial therapy where possible.

A medical practitioner will normally collect the specimen.

Collect specimens into appropriate CE marked leak proof containers and place in sealed plastic bags.

#### General

If specimen is small, place it in sterile water to prevent desiccation.

**Note:** Specimens received in formal saline are not suitable for culture.

#### Suspected *Legionella* species (lung tissue and biopsy)

If specimen is small place, it in sterile water to prevent desiccation.

**Note:** This would not be appropriate for specimens undergoing processing for diagnosis by molecular methods.

**Note:** Avoid the use of saline, as it is known to be inhibitory to *Legionella* species.

The specimen should, ideally, be large enough to carry out all microscopy preparations and cultures.

Minimum specimen size will depend on the number of investigations requested.

Specimens should be transported and processed as soon as possible.

If processing is delayed, refrigeration is preferable to storage at ambient temperature.

The volume of the specimen influences the transport time that is acceptable. Larger pieces of tissue maintain the viability of anaerobes for longer.

### Investigation of intravascular cannulae and associated specimens

Collect specimens before starting antimicrobial therapy where possible.

Cannulae should be collected in appropriate CE marked leak proof containers and transported and processed as soon as possible.

Unless otherwise stated, swabs for bacterial and fungal culture should be placed in appropriate transport medium.

#### Correct specimen type and method of collection:

##### Cannulae

Disinfect the skin around the cannula entry site, remove cannula using aseptic technique, and ideally cut off 4cm of the tip which has been inside the patient into an appropriate CE marked leak proof container using sterile scissors. Place in sealed plastic bags for transport.

**Note 1:** skin disinfection procedures depend on local protocols and may vary.

**Note 2:** cannulae should only be sent if there is evidence of infection.

##### Swabs

Sample the inflamed area / exudate around the catheter insertion site using an appropriate swab.

### Blood

At least two blood cultures should be obtained when catheter infection is suspected by peripheral venepuncture.

### Investigation of Cerebrospinal Fluid Shunts

Collect specimens before antimicrobial therapy where possible.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

When a shunt is removed all three portions should be sent in separate microbiologically approved containers of the appropriate size. This will include the proximal catheter, a valve or reservoir, and a distal catheter. CSF is usually obtained from the shunt reservoir and sent concurrently for investigation.

### Investigation of Continuous Ambulatory Peritoneal Dialysis Fluid

Collect specimens before antimicrobial therapy where possible.

Unless otherwise stated, swabs for bacterial and fungal culture should be placed in appropriate transport medium.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Receipt of the whole dialysate bag is preferable so that sampling under controlled laboratory conditions may be performed.

Where safe transport and receipt of the whole bag is considered impractical, withdraw fluid aseptically from the injection port of the plastic dialysate bag with a sterile needle and syringe and transfer to a microbiologically approved container.

If blood culture bottles are used, they should be inoculated aseptically with 5-10mL of dialysate according to local protocol agreed between the laboratory and clinical staff.

A volume of 10-50mL of fluid is considered suitable. Blood culture bottles may also be inoculated and submitted to the laboratory in addition to the pure sample.

### Investigation of Fluids from Normally Sterile Sites

Collect specimens before antimicrobial therapy where possible.

Samples of fluid rather than swabs of the fluids are the preferred specimen type to facilitate comprehensive investigation.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Ideally, a minimum volume of 1mL.

Large volume specimens such as peritoneal fluid and ascitic fluid may contain very low numbers of organisms which require concentration to increase the likelihood of successful culture.

Small volume fluids such as synovial fluids may be received in insufficient volumes. This may impede the recovery of organisms.

### Investigation of Cerebrospinal Fluid

Collect specimens preferably before antimicrobial therapy is started, but this must not be delayed unnecessarily pending lumbar puncture and CSF culture.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

CSF is normally collected sequentially into three or more separate containers which should be numbered consecutively. Collect specimens in appropriate CE marked leak proof containers and transport specimens in sealed plastic bags.

Collection of an additional sample in a container with fluoride for glucose estimation is also recommended, although such tubes should be filled last because they may contain environmental bacteria which might otherwise contaminate samples for culture.

Common practice is to send the first and last specimens taken for microbiological examination and the second specimen for protein. The fluoride sample should not be sent to Microbiology. Ideally testing should be carried out on the last sample with the first one reserved as a backup.

Ideally a minimum volume of 1mL for each tube 1 and 3 taken for microscopy (in adults). When sample volume is below this it is possible to pool samples.

For *Mycobacterium* species, at least 10mL where possible.

**Note:** The larger the volume, the greater the cultural yield particularly in relation to *M. tuberculosis* investigations.

### Investigation of Genital Tract and Associated Specimens

Collect specimens before antimicrobial therapy where possible.

Ideally, inoculation of specimens for *N. gonorrhoeae* is made directly to culture media at the bedside and incubated without delay. Transport time should be as short as possible.

For *H. ducreyi* direct inoculation of media ensures optimal recovery.

Unless otherwise stated, swabs for bacterial and fungal culture should be placed in appropriate transport medium.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Samples should **not** be refrigerated if *N. gonorrhoeae* is suspected.

#### Genital tract swabs

Cervical and high vaginal swabs should be taken with the aid of a speculum. It is important to avoid vulval contamination of the swab. For *Trichomonas*, the posterior fornix, including any obvious candidal plaques should be swabbed. If pelvic infection, including gonorrhoea, is suspected, the cervical os should be swabbed.

For the specific diagnosis of BV, it is recommended that an air-dried smear of vaginal discharge is sent in addition to the swab.

Separate samples should be collected into appropriate transport media for detection of viruses or *C. trachomatis*.

### High vaginal swabs

After the introduction of the speculum, the swab should be rolled firmly over the surface of the vaginal vault. The swab should then be placed in Amies transport medium with charcoal.

### Cervical swabs

After introduction of the speculum to the vagina, the swab should be rotated inside the endocervix. The swab should then be placed in Amies transport medium with charcoal.

### Urethral swabs

Contamination with micro-organisms from the vulva or the foreskin should be avoided. Thin swabs are available for collection of specimens.

The patient should not have passed urine for at least one hour. For males, if a discharge is not apparent, attempts should be made to "milk" exudate from the penis. The swab is gently passed through the urethral meatus and rotated. Place the swab in Amies transport medium with charcoal.

### Intrauterine contraceptive devices (IUCDs)

The entire device should be sent.

### Rectal swabs

Rectal swabs are taken via a proctoscope.

### Throat swabs

Throat swabs should be taken from the tonsillar area and/or posterior pharynx avoiding the tongue and uvula.

### Fluids and pus

These are taken from the fallopian tubes, tubo-ovarian and Bartholin's abscesses, etc... during surgery.

Fluids and pus – preferably a minimum volume of 1mL.

Investigations for Chlamydia, Gonorrhoea and Trichomonas testing by PCR

# BD Molecular Swab Collection Kit: Endocervical swab specimen collection and transfer procedure

## Clinician collection procedure

1. Do not collect specimen at the posterior fornix.
2. Lukewarm water may be used to warm and lubricate the speculum. Do not use lubricants.
3. Holding the swab by the cap, insert the swab into the cervical canal and rotate for 15 to 30 seconds.
4. Withdraw the swab carefully, avoiding contact with the vaginal mucosa.

## Swab-to-tube transfer procedure

Specimens collected using the BD Molecular Collection Swab must be transferred to the BD Molecular Swab Sample Buffer Tube immediately after collection.

To transfer the sample:



1. Unscrew the cap of the BD Molecular Swab Sample Buffer Tube, taking care not to contaminate the contents or the outside of the tube. Immediately after collection, insert the BD Molecular Collection Swab into the tube so that the score mark indicated by the black line is at the lip of the tube.



2. Carefully break the shaft at the score mark and allow the swab to drop into the tube.



3. Tightly re-cap the tube.



4. Label tube with patient information, date, and time collected. Be careful not to obscure the barcodes on the tube.

## Storage and transport

Endocervical swab specimens can be stored for a total of 21 days at 2–30 °C in BD Molecular Swab Sample Buffer Tubes.

### Approved for use with:

- BD CTGC2 for BD MAX™ System
- BD CTGCTV2 for BD MAX™ System

# BD Molecular Urine Transport Kit

## Urine specimen collection

### Collection procedure



1. Have patient collect specimen in a sterile, plastic, preservative-free specimen collection cup.

**NOTE:** Patient should not urinate for at least 1 hour prior to collection of specimen. Patient should collect the first 20 to 60 mL of voided urine.



4. Uncap the BD Molecular Urine Sample Buffer Tube and the urine sample cup. Immediately after collection, use the graduated transfer pipette to gently mix the urine specimen. Then, use the pipette to aspirate approximately 2 mL of the urine specimen from the collection cup.



2. Have the patient securely place the cap on the urine collection cup.



5. Transfer 2 mL of the urine specimen into the BD Molecular Urine Sample Buffer Tube. Use the graduations on the transfer pipette as a guide. DO NOT overfill or underfill the tube.

**NOTE:** The transfer pipette is intended for use with a single specimen only.



3. Label collection cup with patient identification, date, and time collected.

**NOTE:** Wear clean gloves when handling BD Molecular Urine Transport Kit components and urine specimens. If gloves come into contact with the specimen, immediately change gloves.



6. Tighten the cap securely on the BD Molecular Urine Sample Buffer Tube. Invert the BD Molecular Urine Sample Buffer Tube 3 to 4 times to ensure that the specimen and reagent are well mixed.

### Storage and transport

Urine specimens can be stored for a total of 21 days at 2–30 °C in BD Molecular Urine Sample Buffer Tubes.



7. Label the BD Molecular Urine Sample Buffer Tube with patient identification, date, and time collected. Be careful not to obscure any bar codes on the tube.

8. Transport to the testing laboratory following the storage and stability requirements.

#### Approved for use with:

- BD CTGC2 for BD MAX™ System
- BD CTGCTV2 for BD MAX™ System

## BD Molecular Swab Collection Kit: Vaginal swab specimen clinician collection and transfer procedure

### Clinician collection procedure

1. Collect swab prior to pelvic, speculum, or bimanual exam.
2. Gently slide the swab no more than 2 inches (5 cm) into the vagina. Do not use lubricants or other products containing substances such as carbomers.
3. Rotate the swab for 10 to 15 seconds.
4. Withdraw the swab without touching the skin outside the vagina.


### Swab-to-tube transfer procedure

Specimens collected using the BD Molecular Collection Swab must be transferred to the BD Molecular Swab Sample Buffer Tube immediately after collection.

To transfer the sample



1. Unscrew the cap of the BD Molecular Swab Sample Buffer Tube, taking care not to contaminate the contents or the outside of the tube. Immediately after collection, insert the BD Molecular Collection Swab into the tube so that the score mark indicated by the black line is at the lip of the tube.



2. Carefully break the shaft at the score mark and allow the swab to drop into the tube.



3. Tightly re-cap the tube.



4. Label tube with patient information, date, and time collected. Be careful not to obscure the barcodes on the tube.

| Assay                                                        | Condition | Duration      |
|--------------------------------------------------------------|-----------|---------------|
| BD CTGC2 for BD MAX™ System<br>BD CTGCTV2 for BD MAX™ System | 2 – 30 °C | Up to 21 days |
|                                                              | 2 – 8 °C  | Up to 14 days |
| BD MAX™ Vaginal Panel                                        | 2 – 30 °C | Up to 8 days  |

Approved for use with:

- BD CTGC2 for BD MAX™ System
- BD CTGCTV2 for BD MAX™ System
- BD MAX™ Vaginal Panel

# BD Molecular Swab Collection Kit: Vaginal swab specimen self-collection procedure





## For clinician staff

- Do not use a lubricant with the BD Molecular Swab Collection Kit to aid in self-collection.
- Patient must collect their specimen before any vaginal exam is performed with a lubricant.
- Self-collected vaginal swabs are approved specimen types for BD CTGCTV2 for BD MAX™ System and BD MAX™ Vaginal Panel

## Patient instructions for self-collection

Please read all instructions before collecting specimens. If you have any questions about this procedure, please ask your doctor or nurse.

- Wash hands with soap and water. Rinse and dry.
1. Remove the sterile swab from its sheath, taking care not to contaminate the tip or shaft. Carefully pull the cap with attached swab off the tube. Do not touch the soft tip or lay the swab down. If you touch or drop the swab tip or the swab is laid down, discard the swab and request a new vaginal swab. Check for presence of the swab tip. If the swab has no tip, discard it and request a new vaginal swab.
  2. Hold the swab by the cap with one hand so the swab tip is pointing toward you (Figure 2). With your other hand, gently spread the skin outside the vagina. Insert the tip of the swab into the vaginal opening (Figure 2). Point the tip toward your lower back and relax your muscles.
  3. Gently slide the swab no more than 2 inches (5 cm) into the vagina (Figure 3). If the swab does not slide easily, gently rotate the swab as you push. If it is still difficult, do not attempt to continue self-collection; consult your clinician at this point.
  4. Rotate the swab for 10 to 15 seconds (Figure 4).
  5. Withdraw the swab without touching the skin outside the vagina. Place the swab in the sheath and cap the sheath securely (Figure 5).
- After collection, wash hands with soap and water, rinse, and dry. Return the swab in its sheath to the nurse or clinician as instructed.



## Investigation of Specimens for Screening for MRSA

Please take one specimen from each of the following

**Nose mucosal surface and Groin or perineum.**

Additional separate specimens may be obtained from the following (if relevant):

- skin lesions and wound swab
- sites of catheters, including a catheter urine
- tracheostomy or other skin penetrating devices

### **Collecting a nasal swab:**

Use a cotton-tipped culture swab moistened with sterile saline, sterile water or transport media from the swab.

DO NOT lubricate the swab with anything other than sterile saline, sterile water or media from the swab.

Insert the swab into the anterior nares (less than 1cm) and rotate it gently for approximately 10–15 seconds.

### **Collecting perianal or groin swab:**

For perianal specimens (preferred specimen type), swab the perianal area (3) times (i.e. swab as if you are wiping after a bowel movement).

If you ask the patient to lie on their side and draw their knees up this may facilitate collection.

Groin- Rotate the moistened swab gently but firmly over the area on each side. One swab can be used.

### **Investigation of Faecal Specimens for Enteric Pathogens**

Collect specimens soon as possible after onset of symptoms.

Collect specimens before antimicrobial therapy where possible.

Specimen may be passed into a clean, dry, disposable bedpan or similar container and transferred into an appropriate CE marked leak proof containers and place in sealed plastic bags. The specimen is unsatisfactory if any residual soap, detergent or disinfectant remains in the pan.

Faecal samples should be liquid, or semi formed (i.e. take the shape of the container).

1-2g is sufficient for routine culture. Tests for quantifying food poisoning organisms may require up to 10g.

If more than one specimen is taken on the same day the specimens may be pooled.

### **Investigation of specimens other than blood for parasites**

Collect specimens in appropriate CE marked leak proof containers and transport in sealed plastic bags, except for perianal swab for *E. vermicularis* ova which should be transported in a sealed plastic bag.

In the case of CSF, any inoculated plates should also be transported in a robust, CE marked leak proof container.

Collect specimens before antimicrobial therapy where possible.

**Faeces**

Faeces should be presumably collected before antimicrobial or anti-diarrhoeal therapy where possible and between 10pm and midnight, or early in the morning, before defecation or bathing.

Perianal swab should be collected for *E. vermicularis* ova.

Fresh faeces specimens are essential for the examination of trophozoites.

Faeces may be passed directly to a sterile wide-mouthed CE marked leak proof container or may be passed to a clean, dry bedpan or similar container and transferred to a CE marked leak proof container.

Fresh, unpreserved specimens should be transported immediately. Cysts will not form once the specimen has been passed.

Protozoan trophozoites will not survive if the specimen dries out. Use of 10% formalin will kill trophozoites and renders them immotile. Liquid stool should therefore be examined ideally within 30 minutes from the time of collection without the addition of formalin (usually with a drop of saline) if trophozoites are sought. If delays cannot be avoided, the specimen should be preserved to avoid disintegration of the trophozoites.

Soft stools (which may contain both trophozoites and cysts) should preferably be examined within 1hr of passage.

Formed specimens (less likely to contain trophozoites) can be kept for up to one day, with overnight refrigeration if needed, prior to examination.

**Microscopy for *E. vermicularis* ova****Perianal swab**

Perianal specimens are best obtained in the morning before bathing or defecation. Three specimens should be taken on consecutive days before pinworm infection is ruled out.

Cotton-wool swab in dry container should be used for collection.

Spread buttocks apart and rub the moistened cotton wool swab over the area around the anus, but do not insert into the anus. Place cotton wool swab back in its container (no transport medium required). Occasionally, an adult worm may be collected from a patient and sent in saline or water for identification.

**Urine (for *S. haematobium*)**

In urinary schistosomiasis, very few ova are present in the urine. The number of ova in the urine varies throughout the day, being highest in urine obtained between 10am and 2pm. In patients with haematuria, eggs may be found trapped in the blood and mucus in the terminal portion of the urine specimen. It is therefore preferable to obtain total urine collected over the time period between 10am and 2pm. Alternatively, a 24hr collection of terminal samples of urine may be helpful. Sterile containers without boric acid must be used.

If the urine cannot be examined within an hour of collection, it is advisable to add 1mL of undiluted formalin to preserve any eggs that may be present.

**CSF**

Specimens will be obtained by specialist collection according to local protocols.

### **Tissues, biopsies, hydatid cyst and pus from abscesses, bile, duodenal/jejunal aspirates**

Specimens will be obtained by specialist collection according to local protocols.

### **Sputum/bronchoalveolar lavage**

Sputum from the lower respiratory tract expectorated by deep coughing is required. When the cough is dry, physiotherapy, postural drainage or inhalation of an aerosol before expectoration may be helpful.

### **Quantity and number of specimens**

#### **Faeces**

Ideally three stool specimens collected over no more than a 10-day period. It is usually recommended that specimens are collected every other day. Unless the patient has severe diarrhoea or dysentery, no more than one specimen should be examined within a single 24-hour period, as shedding of cysts and ova tends to be intermittent.

If *E. histolytica* is suspected and the first three specimens are negative, consideration should be made for referral where available for molecular tests.

There are no prescribed limits for the size of sample required, as some laboratory procedures will require larger quantities than others.

#### **Perianal swab for *E. vermicularis* ova**

It is recommended that samples should be taken for at least four to six consecutive days. If the results of all these are negative the patient can be considered free from infection. In practice, more than one specimen is rarely received.

#### **Urine (for *S. haematobium*)**

Ideally, a minimum volume of 10mL is required.

#### **CSF**

Ideally, a minimum volume of 1mL is required.

#### **Pus**

Ideally, the entire volume of pus or a minimum of 1mL is required.

#### **Tissues/biopsies**

Ideally, the specimen should be large enough to carry out all investigations required.

#### **Bile, duodenal/jejunal aspirates**

Ideally, a minimum volume of 1mL is required.

#### **Sputum/bronchoalveolar lavage**

Ideally, a minimum volume of 2mL is required.

### Investigation of Blood Cultures (for Organisms other than *Mycobacterium* species)

Collect specimens before antimicrobial therapy where possible.

Collect specimens as soon as possible after the onset of clinical symptoms. Although blood can be sampled at any time, drawing blood at, or as soon as possible after a fever spike is optimal, except in endocarditis where timing is less important.

Collect specimens in appropriate CE marked leak-proof containers and place in sealed plastic bags.

Consider the use of a single low volume bottle for small volumes of blood. If a low volume bottle is unavailable, use a single aerobic bottle. If necrotising enterocolitis is suspected and sufficient blood is obtained, inoculate a 'low volume' and an anaerobic bottle.

**Note:** The use of iodine-based disinfectants is not recommended for disinfection of the butyl rubber septum for some commercial systems as this may affect the septum's integrity.

**Note:** The use of blood collection adapters without 'winged' blood collection sets is not recommended as it is not possible to accurately judge the sample volume and there may be the potential for backflow of blood culture media to patient veins.

**Note:** If blood for other tests such as blood gases or ESR is to be taken at the same venepuncture, the blood culture bottles should be inoculated first to avoid contamination. It is preferable to take blood for culture separately.

Blood culture is a culture of blood collected from a single venepuncture site inoculated to one or multiple bottles.

A blood culture set is defined as one aerobic and one anaerobic bottle. For infants and neonates, a single aerobic bottle may be requested.

#### Quantity

##### Adults

Must be filled correctly 8-10mls per bottle / two sets to be taken if patient is septic / bottles must be sent to agreed testing lab to arrive within 4 hours of collection. **Note:** More than 2 bottles per set may be indicated.

##### Children and neonates

No more than 1% of the total blood volume.

**Note:** Do not exceed the manufacturer's recommended maximum volume for each bottle. Different manufacturers market different bottle formats.

**Note:** If the volume of blood is insufficient for two bottles, the aerobic bottle should be inoculated first and then the rest inoculated to an anaerobic bottle.

#### Number

The number and frequency of specimen collections is dependent on the clinical condition of the patient.

Take two consecutive sets from two separate venepuncture sites during any 24hr period for each septic episode. For neonates, take a single aerobic bottle or special low volume bottle.

Take two sets during the first hour in cases of severe sepsis prior to commencing antibiotic treatment, provided this does not significantly delay antibiotic administration.

Take at least three sets during a 24hr period where the patient has suspected infective endocarditis.

### Procedure

#### Preparation

Ensure the patient is lying or sitting comfortably – place a pillow under their arm if possible.

1. Prepare blood collection set using aseptic non-touch technique (ANTT)
2. Position the patient's arm in a comfortable extended position that provides adequate exposure of the planned venepuncture area
3. Inspect the antecubital fossa or forearm for a suitable vein (it should ideally be visible without applying the tourniquet)
4. Apply the tourniquet with about 4-5 finger widths above the planned venipuncture site
5. Palpate the vein:
  - Choose a vein has a sizeable lumen and feels “springy.”
  - Tapping a vein gently can make it easier to visualise and feel.
6. Thoroughly clean the site:
  - Use 2% chlorhexidine in 70% isopropyl alcohol to disinfect the patient's skin and allow it to dry.
  - If the patient's skin is visibly soiled use soap and water to clean the site
  - Once the skin has been disinfected you should not touch the site again (even with gloves on)
7. Wash your hands:
  - Using alcohol gel and the World Health Organisation's hand hygiene technique
  - If your skin is visibly soiled, you should wash your hands using soap and water.
8. Don apron and gloves
9. Remove caps from the blood culture bottles immediately prior to taking the sample and clean the top of each with a separate cleaning swab, allowing the alcohol to evaporate for 30 seconds before proceeding with bottle inoculation.
10. Place the sharps bin and equipment tray (containing your sample bottles, gauze and plaster) within easy reach in preparation for venipuncture.

#### Insertion of the needle

1. Prepare the blood collection system using ANTT (some blood collection systems require some assembly such as attaching a to the needle)
2. Unsheathe the needle

3. Anchor the vein from below with your non-dominant hand by gently pulling on the skin distal to the insertion site
4. Warn the patient of a sharp scratch
5. Insert the needle through the skin at a 30-degree angle or less, with the bevel facing upwards (you should feel a decrease in resistance as the needle enters the vein)
6. Advance the needle a further 1-2 mm into the vein after the decrease in resistance is felt
7. Lower and anchor the needle to the patient's skin
8. Use the other hand to attach the aerobic blood culture bottle to the adapter, piercing the blood culture septum and allowing the bottle to fill with 10ml of blood
9. Remove the aerobic bottle and then attach the anaerobic bottle, also filling it with 10ml of blood
- For adults, collecting 8 - 10 ml; two or three blood cultures (by separate stick) per septic episode is sufficient. Paediatric blood cultures are not taken within Spire Healthcare
10. Release the tourniquet
11. Withdraw the needle and then apply gentle pressure to the site with some sterile gauze
12. Ask the patient to hold the gauze in place whilst you dispose of the needle into a sharp container
13. Apply a dressing to the patient's arm (cotton wool / gauze / plaster)
14. Discard the used equipment into the appropriate waste bin

To complete the procedure

Thank the patient and wash hands.

Fill out patient details on the sample bottles at the bedside - do not obscure the bottle bar codes with an addressograph label, do not remove any barcode labels, do not cover any part of the bottom of the bottle with labels and send the blood samples to the lab for testing. Document the following in the patient's notes:

- Reason for sample
- Time and date of sample
- Site the sample was obtained from.
- Your name, signature and contact details.

### Investigation of bone marrow

Ideally, specimens for culture should be collected directly into blood culture bottles and transported in sealed plastic bags.

Additional bone marrow specimens should be submitted in an appropriate CE marked leak-proof containers and transported in sealed plastic bags.

Collect specimens before starting antimicrobial therapy where possible.

Specimens for culture should ideally be collected in blood culture bottles.

Additional specimens for direct culture, microscopy and molecular techniques should be collected in appropriate CE marked leak-proof containers.

As large a sample as possible should be obtained, with the caveat that volumes of >3mL are likely to be contaminated with peripheral blood which may have a dilution effect.

### Investigation of Dermatological Specimens for Superficial Mycoses

Collect specimens before antifungal therapy where possible.

Specimens should be transported and processed as soon as possible.

Specimens should be kept at room temperature and transported and processed as soon as possible although, provided the samples are kept dry, the fungus will remain viable for several months.

Samples should be allowed to dry out and kept at room temperature.

#### Skin

Patients' skin and nails can be swabbed with 70% alcohol prior to collection of the specimen, this is especially important if creams, lotions or powders have been applied. The edges of skin lesions yield the greatest quantities of viable fungus. Lesions should be scraped with a blunt scalpel blade. If insufficient material can be obtained by scraping and being placed in a container, then a swab or sticky tape can be pressed on the lesion and transferred to a clean glass slide for transport to the laboratory ('stripping'). Samples in containers achieve the optimum results.

#### Nail

Good nail samples are difficult to obtain. It should be specified whether the sample is from the fingernails or toenails. Material should be taken from any discoloured, dystrophic or brittle parts of the nail. The affected nail should be cut as far back as possible through the entire thickness and should include any crumbly material. Nail drills, scalpels and nail elevators may be helpful but must be sterilized between patients. When there are superficial involvement (as in white superficial onychomycosis) nail scrapings may be taken with a curette. If associated skin lesions are present samples from these are likely to be infected with the same organism and are more likely to give a positive culture. Samples from associated sites should be sent in separate packets.

#### Hair

Samples from the scalp should include skin scales and hair stumps. Cut hairs are not suitable for direct examination as the infected area is usually close to the scalp surface. Scraping for direct examination is the preferable sample collection method, however plastic hairbrushes, scalp massage pads, swabs or plastic toothbrushes may be used to sample scalps for culture where there is little obvious scaling. If sufficiently long, hairs should be plucked with forceps and wrapped in black paper or commercial transport packs together with flakes of skin. Collect specimens other than swabs into appropriate CE marked leak-proof containers and place them in sealed plastic bags.

### Investigation of specimens for Mycobacterium species

Collect specimens before antimicrobial therapy where possible.

For the initial diagnosis of mycobacterial infection all specimens should be fresh and taken, whenever possible, before anti-tubercular treatment is started. 'Other' antimicrobials may also have significant anti-mycobacterial activity, notably the fluoroquinolones such as ciprofloxacin, levofloxacin or moxifloxacin, and the macrolides such as clarithromycin or azithromycin.

### **Use appropriate hazard labelling according to local policy.**

Refer to the relevant HSE/COSHH guidelines on the collection and safe handling of specimens likely to contain Hazard Group 3 organisms.

Aerosol generating procedures, such as bronchoscopy or sputum induction, should be performed in an appropriately engineered and ventilated area.

### **Specimens other than blood**

Specimens other than blood or bone marrow should be refrigerated if transport to the laboratory or specimen processing is delayed for >1hr.

### **Gastric washings**

Gastric washings should be neutralised by adding approximately 100mg of sodium carbonate to approximately 50mL of the specimen if processing is delayed for >4hr.

### **Blood and bone marrow cultures**

Blood and bone marrow aspirate cultures should be transported and loaded into the automated culture system as soon as possible.

**Note:** These samples should not be collected in EDTA tubes as this inhibits the growth of mycobacteria. Lithium Heparin tubes are recommended.

### **Correct specimen type and method of collection**

#### **Sputum specimens**

Sputum specimens should be relatively fresh (less than 1 day old) to minimise contamination. Purulent specimens are best. Two to three samples of 5mL should be collected approximately 8-24 hours apart with at least one from early morning.

Samples taken early morning (that is, shortly after patient waking) have the greatest yield. When the cough is dry, physiotherapy, postural drainage or inhalation of nebulised saline ('sputum induction') before expectoration may be helpful.

**Note:** Decontaminated and neutralised samples are not recommended as they may lose viability during transit to the laboratory.

#### **Bronchoalveolar lavage/bronchial washings**

These may be sent if spontaneous or induced sputum is unavailable or if such specimens are AFB smear negative.

**Note:** Contamination of the bronchoscope with tap water, which may contain environmental Mycobacterium species, should be avoided. Minimum sample size is preferably 5mL.

### Gastric washings

Gastric washings are usually used for children where there are problems obtaining sputum. Young children will often swallow their respiratory secretions rather than cough them up. Induced sputum is considered preferable to gastric washings, if possible. Collect samples early in the morning (before breakfast) on 3 consecutive days. Preferably, a minimum volume of 5mL should be collected. Aspirates should be promptly delivered and processed to avoid acidic deterioration of organisms (see under neutralisation, section 4.5). Results of direct microscopy on gastric washings can be misleading because other acid-fast bacilli are normally present in the stomach.

### Sterile site body fluids

Sterile site body fluids (CSF, pleural fluid, etc) will normally not require decontamination and can be inoculated directly to neutral media. However, these samples can be assessed for contamination by setting up purity plates. If contaminated, they can be treated with acid and if pure they can be directly inoculated. Collect aseptically as much (for example >6mL in adults) CSF sample as possible into a CE Marked leak proof container in a sealed plastic bag. If only a small volume is available after initial lumbar puncture, and the findings of cell counts and protein suggest TB meningitis, a second procedure should be considered to obtain a larger volume to improve chances of achieving positive cultures.

It should be noted that pleural or pericardial fluids are not very sensitive samples for the detection of *M. tuberculosis*, and that a concurrent pleural or pericardial biopsy taken with the fluid is more useful. A negative result on these fluids does not rule out the diagnosis.

### Urine specimens

Urine specimens should be collected in the early morning on three consecutive days in a CE marked leak proof container (that does not contain boric acid) and placed in a sealed plastic bag. If there are no appropriate containers for a whole Early Morning Urine (EMU) sample, a midstream EMU sample is an acceptable, but not ideal alternative.

### Skin, bone, and tissue including post mortem specimens

Specimens of such type should be homogenised, except for bone. It may be necessary to select and cut out a suitable piece of tissue if a large piece is received. Similarly, some pieces of tissue may need to be 'minced' using sterile scissors and forceps before they can be successfully homogenised. Specimens should be collected aseptically and placed in a CE Marked leak proof container without preservatives in a sealed plastic bag, and sterile distilled water added to prevent desiccation. A caseous portion should be selected if possible: the majority of organisms will be found in the periphery of a caseous lesion.

Tissue biopsy specimens received in formalin are unacceptable and should not be processed.

### Faecal samples

*Mycobacterium tuberculosis* and *Mycobacterium avium-intracellulare* group have been isolated from faeces, notably in patients who are immunocompromised such as those with HIV-AIDS. However, NTMs can often be isolated from healthy individuals, representing colonisation only. If *M. tuberculosis* is isolated, this may well be due to the ingestion of infected respiratory secretions rather than intestinal disease. The isolation procedure is unreliable and has a low success rate due to the heavy contamination with other bacteria; hence culturing faecal samples for mycobacteria is not

recommended in this UK SMI. *M tuberculosis* and NTMs, including MAI, may be isolated from blood cultures in disseminated infection.

### **Pus or pus swabs**

Pus, or pus swabs, should be collected aseptically, and the largest practical sample submitted in CE marked leak-proof container in a sealed plastic bag. Pus is the sample type of choice. Swabs are less preferable as mycobacteria, if present, may adhere to the swab rather than be transferred successfully to the culture media.

### **Bone marrow**

As large a sample of bone marrow as possible should be aspirated and added directly to the culture medium in accordance with the manufacturer's instructions.

### **Blood**

For more information on blood cultures, refer to Blood Culture section

**Note:** EDTA, even in trace amounts, inhibits the growth of some *Mycobacterium* species and so is not acceptable.

### **Investigation of urine**

There is a patient information leaflet available should you wish to give a patient instruction to perform this from home Ref: SPS-GP-WI1403, available in the Pathology section of the Spire Clinical Intranet

Collect specimens before antimicrobial therapy where possible.

### **Mid-stream urine (MSU)**

MSU is the recommended routine collection method.

Periurethral cleaning is recommended (water is considered sufficient).

The first part of voided urine is discarded and, without interrupting the flow, approximately 10mL is collected into a CE marked leak proof container. The remaining urine is discarded. If boric acid preservative is used, the container is filled up to the mark in a similar manner and the contents mixed well.

### **Clean-catch urine**

A reasonable alternative to MSU.

Periurethral cleaning is recommended. The whole specimen is collected and then an aliquot sent for examination in a CE marked leak proof container.

### **Suprapubic aspirate (SPA)**

Urine is obtained aseptically, directly from the bladder by aspiration with a needle and syringe. The use of this invasive procedure is usually reserved for clarification of equivocal results from voided urine (e.g. in infants and small children). Ultrasound guidance should be used to show presence of urine in the bladder before carrying out SPA.

**Catheter urine (CSU)**

The sample may be obtained either from a transient ('in and out') catheterisation or from an indwelling catheter. In the latter case, the specimen is obtained aseptically from a sample port in the catheter tubing or by aseptic aspiration of the tubing. The specimen should not be obtained from the collection bag.

**Bag urine**

Used commonly for infants and young children. The sterile bags are taped over the freshly cleaned and dried genitalia, and the collected urine is transferred to a CE marked leak proof container. There are frequent problems of contamination with this method of collection.

**Pad urine**

An alternative to collecting bag urine from infants and young children. After washing the nappy area thoroughly, a pad is placed inside the nappy. As soon as the pad is wet with urine (but no faecal soiling), push the tip of a syringe into the pad and draw urine into the syringe. Transfer specimen to a CE marked leak proof container. If difficulty is experienced in withdrawing urine, the wet fibres may be inserted into the syringe barrel and the urine squeezed directly into the container with the syringe plunger.

**Ileal conduit – urostomy urine**

Urine is obtained via a catheter passed aseptically into the stomal opening after removal of the external appliance. Results from this type of specimen may be difficult to interpret.

**Cystoscopy urine**

Urine is obtained directly from the bladder using a cystoscope.

**Ureteric urine**

Urine samples are obtained from one or both ureters during cystoscopy via ureteric catheters inserted from the bladder.

Urine samples may also be sent following nephrostomy, other surgical procedures, or bladder washout.

Meares and Stamey localisation culture method for diagnosis of prostatitis

The following specimens are collected:

- The initial 5–8mL voided urine (urethral urine)
- MSU (bladder urine)
- Expressed prostatic secretions following prostatic massage
- The first 2–3mL voided urine following prostatic massage

**Urine for *S. Typhi* and *S. Paratyphi* cultures**

Any urine samples from suspected cases or contacts of cases. Please ensure suspicion of this is indicated in the Clinical details on the sample request form

### Investigation of bone and soft tissue associated with osteomyelitis

Collect specimens before starting antimicrobial therapy where possible.

Unless otherwise stated, swabs for bacterial and fungal culture should be placed in appropriate transport medium.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

Direct collection in theatres can be placed into a CE marked leak proof container with Ringer's or saline solution and Ballotini beads (as an option) which is placed into sealed plastic bags. However, microbiology and histology specimen pots can be confused leading to difficulties in processing samples.

In surgery for chronic osteomyelitis collection of multiple (4-5) intra-operative samples with separate instruments (usually sterile forceps and scalpel) is important. Duplicate samples must be taken for histology. Swabs are not recommended.

Minimum specimen size will depend on the number of investigations requested.

Specimens should be transported and processed as soon as possible. To enable timely clinical management, samples should be processed urgently.

The Infectious Diseases Society of America (IDSA) guidelines recommend that specimens should be transported at room temperature, and should be processed immediately, and within a maximum of 2hr.

If processing is delayed, refrigeration is preferable to storage at ambient temperature.

If possible, stop all antibiotics at least 2 weeks prior to sampling and consider not giving routine surgical prophylaxis until after sampling.

The volume of the specimen influences the transport time that is acceptable. Larger pieces of bone may maintain the viability of anaerobes for longer. Samples should not however exceed the size of the CE marked leak proof containers available.

### Investigation of orthopaedic implant associated infections

Collect specimens before antimicrobial therapy where possible.

If possible, stop all antibiotics at 2 weeks prior to sampling and consider not giving routine surgical prophylaxis until after sampling.

Collect specimens into appropriate CE marked leak-proof containers and place in sealed plastic bags.

To enable timely clinical management, samples should be processed urgently.

Swabs are to be discouraged. However, if sent, swabs for bacterial and fungal culture should be placed into appropriate transport medium and transport in sealed plastic bags.

For aspirates and radiologically guided biopsies, it is usually only possible to send one sample to microbiology. In theatres, multiple (three to five) samples should be taken using separate instruments for microbiology. An equivalent set of samples should be taken for histology.

Specimen size should approximate 1mL.

Small volumes of synovial fluid (<1mL) may impede the recovery of organisms.

Specimens should be transported and processed as soon as possible.

The Infectious Diseases Society of America (IDSA) guidelines recommend that specimens should be transported at room temperature, and should be processed immediately, and within a maximum of 2hr.

If processing is delayed, refrigeration is preferable to storage at ambient temperature

In surgery for chronic osteomyelitis collection of multiple (4-5) intra-operative samples with separate instruments (usually sterile forceps and scalpel) is important. Duplicate samples must be taken for histology. Swabs are not recommended.

### Screening for *Neisseria meningitidis*

Collect specimens before antimicrobial therapy where possible.

Specimens should be transported and processed as soon as possible.

Recovery of meningococci is compromised if culture is delayed.

If processing is delayed, refrigeration is preferable to storage at ambient temperature.

Direct plating when the swab is taken should be considered.

### Investigation of gastric biopsies for *Helicobacter pylori*

Collect specimens before starting antimicrobial therapy where possible.

Ideally biopsies should be taken before antimicrobial therapy is begun, however a 'test and treat' strategy for the diagnosis of *H. pylori* is recommended by NICE and therefore most samples referred for culture will be due to treatment failure. A period of at least two weeks should have elapsed since the last dose of antimicrobial therapy before the collection of the specimen.

Gastric biopsy specimens are usually taken from the gastric antrum at endoscopy, and sometimes from the main body of the stomach depending on location of inflammation. Duodenal biopsies will be taken in cases with duodenal ulcers.

Numbers and frequency of specimen collection are dependent on clinical condition of patient at the discretion of the endoscopist as it depends on the individual patient.

### Investigation of bronchoalveolar lavage, sputum and associated specimens

Where possible all specimens should be fresh and taken before antimicrobial treatment is started.

Early morning freshly expectorated sputum is recommended for *Mycobacterium*

Culture for *Legionella* species may still be successful after antimicrobial therapy has been started. For sputum specimens the material required is from the lower respiratory tract, expectorated by deep coughing. When the cough is dry, physiotherapy, postural drainage or inhalation of an aerosol before expectoration may be helpful. Saliva and pernasal secretions are not suitable.

Early morning specimens for examination of *Mycobacterium* species should ideally be collected on at least 3 consecutive days. BAL and associated specimens need specialist collection according to local protocols.

Unless otherwise stated, swabs for bacterial and fungal culture should then be placed in appropriate transport medium.

Collect specimens other than swabs into appropriate CE marked leak proof containers and place in sealed plastic bags.

**Sputum** - Ideally, a minimum volume of 1mL.

**BAL** - It is difficult to be specific on volume required; in principle, as large a volume as possible is preferred.

Numbers and frequency of specimens collected are dependent on clinical condition of patient.

**Note:** Spire Laboratory Medicine do not perform Medico-legal work. Any specimens requiring a chain of custody cannot be processed.

Collect specimens before starting antimicrobial therapy where possible.

BAL and sputum should be processed promptly to give the best opportunity to culture pathogenic organisms and reduce the risk of overgrowth with contaminants. If processing has to be delayed up to 24 hours, refrigeration is preferable to storage at ambient temperature. If specimens are not processed on the same day that they are collected, this should be noted on the report and interpretation of results should be made with care

### Detection of Carriage of Group B Streptococci

Collect specimens before antimicrobial therapy where possible.

Unless otherwise stated, swabs for bacterial and fungal culture should then be placed in appropriate transport medium.

Rayon or Dacron, Fibre or Flocked swabs, with non-nutritive transport media (e.g. Amies or Stuart's), preserve the viability of the organism by providing moisture, and buffering to maintain the pH.

Specimen(s) for culture may be collected either by the physician or other qualified caregiver (or may be self-collected by the patient, with appropriate instruction). This involves swabbing the distal vagina (vaginal introitus), followed by the rectum.

A single swab for both sites of collection is rational but two different swabs can be used. Because lower vaginal as opposed to cervical cultures are recommended, cultures should not be collected by speculum examination.

### Detection of Enterobacteriaceae producing extended spectrum $\beta$ -lactamases

Collect specimens before starting antimicrobial therapy where possible.

Unless otherwise stated, swabs for bacterial culture should be placed in appropriate transport medium

Collect specimens into appropriate CE marked leak proof containers and place in sealed plastic bags.

There should be visible faecal material on the rectal or peri-rectal swabs taken

### Detection of bacteria with carbapenem-hydrolysing $\beta$ -lactamases carbapenemases)

Screening specimens including stool, rectal or peri-rectal swabs, any clinical specimens such as blood, wounds or urine

The potential for spread of acquired carbapenemases means that an indicator carbapenem should ideally be tested against all clinically significant Gram negative bacteria. Minimum testing should include isolates from 'high-risk' patients and settings in accordance with current national guidance, such as patients who have been in-patients in a hospital abroad or in a hospital in the UK known to have problems with spread of CPE or patients known to have been previously colonised or infected

with CPE, when the information has been provided on the request form accompanying the specimen and any isolates found grossly resistant to co-amoxiclav.

### Investigation of specimens for ectoparasites

Specimens should be handled with care to avoid damage to taxonomic features required for identification. Specimens should be collected directly from the patient whenever possible or from the environment in which the patient lives. Specimens should be collected into a CE marked leak proof container in a sealed plastic bag.

Ideally specimens should be killed before postage. All soft-bodied specimens (lice, fleas, bedbugs, ticks and fly larvae) should be killed by immersion in hot water, transferred to and transported in 70% ethanol. All hard bodied specimens (including beetles and adult flies) should be killed by exposure to ethyl acetate vapour and transported dry. Mites may be killed and transported in 70% ethanol. Refer to the appropriate section for further details. A short patient history and details of any foreign travel should be included.

Inner packaging containing the specimen should be examined prior to opening to ascertain if the insect/arachnid is still living. Living specimens should be killed with hot water or ethyl acetate vapour prior to examination. Where there is a risk that live specimens may escape when the container is opened, they should be chilled in a refrigerator before processing.

To ensure specimens are suitable for taxonomic anatomy live leeches should be narcotised in 15% ethanol. When fully narcotised the leeches should be extended flat for fixing in 70% ethanol or 5% formalin. Specimens dropped live to formalin or concentrated ethanol contract violently, harden and are useless for identification

## Appendix 6 – Form & Sample labelling guidelines

### Correct labelling of Cellular Pathology

Demographic labels may be used on the form & sample but must be the same size as the information label.

Handwritten samples in BLOCK CAPITALS

**SPiRE HEALTHCARE PATHOLOGY SERVICES**

**HISTOLOGY / CYTOLOGY**

**Patient details must be written here and correlate with the information on the sample pot**

**Requesting department and consultant name must be written here**

**Date of collection and time of collection written here**

**Tick if urgent or not based on clinical condition. Please only select urgent when appropriate. It is also useful if this section is highlighted if urgent ticked.**

**Request form must be signed Number and email of consultant must be written here. Required in case an unexpected cancer is found to enable the Histopathologist to contact urgently**

**Detailed clinical details written here. Diagram must be displayed here**

**Detailed specimen information to must be written here**

**HISTOLOGICAL EXAMINATION & CLINICAL INTERPRETATION LAB No.**

Surname: Forename: Date of collection

D.O.B.: Sex: M / F Time of collection

Hospital Number: Consultant: Routine ☐ Urgent ☐

Address: Referral site/Source: Date and time received in laboratory

**SPECIMEN**

**CLINICAL DETAILS / DIAGRAM**

Histopathologist

Please ensure the pathology request form and sample are labelled correctly and correct samples present

Consultant signature

Practitioner signature

Consultant Mobile number

Consultant Email

**FOR BLOOD TESTS, BLOOD TRANSFUSION OR CERVICAL CYTOLOGY PLEASE USE RELEVANT FORM**



Patient name  
NHS number  
Date of collection  
Specimen details



Patient DOB  
Date of collection  
Time of collection

### Products of Conception

The laboratory must receive:

Histology request form

Clini 30

Appendix 2 consent form

Appendix 3 Certificate of Medical practitioner non-viability of pregnancy loss

Appendix 4 Authorisation for Release of Pregnancy Loss

### Correct Labelling for Ordercomms Samples

Label all Ordercomms sample this way



#### CHECK YOUR SAMPLE TUBES


- Ensure you have the **correct sample type tubes** for the tests requested.
- **One specimen tube per label** printed via HMS.

#### LABELLING MATTERS

- Position the label **straight and close to the lid**.
- Incorrect labelling can cause analyser errors and **require label reprinting**.

#### NO ROOM FOR ERROR

- Here's an example of a test tube in an analyser rack:  
Label placement must be precise - **there is NO room for error.**



## How to label Blood tube sample correctly:

Demographic labels may be used but must be the same size as the information label.

Handwritten samples in BLOCK CAPITALS



Surname  
Forename / DOB



Address / Sex  
Department  
Time / Date of collection




Hospital number / Signature

## How to label Transfusion sample & request form correctly:

Samples **must be** handwritten in BLOCK CAPITALS


No amendments accepted. If in doubt, REBLEED the patient.



Surname / Forename  
Department / Sex



Address / NHS if known  
DOB / Date of collection



Hospital number  
Time of collection  
Signature

Patient details must be written here and correlate with the information on the sample tube

Detailed clinical details written here along with date of the planned procedure

Date and time of collection must correlate with the date and time on the sample tube, request department to be noted

Tick if the samples are for pre-admission, ensure case number is noted down

Tick if this sample is urgent. If ticked, please contact the laboratory

Please circle relevant information

Requesting clinician signature along with the signature of the person who took the sample (should correlate with the signature on the sample tube)

If blood components are required, please state what is needed and quantity along with the reason

Special requirements noted here (if known)

Select the test that is required e.g., group and save

**SPINAL HEALTHCARE PATHWAYS**

**AFFIX ADDRESSOGRAPH TO BOTH COPIES**

Surname: \_\_\_\_\_ Forename: \_\_\_\_\_  
D.O.B.: \_\_\_\_\_ Sex: M / F  
Hospital Number: \_\_\_\_\_ Consultant: \_\_\_\_\_  
Address: \_\_\_\_\_ Requesting Clinician: \_\_\_\_\_

Relevant Clinical Data:  
TCI Date: \_\_\_\_\_  
Report to: \_\_\_\_\_ Date and time in laboratory: \_\_\_\_\_  
Request origin: \_\_\_\_\_ Date of collection: \_\_\_\_\_ Time of collection: \_\_\_\_\_

ALL THE INFORMATION ON THIS FORM IS NECESSARY TO ENSURE SAFE TRANSFUSION  
**FILL IN ALL DETAILS**

Are these pre-admission samples? please tick if yes ☐  
Case number: \_\_\_\_\_

**REQUEST DETAILS**

☐ Group and save sample  
☐ Crossmatch  
☐ Direct antiglobulin test

☐ 6ml EDTA sample  
☐ Blood Group Only

Chemotherapy Patient YES/NO  
Cardiac Disease YES/NO  
Previous Transfusions YES/NO  
Previous Reactions YES/NO  
Pregnant in last 3 months YES/NO

**URGENT**  
CONTACT LABORATORY OR  
ON-CALL SMS IF OUT OF HOURS

LAB No. \_\_\_\_\_

Patient's Group (if known) \_\_\_\_\_  
Antibody Status (if known) \_\_\_\_\_

**PRODUCTS REQUIRED**

| PRODUCT                                                   | No. UNITS | DATE/TIME | STATE REASON |
|-----------------------------------------------------------|-----------|-----------|--------------|
| Red Cells                                                 | _____     | _____     | _____        |
| Platelets                                                 | _____     | _____     | _____        |
| FFP                                                       | _____     | _____     | _____        |
| Cryoprecipitate                                           | _____     | _____     | _____        |
| Other - Please state type and number of units/dose: _____ |           |           |              |

**SPECIAL REQUIREMENTS**

☐ CMV Negative  
☐ Irradiated Products

Contact laboratory in all cases where required. Non-completion implies no specific requirements necessary.

REQUESTING/PRESCRIBING CLINICIAN SIGNATURE: \_\_\_\_\_  
SAMPLE COLLECTED BY: \_\_\_\_\_

IF CORRECT PATIENT DETAILS ARE NOT PROVIDED ON FORM AND SAMPLE THIS REQUEST MAY BE REJECTED  
ENSURE SAMPLE IS SIGNED BY PERSON TAKING BLOOD

**24 HOURS NOTICE MUST BE GIVEN FOR ALL ROUTINE REQUESTS FOR BLOOD**

**BIOHAZARD**

Specimens known or suspected to contain Category 3 pathogens, such as Hepatitis B&C or H.I.V. etc

All samples and request form MUST be labelled with Biohazard stickers.

Place specimens in the attached bags as detailed in the instructions for use section. Do not overfill the plastic bag.

**LABORATORY SERVICES**

For laboratory opening hours and contact details please refer to the Laboratory User Guide.

**TIMING OF SAMPLES**

If a patient has been transfused or pregnant within the last 3 months, a new sample is required up to 3 days prior to the expected transfusion. This is the time between the sample being taken and the subsequent completion of the transfusion.

If a patient has not been transfused or pregnant within the last 3 months a new sample is required within 7 days of the scheduled transfusion.

**INSTRUCTIONS FOR USE:**

1. Please enter all details on request form clearly.
2. The hospital number is very important and must always be included in the patient ID.
3. Ensure you have the correct sample.
4. Label specimen tube and insert into sample bag.
5. Remove adhesive covering strip, fold top over, press firmly to seal bag.
6. If the request is URGENT please tick the box and inform the laboratory ASAP.

A comprehensive description of services provided is to be found in the Laboratory User Guide. This includes information of reference ranges, collection of samples and test information

**SAMPLE REQUIREMENTS**

All samples must be collected into a 6.0ml EDTA (PINK) transfusion bottle with the details clearly handwritten in ballpoint pen by the member of staff taking the sample.

Samples must be labelled at the time of collection (e.g. at the bedside)

- Patient's surname & forename, correctly spelt (initials are not sufficient)
- Hospital number and/or NHS number and/or first line of the patients address
- Date of birth (not age)

The sample must be signed and dated by the person collecting the sample. All details are required on both the sample and this request form.

It is a statutory requirement that separate second sample should be taken to confirm patients group prior to requesting blood components. If possible, this should be performed by 2 different members of staff with at least 20 mins between samples being taken.

Failure to complete sample details correctly will result in sample rejection.

Version 3.0 - 08/2017

**BLOOD TRANSFUSION**

## LABORATORY MEDICINE SERVICE USERS GUIDE

**USE ORDERCOMM HMS.** If HMS is unavailable, complete a Manual Request Form.

Demographic labels may be used but must be the same size as the information label.

Patient details must be written here and correlate with the details on the sample tube / or addressograph be used **1**

Detailed clinical details written here along with date of the planned procedure **2**

Tick if the samples are for pre-admission, ensure case number is noted down **3**

Requesting department, date of collection and time of collection written here **4**

Please circle if the patient sample is under fasting conditions. Circle if urgent or not based on clinical condition. Please only select urgent when appropriate – e.g., major haemorrhage. It is also useful if this section is highlighted if urgent circled. **5**

**SPIRE PATHOLOGY SERVICES**

Surname: \_\_\_\_\_ Forename: \_\_\_\_\_ Relevant Clinical Data / TCI Date: \_\_\_\_\_

D.O.B.: \_\_\_\_\_ Sex: M / F \_\_\_\_\_

Hospital Number: \_\_\_\_\_ Consultant: \_\_\_\_\_

Address: \_\_\_\_\_

Copy to: \_\_\_\_\_ Date and Time Received in Laboratory: \_\_\_\_\_

Are these pre-admission samples? ☐ Yes ☐ No Case number: \_\_\_\_\_

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| <b>HAEMATOLOGY</b><br><input type="checkbox"/> FBC & Differential<br><input type="checkbox"/> ESR<br><input type="checkbox"/> HB Electrophoresis<br><input type="checkbox"/> Prothrombin Time / INR<br><input type="checkbox"/> Coagulation Screen<br><input type="checkbox"/> Partial Thromboplastin time<br><input type="checkbox"/> Thrombophilia Screen<br><input type="checkbox"/> D-Dimer<br><input type="checkbox"/> B12<br><input type="checkbox"/> Folate<br><input type="checkbox"/> Ferritin | <b>BIOCHEMISTRY</b><br><input type="checkbox"/> Urea & Electrolytes<br><input type="checkbox"/> Liver Function Tests<br><input type="checkbox"/> Lipid Profile<br><input type="checkbox"/> Bone Profile<br><input type="checkbox"/> Uric Acid<br><input type="checkbox"/> Calcium<br><input type="checkbox"/> CRP<br><input type="checkbox"/> Blood Glucose<br><input type="checkbox"/> HbA1C<br><input type="checkbox"/> Gentamicin<br><input type="checkbox"/> Vancomycin<br><input type="checkbox"/> Immunoglobulins<br><input type="checkbox"/> Protein Electrophoresis | <b>MICROBIOLOGY</b><br><input type="checkbox"/> Urine (specify type) _____<br><input type="checkbox"/> Micro/cult/sens (specify site) _____<br><input type="checkbox"/> MRSA screen<br><input type="checkbox"/> CPE screen<br><input type="checkbox"/> Blood Culture<br><input type="checkbox"/> TB Culture<br><input type="checkbox"/> Mycology (hair, nail, skin scraping only)<br><input type="checkbox"/> Ova, cysts and parasites<br><input type="checkbox"/> C. difficile toxin<br><input type="checkbox"/> Chlamydia/Gonorrhoea<br><input type="checkbox"/> Trichomonas/PCR<br><input type="checkbox"/> Swab<br><input type="checkbox"/> Urine | Recent history of foreign travel?<br>Contact with imported animals? (in particular dogs from Eastern Europe)<br>Association with an outbreak scenario?<br>Consumption of unpasteurised milk products?                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Requesting Dept: _____<br>Date of collection: _____<br>Time of collection: _____<br><b>FASTING</b> Yes / No<br><b>URGENT</b> Yes / No |
| <b>ENDOCRINOLOGY</b><br><input type="checkbox"/> LH<br><input type="checkbox"/> FSH<br><input type="checkbox"/> Oestradiol<br><input type="checkbox"/> Progesterone<br><input type="checkbox"/> Prolactin<br><input type="checkbox"/> Testosterone<br><input type="checkbox"/> SHBG<br><input type="checkbox"/> Free T4<br><input type="checkbox"/> TSH<br><input type="checkbox"/> Cortisol                                                                                                            | <b>TUMOUR MARKERS</b><br><input type="checkbox"/> CEA<br><input type="checkbox"/> HCG<br><input type="checkbox"/> CA125<br><input type="checkbox"/> CA 19-9<br><input type="checkbox"/> CA 15-3<br><input type="checkbox"/> AFP<br><input type="checkbox"/> PSA<br><input type="checkbox"/> Free PSA<br>(please sign) _____                                                                                                                                                                                                                                                 | <b>24 HOUR URINE</b><br><input type="checkbox"/> Urine Calcium<br><input type="checkbox"/> Urine Phosphate<br><input type="checkbox"/> Urine Protein<br><input type="checkbox"/> Urine Metanephrines<br><input type="checkbox"/> Urine U & E<br><input type="checkbox"/> Urine 5HIAA<br><input type="checkbox"/> Urine Creatinine Clearance<br><input type="checkbox"/> Urine Acid                                                                                                                                                                                                                                                                    | <b>IMMUNOLOGY</b><br>Please use separate request form for Immunology Testing<br><b>VIROLOGY / SEROLOGY</b><br><input type="checkbox"/> Hepatitis A IgM<br><input type="checkbox"/> Hepatitis B Antibody<br><input type="checkbox"/> Hepatitis B Surface Antigen<br><input type="checkbox"/> Hepatitis B Total Core Antibody<br><input type="checkbox"/> Hepatitis C Antibody<br><input type="checkbox"/> HIV 1+2<br><input type="checkbox"/> Rubella IgG<br><input type="checkbox"/> Syphilis Serology<br><input type="checkbox"/> VZ IgG<br><input type="checkbox"/> EBV Serology<br><input type="checkbox"/> CMV IgG and IgM<br><input type="checkbox"/> Herpes 1+2 IgG | LAB No. _____<br>LAB No. _____<br>LAB No. _____<br>LAB No. _____                                                                      |

**MISCELLANEOUS TESTS**

BLOOD ☐ URINE ☐ FAECES ☐ OTHER \_\_\_\_\_

**FOR BLOOD TRANSFUSION, HISTOLOGY/CYTOLOGY or CERVICAL CYTOLOGY use RELEVANT FORM**

Select what tests are required. If not sure on the sample tubes needed, please see overleaf **6**

Handwritten here any tests which are not detailed on the form **7**

Request form must be signed **8**

Tick what samples are sent e.g. blood **9**

### BIOHAZARD

All specimens known or suspected to contain Category 3 pathogens, such as Hepatitis B&C or H.I.V. samples and request form MUST be labelled with Biohazard stickers.

Place specimens in the attached bags as detailed in the instructions for use section.

### LABORATORY SERVICES

For laboratory opening hours and contact details please refer to the Laboratory User Guide.

### IMPORTANT:

This form is intended to be used internally at Spire. This form is not a request for pathology services from Spire to a third party, and Spire is not obliged to pay a third party for providing any pathology services marked on this form, unless otherwise agreed.

### INSTRUCTIONS FOR USE:

- Please enter all details on the request form clearly.
- The hospital unit number is very important and must always be included in the patient ID.
- Ensure you have the correct sample.
- Label specimen tube and insert in attached bag.
- Remove adhesive covering strip, fold top over, press firmly to seal bag.
- Send to laboratory ensuring that if the request is URGENT that the appropriate box has been ticked.

A comprehensive description of services provided is to be found in the Laboratory User Guide. This includes information of reference ranges, collection of samples and test information.

For all sample types please refer to the Pathology User Guide.



COMBINED REQUEST



Sample types please refer to User Guide

Instructions for use

Further notable info/H&S information